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 ABSTRACT 
Despite high cure rates achieved in the last two decades, treatment resistance 
and therapy-associated toxicity is still observed in a significant proportion of 
children with ALL, warranting alternative therapeutic approaches. Results 
obtained in our laboratory suggest that transcriptional upregulation of 
prosurvival pathways plays a key role in paediatric B-precursor ALL 
chemoresistance, thus providing a strong rationale for the inhibition of 
prosurvival gene transcription. In this study, I investigated the role and feasibility 
of the epigenetics-regulating BET family of proteins as therapeutic targets. I 
showed that BRD4 is ubiquitously expressed in paediatric ALL tumours and that 
treatment with the BET protein inhibitor JQ1 led to potent in vitro sensitisation of 
ALL tumour cells regardless of cellular phenotype, as well as in vivo 
sensitisation using xenograft models of ALL. I observed strong in vitro synergy 
in ALL cell lines and primary tumours treated with a combination of JQ1 and 
dexamethasone. Using microarray technology I confirmed BET protein inhibition 
involves transcriptional downregulation of prosurvival pathways and identified 
potential biomarkers predictive of JQ1 sensitivity. I characterised the cellular 
effects of BET protein inhibition in pre-B ALL and showed this was associated 
with inhibition of cell cycle progression, downregulation of c-Myc protein, direct 
inhibition of DNA replication and induction of caspase-dependent apoptosis that 
was independent of p53 activity. Thus, pharmacological inhibition of BET 
proteins provides an alternative strategy by which to downregulate prosurvival 
signaling and target B-precursor ALL. Finally, I explored PIM kinases that co-
operate with BET proteins during the regulation of transcription as alternative 
therapeutic targets in B-precursor ALL. I was able to show this therapeutic 
approach holds promise, and warrants further study.  
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1. INTRODUCTION 
1.1. Overview 
Leukaemias are the most common malignancy of childhood with acute 
lymphoblastic leukaemia (ALL) accounting for approximately 25% of all 
paediatric tumours [1]. ALL is a disease that affects both children and adults of 
all ages, with prevalence peaking between the ages of 2 and 5 years [2]. This 
disease is characterised by deregulation of the B-cell development process that 
can result in a block at specific stages of differentiation and uncontrolled clonal 
proliferation of early lymphoid progenitor cells of either T- or B-cell lineage, 
which invade the bone marrow, peripheral blood, and organs such as the liver 
and spleen [2].  Although ALL can occur in either cell lineage, Pre-B ALL 
accounts for the greatest proportion of cases (80%) in comparison to pre-T cell 
ALL (15%) [3].  
As recently as the 1960s ALL was largely untreatable with nearly all cases 
proving fatal [1]. However, major improvements in paediatric haematology and 
oncology, together with independent clinical and molecular risk-stratification 
over the past 40 years have successfully increased overall survival to over 80%. 
Nevertheless, ALL is still a major cause of morbidity and mortality in children 
around the world with over 15% of patients suffering from disease relapse 
following first line therapy[1]. This, together with the fact that current treatment 
options lead to significant toxic side-effects, provide the rationale for the 
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requirement of alternative therapies with far less toxic consequences, whilst 
remaining specific and effective in reducing the burden of leukaemia [1]. 
1.2. Clinical classification of paediatric ALL 
1.2.1. B-cell differentiation  
Since ALL represents the proliferation of lymphoid progenitor cells that are 
unable to fully differentiate, it is important to consider B-cell development within 
the context of ALL. 
Haematopoietic stem cells (HSCs) are pluripotent progenitor cells that may 
differentiate into either lymphoid cells (B- and T- lymphocytes), or myeloid cells 
(red blood cells, granulocytes, megakaryocytes, and macrophages) depending 
on the cellular signals they receive [4]. Mature immunocompetent B-cells are 
required for the production of antibodies essential to the adaptive humoral 
immune response. The formation of mature B-cells is a highly complex and 
tightly regulated process, which begins with B-cell lineage commitment of HSCs 
in the bone marrow compartment, and ends with the production of mature B-
cells in secondary lymphoid organs such as the liver, thymus, and spleen, which 
also maintain proliferation and differentiation of HSCs throughout most of 
embryonic development [4]. 
Several transcription factors play critical roles in determining the cell fate of 
HSCs. The commitment of HSCs to the lymphoid lineage is regulated by 
transcription factors such as E2A, Early B cell Factor (EBF) and Pax5 [5-7]. 
Such transcription factors are essential for maintenance of B cell progenitors 
through the various stages of B cell differentiation and ensuring normal B cell 
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lymphopoiesis takes place. Thus, deregulation of B cell development often 
leads to malignant transformation, including B-precursor ALL [4].  
More specifically, B-precursor ALL in particular is characterised by lymphoid 
cells showing maturation arrest within the late pro-B, large pre-B, and small pre-
B stages of differentiation, meaning this type of leukaemia may be subdivided 
into pro-B (null), common, and pre-B ALL, respectively [8].  
1.2.1.1. The early stages of B cell development 
In order for a common lymphoid progenitor cell to undergo full maturation into a 
mature B cell capable of producing antibody, it must go through several stages 
of differentiation. These stages include the common lymphoid progenitor, the 
early B cell, the pro-B, pre-BI, pre-BII cells, and the immature B cell, before 
ending with the mature B cell [8, 9]. Rearrangement of the variable, diversity, 
joining, and constant regions of the immunoglobulin heavy chain (IgH) takes 
place at specific stages of the maturation process, together with the expression 
of a number of surface markers that allow for the identification and classification 
of different subtypes of leukaemia [8].  
1.2.1.2. Immune system gene rearrangements 
The development and maturation of B cells is required for the generation and 
expression of unique B cell receptors (BCRs), which specifically bind to new or 
recurrent antigens encountered by the human body [10]. The BCR is an 
immunoglobulin (Ig) expressed on the B cell membrane and consists of a 
heterodimer of matching pairs of Ig heavy chains (IgH) and two Ig light chains 
(IgL). 
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Figure 1.1: Stages of B-cell development 
a)  Rearrangement of the immunoglobulin heavy and light genes (H and L, 
respectively) during B-cell development. 
b) Expression of markers that are characteristic of specific stages of B-cell 
differentiation and are used to identify leukaemia subtypes.  
(n, nuclear; c, cytoplasmic; *, not expressed in all cells of this type; µH, µ heavy chain 
surface expression; V, variable; D, diversity; J, joining; AUL, acute undifferentiated 
leukaemia; cALL, common ALL) 
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These portions of the BCR are peptides with a C terminal region that exists in a 
limited number of forms, and which determines the class and effector function of 
the respective antibody molecule. Five classes of antibody exist, namely α 
(IgA), δ (IgD), ε (IgE), γ (IgG), and μ (IgM), with each class being specialised for 
the particular method by which it binds, neutralises and removes antigens [10]. 
However, the IgH and IgL heterodimer is itself unable to activate biological 
responses following the binding of a specific antigen. It is the disulphide-
coupled heterodimer of Igα (CD79a) and Igβ (CD79b) located towards the C-
terminal region of the IgH and IgL peptide chains that transduces the binding of 
specific antigens into alterations in intracellular signalling pathways. The IgH 
and IgL heterodimer contains the variable amino acid sequence (antibody 
variable region) that give rise to the binding specificity required for antigen 
recognition, and it is the ordered expression and assembly of these components 
of the BCR that allow for the definition and characterisation of each stage of B 
cell development [11]. 
1.2.1.3. VDJ recombination 
In order for clonal diversity to be achieved, the genes encoding the IgH and IgL 
chains contain constant and variable regions that made up of segments know 
as V (variable), D (diversity), and J (joining), and are arranged and put together 
by a tightly regulated, site-specific recombination process known as VDJ 
recombination [4]. This process is essential for the adaptive immune function of 
the lymphocyte, and consists of rearrangement of the D and J fragments, after 
which the V fragment is joined to the DJ fragment. This occurs first in the heavy 
chain loci, then in the light chain loci, and is a process regulated by enzymes 
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encoded by recombination activating gene (RAG)-1 and RAG-2 [12, 13]. The 
fact that there are over 200 variable (VH), 30 diversity (DH), and 6 joining (JH) 
IgH chain genes means that a very large number of rearrangement 
combinations are possible [14-16]. Enzymes involved in DNA double strand 
(DSB) repair, such as DNA-PK, XRCC4, Artemis and DNA ligase IV, are all 
involved in the re-ligation of cleaved segments of V, D and J genes [17]. Further 
diversity is also attained by imprecise relegation of gene segments, as well as 
the random insertion of nucleotides between segments by the enzyme terminal 
deoxynucleotidyl transferase (TdT) [18]. The pro-B stage of B development is 
the first stage that exhibits B cell lineage commitment and is characterised by 
rearrangement of IgH. The pro-B stage may be further divided into sub-phases 
according to the extent of heavy chain recombination. When the heavy chain is 
in the germ line state, this is described in humans as early pro-B. The point at 
which D and J segments are recombined is known as pro-B. Finally, the point at 
which V-DJ recombination has occurred is known as pre-B I [4].  
In the pro-B stage, chaperone proteins such as calnexin associate with Igα and 
Igβ, which are expressed on the cell surface [19]. Once the IgH chain is 
recombined, it is assembled together with Igα and Igβ, as well as IgL chain 
components, and expressed as an immature pre-BCR on the surface of the B 
cell membrane. Expression of this receptor marks entry into the pre-B stage of 
development [20].  
Any errors during the VDJ recombination process or assembly of the pre-BCR 
components, prevents any further B cell development due to a block in signal 
transduction from the immature receptor, preventing pro-B cells from entering 
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the pre-B stage and instead leading to apoptosis. Cells in the pre-B stage 
undergo recombination of the IgL chain V and J fragments, allowing for the 
assembly of the BCR and marking the entry of cells into the pre-B I step [21-24]. 
The proliferative state and expression of surface markers also allow for the 
identification of pro-B and pre-B stages of B cell differentiation. Pro-B and pre-B 
stages are characterised by waves of VDJ recombination followed by waves of 
proliferation that do not occur simultaneously. These waves of activity are 
initiated and maintained by tightly regulated expression of recombinase 
associated genes 1 and 2 (RAG1 and RAG2) during G0, which encode two 
enzymes that are key to VDJ rearrangement and are then degraded before cells 
enter into S phase [25]. Keeping these two waves separate is important since 
VDJ rearrangement is associated with non-homologous recombination and 
would increase the mutation rate during DNA replication. The proliferative pro-B 
and pre-B stages of differentiation are often found to be deregulated in B cell 
ALL and so it is suggested that failure in keeping DNA replication and VDJ 
recombination separate during B cell development could be a factor in blocking 
differentiation and driving leukaemogenesis [4].  
1.2.1.4. Immunophenotypic classification 
Previous studies investigating immunological markers of lymphoid leukaemias 
provided invaluable information regarding cell lineage and stages of 
differentiation of leukaemia cells, which consequently greatly improved the 
precision with which ALL is diagnosed [26].   
 8 
 
The maturation of HSCs into fully developed B cells is associated with changes 
in gene expression that modulate the presence of a variety of surface markers. 
Examples of such markers are the receptor and ligand proteins known as 
cluster of differentiation (CD) molecules. Studies that began including the 
assessment of immunologic markers revealed that immunophenotypically 
distinct subpopulations of ALL correlated with specific molecular and karyotypic 
abnormalities, and also provided further insight into the mechanisms of 
lymphocyte signal transduction [26]. Furthermore, antigen expression studies 
led to the notion that malignant lymphoblasts were a result of normal lymphoid 
progenitor cells arrested at various stages of differentiation [27, 28]. It is 
therefore clear to see how important the recognition of lymphocyte 
differentiation antigens and specific immunophenotypes are within the context 
of this disease. 
B cells derived from common lymphoid progenitors are known to express CD34, 
CD10, and CD45 [29]. However, the pan B cell marker CD19 is not expressed 
and it is uncommon for surface CD127 (IL-7R) and nuclear TdT to be expressed 
[30].  
Common lymphoid progenitor cells that enter the early B cell stage of 
differentiation begin to express B-lineage specific genes such as the Vpre-B 
and cytoplasmic CD79a (cCD79a) genes, which encode components of the 
surrogate light chain [31, 32]. Cells at the pro-B stage of B cell differentiation 
express CD34 and CD19, and sometimes CD10 [33].  
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Cells that are at the pre-B-I stage express surface markers CD34, CD45, CD10, 
and CD19. Nuclear TdT is also expressed at pre-B-I [34]. Further maturation 
into the pre-B-II stage is characterised by loss of nuclear TdT expression, along 
with CD34 [8]. At this point CD79 may be expressed, which coincides with 
expression of surface μ heavy chains [35]. 
Immature B cells express CD10, CD19, IgM, and increasing levels of CD45. 
Further development to mature B cells is characterised by loss of CD10 and 
surface IgD expression [8, 34]. 
Generally, B cell ALL expresses an immunophenotype that is similar to normal 
B cell progenitors and is characterised by the expression of CD34, CD19, 
cytoplasmic CD79a and nuclear TdT. In addition to these surface markers 
CD10, CD20, CD22, and CD24 are sometimes also expressed [2]. 
Surface expression of CD66c has been reported in approximately 33% of B-ALL 
cases, compared to normal B cell progenitor cells where this molecule is absent 
[36]. Other more discrete examples of deregulated surface markers during B-
cell differentiation include the expression of CD21 on CD19+CD34+ B-ALL 
cells, and not on healthy cells with a similar immunophenotype. In B-ALL, 
CD10, CD19, and CD34 are usually found to be overexpressed, whereas CD45 
and CD38 are commonly underexpressed [36]. 
1.2.2. Morphological classification 
Morphology was for many years a main criterion for primary diagnosis of ALL 
and may be used to differentiate this type of leukaemia from acute myeloid 
leukaemia. The diagnosis of ALL is defined as malignant lymphoblasts being in 
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excess of 5% of the total number of cells in the bone marrow, equating to at 
least 108 lymphoblasts in a 1010 total cell count. 
Morphological classification of ALL first began in 1976 and followed guidelines 
devised by the French-American-British (FAB) Cooperative Group, which 
described three morphological subtypes: L1, L2 and L3 [37, 38]. The L1 subtype 
consisted of small lymphoid cells that contained hardly any cytoplasm but had 
regular nuclei exhibiting homogenous chromatin and no nucleoli. The incidence 
of this subtype in B-ALL is approximately 25-30%. The L2 subtype consists of 
larger heterogeneous cells with cytoplasm and a nucleus with an irregular 
shape that contains net-like chromatin and nucleoli. This particular subtype is 
observed in approximately 65-70% of cases. The third subtype L3, is used to 
describe homogenous cells with a basophilic cytoplasm containing vacuoles. A 
prominent nucleolus and chromatin with a speckled appearance is also 
descriptive of the L3 subtype, which is observed in 5-10% of cases [39]. 
Although cytochemistry is best used for distinguishing ALL from myeloid 
leukaemias, use of morphological examination by light microscopy together with 
cytochemistry often proves to be of limited use, since distinction between the 
subtypes can at times be subjective and difficult. B-ALL lymphocytes tend to 
exhibit a morphology resembling the L1 and L2 subtypes.  ALL of the L3 
subtype is reported to be very similar to Burkitt’s lymphoma in terms of 
biological characteristics and in response to chemotherapy, highlighting the fact 
that the FAB classification system is on its own inadequate [40]. Indeed, 
following recommendation by the World Health Organisation (WHO), 
morphological examination is currently not routinely used for diagnostic 
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purposes. Instead, other more robust methods of diagnosis and risk 
stratification making use of immunophenotype, molecular features and 
cytogenetics have been subsequently adopted [41]. 
 
1.3. Aetiology of paediatric precursor B-cell ALL 
1.3.1. Epidemiology 
Approximately 30% of all cancers that are diagnosed under the age of 15 years 
are leukaemias [42]. Within the UK an estimated 370 children aged 0-14 years 
are diagnosed with ALL every year, whilst the incidence of ALL in Europe 
equates to 35 cases per million children every year [1]. ALL incidence peaks at 
2-5 years of age [43], and is slightly higher in males compared to females, at a 
sex ratio of 1.3:1.0 [44]. A distinct difference in the occurrence of ALL among 
black and white children exists, where the incidence among white children is 
almost 2-fold greater. There is also substantial variation in annual international 
rates, where incidence for males is estimated to range from 9-47 per million 
males, and from 7-43 per million for females [45, 46]. A previous study showed 
that the incidence of lymphoid leukaemias in the UK and Europe between 1978 
and 1997 was rising in children at a rate of 0.6% per year, and in adolescents at 
a rate of 1.9% per year [47].  
1.3.2. Genetics of ALL 
Very little evidence exists for ALL being a directly inheritable disease. Only a 
few sporadic cases exist, involving mothers that suffered from leukaemia whilst 
pregnant [48], and other cases where the offspring of individuals that were 
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treated for paediatric cancer also developed leukaemia themselves [49]. The 
exact pathogenic mechanism leading to ALL still remains unclear. However, 
years of research have led to many interesting observations and associations 
being made, indicating a predisposition towards the development of ALL (Table 
1.1).  
1.3.2.1. Predisposing syndromes 
There are a number of heritable disorders that are known to predispose 
individuals to the development of ALL.  
The incidence of Down’s syndrome (DS) in new-born children within the UK is 
estimated to be 750 babies every year, which equates to approximately 1 in 
every 1000 babies. It is a chromosomal condition caused by the presence of all 
or part of an extra chromosome 21 (trisomy). The association of DS and an 
increased risk of leukaemia development in patients was first described in the 
late 1950s [50], generally occurring within the first 4 years of birth [51]. Although 
some variation in the reported relative risk for ALL exists, most studies have 
found that patients with DS are up to 20 times more likely to develop ALL [52]. 
The pathogenic events leading up to the development of ALL in DS patients 
remains largely unknown. Recent studies have provided evidence for the 
cooperation of multiple genetic events, such as chromosome aneuploidy, 
submicroscopic deletions of genes involved in cellular proliferation and 
differentiation, namely CDKN2A, ETV6, and PAX5, and also activating 
mutations of the JAK2 gene in the development of leukaemia in these cases 
[53]. The observation that these genetic alterations appear to be selective for 
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trisomic cells, suggest a multi-hit model for the development of ALL in DS 
patients [54]. 
Ataxia telangiectasia (AT) is a rare autosomal recessive disease that is 
commonly diagnosed in early childhood and is characterised by cerebella 
ataxia, immunodeficiency, increased sensitivity to ionising radiation, and a 
predisposition to developing lymphoid malignancies [55, 56], including pre B-cell 
ALL [57]. Over 100 mutations have been found among AT patients that span 
across the coding region of the ataxia telangiectasia mutated (ATM) gene [58-
60], of which approximately 80% are believed to encode either a truncated 
protein product or no protein at all [58, 60, 61]. Modelling studies using ATM -/- 
mice have also provided much insight in to the pathogenesis of lymphoid 
tumour development in AT patients [62]. 
Nijmegen breakage syndrome (NBS) is another chromosomal instability 
syndrome, which differs from AT with respects to presenting clinical features, 
but is very similar in terms of radiosensitivity and predisposition to developing 
cancer [63].  In 1998, mutations in a gene involved in double-strand break 
(DSB) repair, NBS1, were identified and are thought to be responsible for many 
of the characteristic features of NBS [64-66]. Like with AT, NBS patients suffer 
from an increased incidence of induced chromosomal aberrations, which may 
give rise to tumour formation, with over 90% of NBS-associated cancers being 
lymphoid malignancies [63]. 
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1.3.2.2. Inheritable germline polymorphisms 
With respects to the B-lymphoid lineage, development of haematopoietic stem 
cells into healthy B-cells is dependent upon tight regulation of various stages of 
differentiation by multiple transcription factors that determine lineage 
commitment, repress signalling that promotes alternate lineage fates, and 
ultimately drive the maturation of B lymphocytes. Over 65% of patients suffering 
from B precursor ALL have genetic alterations that disrupt healthy B-cell 
development [67, 68]. 
Inherited genetic syndromes, such as AT and DS, constitute less than 5% of 
ALL cases [69]. The heritability of other predisposing factors that may influence 
ALL susceptibility are of great interest and still largely unknown. Data from large 
familial cancer registries indicate a heritable component to developing ALL [70]. 
However, until recently no clear susceptibility genes had been discovered, 
prompting the use of higher resolution genome-wide approaches to identify 
recurrent somatic alterations and gene polymorphisms. In recent years, an 
association between multiple low-risk gene variants, such as those involving the  
nicotinamide N-methyltransferase (NNMT) and reduced folate carrier (RFC1) 
genes, and an increased disease risk have become apparent [71]. 
1.3.2.3. Genetic alterations in B-cell development genes  
The recent use of high-resolution, single-nucleotide polymorphism arrays and 
genomic DNA sequencing approaches have helped identify oncogenic lesions 
that disrupt pathways involved in the regulation of B-cell differentiation and 
contribute to B-cell ALL pathogenesis. 
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The transcription factor PAX5 is the only PAX gene of nine family members to 
be expressed in the haematopoietic system [72]. PAX5 is necessary for the 
commitment of lymphoid progenitor cells to the B-cell lineage, and does this in 
co-operation with the early B-cell factor EBF1 [73]. Absence of PAX5 activity 
results in blocked B cell development, since its main functions are to maintain 
the appropriate gene expression program required for B cell lineage specificity 
[7, 74]. PAX5 induces expression of B-cell specific genes such as CD19, CD72, 
CD79A and BLNK, and ensures repression of genes encoding Notch1 and the 
macrophage colony-stimulating factor receptor (Csflr), required for T-cell 
lineage commitment and myeloid cell development, respectively. Genome-wide 
analysis studies have revealed that copy number alterations of the PAX5 gene 
are most common and occur in 29.7% of B cell ALL patients, with deletions 
occurring almost exclusively in a dominant leukaemic clone [67]. 
EBF1 is a transcription factor necessary for the normal development of B cells, 
co-regulating the expression programme required for B-cell lineage specificity 
together with TCF3, also known as E2A [67]. Mice lacking the EBF1 gene have 
B-cells arrested at the pro-B cell stage of differentiation, whereas mice with one 
allele of the EBF1 gene have a normal number of pro-B cells, but also 50% less 
mature B-cells, suggesting haploinsufficiency of this gene as a possible driving 
factor for leukaemogenesis [75]. A recent study also confirmed a synergistic 
initiation of ALL between EBF1 haploinsufficiency and STAT5 in mice [76]. 
Mono-allelic deletions of EBF1 occur in ALL at a frequency over approximately 
3%, and have been shown to play a significant role in ALL pathogenesis [67]. 
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The Ikaros family of transcription factors are essential for B-cell development 
and consist of the Ikaros, Aiolos, and Helios proteins, each expressed as 
multiple isoforms through alternative gene splicing, and share the capacity to 
heterodimerize [77]. Some of these isoforms confer dominant-negative activity 
when dimerized and so tight regulation of the splicing machinery is therefore 
required to avoid abnormalities that may otherwise lead to malignancy. Indeed, 
mouse modelling of the gene encoding Ikaros, Ikaros family zinc finger 1 
(IKZF1), involving targeted deletion of exons 3 to 5, led to the splicing of a 
dominant-negative isoform and gene inactivation, resulting in a complete lack of 
lymphocytes [78]. The Ikaros transcription factor, activates CD19 and down-
regulates genes that are not B-cell lineage specific, such as CD4 [79]. Genome-
wide association studies have confirmed that 15% of pre-B ALL cases harbour 
focal deletions of the IKZF1 gene. Although alterations of the PAX5 gene occur 
more frequently in ALL, they do not correlate with poor treatment outcome [68], 
compared to cases with IKZF1 gene alterations, which occur less frequently yet 
are strongly associated with a poor treatment prognosis in both high-risk BCR-
ABL1 positive ALL [80, 81], and the novel subtype of ‘BCR-ABL1-like’ ALL [68, 
82].  
The ARID5B gene encodes a protein belonging to the ARID family of 
transcription factors, and is involved in cell growth, embryonic development, and 
regulation of gene expression [83]. Double-knockout mouse models exhibit 
disrupted B-cell development, suggesting that germline alterations of ARID5B 
may disrupt its function in lymphoid differentiation [84]. Consequently, genome-
wide studies have confirmed that the presence of genetic polymorphisms within 
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the ARID5B gene predispose patients to the development of ALL. An interesting 
finding is that alterations of the ARID5B gene are enriched in cases of 
hyperdiploid ALL and are also associated with increased accumulation of 
methotrexate polyglutamate, resulting in better responses to treatment [85, 86]. 
 
1.3.2.4. Cytogenetic abnormalities 
Cytogenetic translocations that activate specific genes are a key characteristic 
of ALL. Apart from holding high prognostic value, they are largely responsible 
for the fact this disease is so biologically heterogeneous [2, 87]. Translocations 
tend to occur among genes that encode transcription factors that are critical to 
the regulation of B-cell differentiation [87]. The resulting fusion gene may then 
encode a fusion protein with oncogenic characteristics. 
The t(12;21)(p13;q22) translocation is associated with younger age and low 
white cell count (WCC) is the most frequent translocation in pre-B ALL, 
occurring in approximately 25% of cases [39, 88]. This cytogenetic alteration 
results in the fusion of the ETV6 (TEL) and RUNX1 (AML1) genes. More 
specifically, the helix-loop-helix (HLH) domain found at the N-terminus of the 
TEL gene, along with the RUNT domain and the transactivation (TA) domain of 
the AML1 gene located at the N-terminus and C-terminus of AML1, 
respectively, are retained and encode the chimeric fusion protein TEL/AML1 
[89, 90]. The protein TEL is a member of the ETS-like family of transcription 
factors, and plays a key role in the development of haematopoietic stem cells 
within the bone marrow [91], whereas AML1 is a subunit of the Core Binding 
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Factor (CBF) transcription factor, essential for foetal liver haematopoiesis [92]. 
The TEL/AML1 fusion protein consists of the 336 amino-terminal region of TEL, 
fused to residues 21-480 of the transcription factor, AML1 [93-95]. The retained 
HLH and TA structures cause the TEL/AML1 fusion protein to have an 
increased affinity for co-repressor proteins such as mSin3 and N-CoR (a 
subunit of the nuclear receptor co-repressor complex that exhibits histone 
deacetylase activity), leading to leukaemogenic activity due to abnormal 
repression of TEL and AML1 target genes [89, 90]. 
The second most common translocation occurring at a frequency of between 3 
to 6% of all cases of paediatric ALL and over 23% of all cases of pre-B ALL [96] 
is t(1;19)(q23;p13.3) E2A/PBX1 [97]. The E2A/PBX1 chimera is a fusion of the 
transactivation domains of E2A and the DNA-binding homeodomain region of 
the PBX1 gene [98]. The E2A gene encodes two different protein products 
known as E12 and E47 via alternative splicing [99]. Both E12 and E47 are 
members of the class I family of basic helix-loop-helix (bHLH) proteins and were 
found to bind to E box sequences within promoter and enhancer elements of 
genes encoding immunoglobulin (Ig) [99]. For this reason it was postulated that 
both E2A gene products regulate Ig locus activation and the development of B-
cells. This was later confirmed by targeted disruption of the E2A locus in mice 
[100, 101], which led to the arrest of B-cell development at the early pro-B stage 
of differentiation, and before the start of Ig heavy chain rearrangement.  
The Philadelphia chromosome was the first chromosomal translocation to be 
associated with malignancy and is caused by a t(9;22)(q34;q11) translocation 
[102], resulting in fusion of the 5’ region of the BCR gene to the 3’ region of the 
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ABL1 gene. When expressed, this fusion gene generates an oncogenic chimera 
protein known as BCR/ABL1, which acts as a constitutively active receptor 
tyrosine kinase. Multiple breakpoints in the BCR gene give rise to the 
expression of fusion products with molecular weights of 190, 210 and 230 kDa 
[103]. BCR/ABL1 is detected in B-cell ALL at a frequency of 3% in children and 
25% in young adults [104]. The abnormally increased tyrosine kinase activity 
leads to the upregulation of prosurvival signalling pathways that can cause high 
resistance to treatment [105]. 
The MLL gene located at position 11q23 encodes a DNA-binding protein that 
methylates histone H3 K4 (H3K4) and is known to fuse with over 100 
translocation partners in ALL and acute myeloid leukaemia [106, 107]. MLL is 
found rearranged in 5-8% of paediatric ALL cases, with rearrangements 
occurring in an estimated 80% of infants aged less than a year old at diagnosis 
[108, 109]. The 5’ portion of the MLL gene is believed to translocate with the 3’ 
portion of the partner gene, leading to leukaemogenic effects [107]. The most 
frequent MLL translocation is the t(4;11)(q21;q23)/MLL-AFF1, formerly known 
as AF4 [106, 107]. The next most frequent translocation is 
t(11;19)(q23;p13.3)/MLL-ENL. Fusions of MLL with AF6/6q27, AF9/9p211 and 
AF10/10p12-14 also occur, albeit very rarely and without any age-specificity 
[103]. Of all ALL cases involving translocations of the MLL gene, 70-80% are 
infants (less than 1 year of age), and of these infants approximately 50% 
harbour the t(4;11) translocation [110]. HOX genes are transcription factors 
involved in the regulation of the haematopoietic system [111]. MLL plays a key 
role in regulating HOX genes in order to maintain normal development, and it 
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has been shown that MLL fusion proteins lose their H3K4 methyltransferase 
activity, which greatly enhances transcriptional activity and the expression of 
Hox genes [112]. Consequently, this has been shown to cause disruption of 
normal stem cell growth and lineage commitment, and therefore drive 
leukaemogenesis [113, 114]. 
An estimated 3-5% of paediatric ALL cases have a structurally abnormal 
chromosome 21 containing inversions, deletions, and duplications along the 
long arm of chromosome 21, known as intrachromosomal amplification of 
chromosome 21 (iAMP21) [115, 116], which is commonly detected in children 
with ALL aged between 7 and 13 years old [117]. iAMP21 has been shown to 
be strongly associated with chromosomal instability of chromosome 21, which in 
turn is also associated with recurrent abnormalities observed in B-precursor 
ALL that affect the expression of genes essential for B-cell development such 
as IKZF1 (22%) and PAX5 (8%) [118]. A common feature among all cases is 
the amplification of a 5.1Mb region between 21q22.11 and 21q22.12, which 
includes the RUNX1 gene encoding AML1, as well as a 1Mb deletion at 
chromosome ends found in approximately 80% of patients [118-120].  
High hyperdiploidy is the most common genetic abnormality in ALL, occurring in 
approximately 30% of children with this disease. This type of chromosomal 
abnormality is most frequent in younger patients with a low WCC and an 
phenotype resembling B cell precursors [121]. This condition is defined as the 
gain of between 5 and 19 chromosomes, which would take the total number of 
chromosomes per leukaemic cell to between 51 and 65 chromosomes [122]. 
The majority of trisomies and tetrasomies occur from the gain of specific 
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recurring chromosomes, namely chromosomes 4, 6, 10, 14, 17, 18, 21 and X 
[123].  
Hypodiploidy, defined as cells containing fewer than 44 to 45 chromosomes is 
observed in an estimated 6% of paediatric ALL cases and can fall into three 
different subgroups [124]. 
The first subgroup occurs in an estimated 1% of children suffering from ALL, 
which have a karyotype that is near-haploid as opposed to being diploid. In 
these children it is uncommon for them to only have between 25 and 28 
chromosomes, meaning the majority of chromosomes only have one copy. 
Chromosomes 10, 14, 18, 21, X and Y are rarely lost [124].  
The second hypodiploidy subgroup, known as low hypodiploidy, is defined by 
the presence of between 30 and 39 chromosomes, where karyotypes are 
commonly monosomic for chromosomes 3, 7, 15, 16 and 17, and disomic for 
chromosomes 1, 6, 11 and 18 [124, 125].   
Although only observed at a very low frequency of 0.2% of ALL cases, strong 
evidence exists to suggest a third hypodiploidy subgroup known as high 
hypodiploidy also exists. This subgroup is defined as those ALL patients with 
between 40 and 45 chromosomes. Although there is debate regarding the 
upper limit of the number of chromosomes in high hypodiploid ALL, the 
exclusive presence of t(9;22), t(12;21), and t(1;19) chromosomal translocations 
in high hypodiploidy is a feature that helps to distinguish this subgroup from low 
hypodiploidy [124, 126]. 
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1.3.3. Risk factors associated with ALL development 
1.3.3.1. High birth weight 
Studies have shown that birth weight is modulated by various genetic traits and 
exposures during the gestation period. Epidemiological studies have highlighted 
a positive association between high birth weight and the development of ALL 
[127, 128], especially in girls, where female babies weighing over 4000 g were 
almost twice as likely to develop ALL compared to female babies weighing less 
[129]. The biological mechanisms behind such observations remain speculative 
and unclear; however, it has been suggested that insulin-like growth factors 
(IGFs) may play a role in this association [130, 131]; supported by the fact IGFs 
influence both foetal growth [132], and the likelihood of developing cancer [133]. 
In addition to this, stem cell pool size has also been shown to be associated 
with birth weight, which may increase the risk of developing ALL since IGF 
along with other growth factors increase the total number of replicating cells and 
therefore also increase the risk for cells becoming tumorigenic [128].  
1.3.3.2. Ionising radiation 
The first observation that prenatal exposures could lead to the development of 
ALL in children was first made over 40 years ago by the Oxford Survey of 
Childhood Cancers. An association was made between mothers receiving 
diagnostic X-rays whilst pregnant and the development of ALL in their children 
[134, 135], which was supported by animal studies confirming that in utero 
exposures to ionising radiation and various chemical carcinogens did in fact 
increase the likelihood of cancer developing in the offspring [136]. Further 
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studies also revealed that ionising radiation affected foetuses and children more 
than adults, and more specifically that radiation dose and gestational age were 
of greatest importance [137, 138].  
The idea that leukaemia risk is increased in offspring of individuals exposed to 
low doses of external ionising radiation has been subject to much controversy in 
the past, with many case-control studies conducted near nuclear power plants 
producing contradictory data and being unable to confirm this [139]. Hitherto, 
the lack of complete and comparable data from the exposed work forces 
involved in these studies, together with the fact that nowadays workers are 
exposed to greatly reduced doses of radiation, has made it difficult to draw 
additional human data. However, one particular study based on a substantial 
amount of good data was conducted in 1990 by Gardner et al [140]. Findings 
from this study suggested an association between paternal occupational 
exposure to ionising radiation at the Sellafield nuclear power plant and 
leukaemia incidence in their offspring. Fathers with a cumulative lifetime dose of 
100 mSv or greater before conception, were over eight times more likely to 
have their children develop leukaemia. 
1.3.3.3. Non-ionising radiation 
Throughout the past few decades there have been huge increases in the 
generation of man-made power sources, with electromagnetic fields now being 
thousands of times greater than those which occur naturally. The potential role 
for residential exposures of extremely low-frequency electromagnetic fields 
(ELF-EMF) in the causation of childhood leukaemia was first brought to light in 
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1979, following data published by Wertheimer and Leeper that suggested an 
association [141]. Their findings have since raised substantial public concern 
and provoked further scientific investigations into this area.  
Studies involving the use of animals and cell line models have provided no 
evidence to support the idea that exposure to power frequency fields may lead 
to carcinogenesis. With respects to magnetic force field exposures, a study 
involving over 3000 cancer cases and 10000 control cases from North America 
and Europe reported that exposures to magnetic fields of up to 0.4 μT did not 
lead to increases in relative risks relative to the no-effect level [142]. Although 
inconclusive, the same study also reported a 2-fold increase in cancer incidence 
in 0.8% of cases exposed to magnetic fields above 0.4 μT. With regards to 
electrical field exposures, far fewer studies exist but have so far found no 
evidence to support the association of electrical fields with paediatric 
leukaemias in the UK. 
1.3.3.4. Infection 
It is well documented that certain infectious and parasitic agents, such as 
HTLV-1 in T-cell leukaemia and lymphoma, and Epstein-Barr virus (EBV) in 
Burkitts lymphoma, are able to cause cancer [143]. With respects to childhood 
ALL, there have been no reports of a specific virus being a causative agent. 
However, a series of observations have maintained the idea of infection playing 
a significant role in the development of ALL, and have led to the generation of 
three key hypotheses. 
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In 1988, Kinlen suggested that there was an above average incidence of 
leukaemia in young people living in the vicinity of two nuclear reprocessing 
plants in the UK and that this was due to exposure to new viruses in regions 
that were previously mainly rural and not so densely populated, which were 
transmitted from infected newcomers to susceptible inhabitants already present 
[144]. The reported increase in frequency of leukaemia in children aged 0 to 4 
years in areas where substantial degree of population mixing existed supported 
this theory. 
In 1988, Greaves first presented his two-hit hypothesis that the development of 
ALL was a consequence of at least two separate, spontaneously-occurring 
mutations [145]. He proposed that the first mutation occurs in utero or during 
early infancy and that this first hit is most likely to occur in B-cell precursors, 
since they are highly proliferative and susceptible to spontaneous mutation 
during early stages of development in the liver and bone marrow. This would 
give rise to a pre-leukaemic clone of B-cells. The second mutation occurs post-
natally after an average of 3-4 years during the infant’s first exposure to 
antigens and subsequent proliferation of antibody-producing cells, which then 
drives the leukaemogenic process. 
Greaves also suggested that the timing of an individual’s exposure to antigens 
in early infancy may play an important role in the development of childhood 
leukaemia [145]. Delays in exposure to antigens and infection might lead to an 
accumulation of pre-leukaemic lymphoid cells that were susceptible to acquiring 
the second spontaneous mutation and lead to overt leukaemia. Therefore a 
child’s response to infection and the risk of developing leukaemia may be 
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affected by many factors such as the duration of breast-feeding, genetic 
background, socioeconomic status, and vaccinations, which all modulate the 
timing and level of positive feedback stimulation in lymphoid precursor cells 
[146]. Case-control studies have supported Greaves’ hypothesis, with results 
showing that a statistically significant increase in the risk of developing ALL 
exists if there is a delay in an individual’s exposure to infections, and other 
studies also reporting that exposure to infection early on in infancy confers a 
statistically significant protective effect [147, 148]. 
Maternal breast feeding has proved to be important in providing a means by 
which children are exposed to infection in early infancy and protected from 
developing leukaemia. A paper published by the UK Childhood Cancer Study 
(UKCCS), in which a total of fifteen case-control studies looking at the 
protective effects of breast feeding were reviewed, showed that overall 
leukaemia risk was decreased in children who were breast fed, and that longer 
duration of breast feeding was associated with an enhanced protective effect 
against the development of leukaemia [149]. It is postulated that the protective 
effect may be due to modulation of a child’s immune system during early 
infancy to respond to infections effectively in later life [150]. 
Studies investigating the effects of different socio-economic status levels and 
their effect on leukaemia incidence have shown that richer families with higher 
status are associated with an increased incidence of childhood leukaemia, with 
as much as a two-fold difference in peak incidence observed between most 
affluent and least affluent countries [151].  
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Table 1.1: Aetiological risk factors for ALL 
The above table summarises risk factors associated with the development of B-
precursor ALL that have been described in section 1.3. 
 
 
 
• Age (peak incidence 2-5 years) 
• Gender (males at greater risk) 
• Ethnicity (white children at greater risk) 
• High birth weight 
• Genetics: 
o Inheritable syndromes: 
 Down’s syndrome (DS) 
 Ataxia telangiectasia (AT) 
 Nijmegen breakage syndrome (NBS) 
o Germline polymorphisms (e.g. NNMT and RFC1 genes) 
o Alteration of B-cell development genes (e.g. PAX5, EBF1, IKZF1, ARID5B) 
o Cytogenetic abnormalities: 
 t(12;21)ETV6-RUNX1 (TEL/AML1) 
 t(1;19) E2A-PBX1 
 t(9;22) BCR/ABL1 
 MLL gene rearrangements 
 iAMP21 
 Ploidy 
• Environmental factors: 
o Ionising radiation (e.g. X-rays) 
o Non-ionising radiation (e.g. Extremely low-frequency electromagnetic fields) 
o Infection (i.e. delayed exposure) 
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1.3.3.5. Two-hit model for ALL tumorigenesis  
Many studies have shown evidence that support the idea of tumorigenesis 
being a multi-step process, first suggested in 1953 by Carl Nordling [152], which 
involves the accumulation of multiple genetic alterations that cause instability 
within the genome and promote the transformation of normal human cells into 
malignant tumour cells. Many diagnosed cancers demonstrate an age-
dependent incidence, whereby an average of four to seven rate-limiting genetic 
alterations appear to be required for highly malignant tumours to form, following 
progression through multiple pre-malignant states into more aggressive cancers 
capable of metastasis; a process not very different to the principles of Darwinian 
evolution, whereby a distinct growth advantage is acquired [153]. Cells cultured 
in vitro require the introduction of multiple genetic alterations for transformation 
to occur, with rodent cells requiring at least two genetic alterations and human 
cells being slightly harder to efficiently transform [154]. Transgenic mouse 
models have also supported the idea that multiple rate-limiting steps are 
required for tumorigenesis. The ‘Knudson hypothesis’ derived from 
retinoblastoma studies in 1971 supports this concept and states that two 
mutational events are required to allow cancer to form. One of the mutations 
may be hereditary, or both may occur in somatic cells [153]. 
Monozygotic twin studies conducted by Mel Greaves investigating the natural 
history of leukaemia, closely relate to the two-step model proposed by Knudson. 
Using Guthrie cards with bloodspots taken from new-borns, Greaves showed 
that in most cases of ALL the TEL-AML1 translocation exists and occurs 
prenatally [155]. He also found that in ALL discordance rates amongst twins are 
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approximately 90%, suggesting that leukaemic clones initiated by TEL-AML1 
fusions, for example, are insufficient to cause overt leukaemia and require a 
second postnatal ‘hit’ [156]. The peak in childhood ALL incidences at 2-5 years 
of age is therefore thought to be a reflection of the time taken for the second 
genetic alteration to take place following the first leukaemia-initiating lesion. The 
fact that the disruption of multiple cellular processes, such as proliferation, 
differentiation, and apoptosis, is commonly required for leukaemogenesis to 
occur, also provides support to the concept of at least two mutational events 
being needed for complete leukaemic transformation. 
Despite the large number of cytogenetic abnormalities that exist in ALL, there is 
limited evidence for a single causal event in the aetiology of this disease, and 
so a “two-hit” model of leukaemogenesis is more applicable. Events which 
occur after the first hit and which are likely to drive the leukaemic 
transformation, may be derived from genetic, environmental, or other unknown 
factors.  
1.4. Presentation and patient management  
Presenting symptoms of ALL are mainly due to the expansion of lymphoblast 
populations within the bone marrow (commonly >90% blast cell infiltration), as 
well as the infiltration of other body organs. The most common symptom of 
patients with ALL is fever, occurring in approximately 55% of cases [157]. Many 
children also show presenting symptoms such as pallor, lethargy, recurrent 
infection (due to the suppression of normal haematopoiesis), swollen or tender 
lymph nodes, liver or spleen (due to leukaemia involvement and enlargement of 
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haemopoietic organs), as well as bone and joint pain [158, 159]. However, 
some clinical findings require special consideration, such as respiratory 
complications resulting from severe anaemia, mediastinal obstruction, or 
respiratory infection [157]. Although rare, complications also arise when white 
cell counts reach levels greater than 100x109/L, which can lead to leukostasis 
and cause respiratory and neurological events. In severe cases, where counts 
reach greater than 400x109/L, haemorrhages within the central nervous system 
may occur [160]. 
Painless enlargement of the testis in males indicates testicular involvement. 
Bone marrow aspirates and flow cytometry are used to identify the 
immunophenotype of the leukaemia in order to determine the lineage and stage 
of differentiation of the leukaemic cells, and allow for appropriate minimal 
residual disease monitoring by flow cytometry. Cytogenetic and molecular 
genetic techniques are then used to identify those patients that are at highest 
risk and to allow for correct treatment stratification and to consider use of 
molecularly targeted therapy if appropriate [69, 161-163]. 
1.5. Risk stratification 
Risk stratification of patients is used to determine the relative risk of treatment 
failure and disease relapse. Stratification also ensures that the most aggressive 
forms of treatment are only given to those patients who are in the high risk 
category, thus sparing patients at lower risk from suffering unnecessary toxic 
side-effects. However, this does not imply that low-risk patients should not 
receive treatment intensification, since this is necessary in order to avoid 
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increased relapse rates [2]. Patients may be categorised into one of three risk 
groups: standard, intermediate, and high risk.  
Advances in treatment and refinement of treatment protocols over recent years 
have led to patient survival rates now exceeding 80% [164, 165]. Studies 
showed that adolescents and young adults who were treated using adult 
protocols showed poor response, whereas patients from the same age-groups 
fared far better when treated with paediatric protocols instead [166-168]. 
Likewise, although national studies have shown that black children have a 
poorer outcome, independent institutions have reported high cure rates similar 
to those seen in white children [169].  Many clinical and biological variables that 
previously served as prognostic factors in ALL are today rendered obsolete, 
with treatment regimen now being the most important indicator of prognosis 
[163]. 
 
1.5.1. Prognostic factors 
Age is a strong prognostic indicator of treatment outcome among patients with 
B cell ALL [170]. Studies conducted at St Jude Children’s Research Hospital 
showed that children aged 1 to 9 years had a significantly better outcome than 
either infants or adolescents [171, 172]. Additionally, studies showed that 5-year 
event-free survival rates were estimated to be 88%, 73%, 69%, and 44% for 
children aged 1 to 9 years, adolescents aged 10 to 15 years, those aged over 
15 years, and babies aged less than a year, respectively [173, 174].  
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An equally strong prognostic indicator of outcome is leucocyte count, with 
higher counts correlating with poorer outcomes [172, 175]. Some patients may 
suffer from extreme hyperleukocytosis, defined as a WCC greater than 
400x109/L, and are at an increased risk of complications such as CNS 
haemorrhage. Leucostasis may also occur, and lead to neurological and 
pulmonary events [160]. In order to compare responses to treatment in children 
with leukaemia, a risk-classification system was made which incorporated both 
age and WCC, and defines that children aged between 1 and 9 years with a 
WCC <50x109/L have a standard risk of suffering from relapse, and those in the 
same age group with a WCC >50x109/L are at high risk [171]. However, this 
method of risk assessment has its drawbacks since almost a third of standard 
risk patients may relapse and amongst high-risk patients it is difficult to 
differentiate between those at the highest risk requiring stem cell transplantation 
[171]. 
Gender has also been shown to influence patient prognosis in ALL. A study 
involving over 4000 cases of paediatric ALL treated on MRC UKALL trials 
showed that girls fare significantly better than boys, with 5-year event-free 
survival rates of 51-71% and 31-57%, respectively, independent of age and 
leucocyte count [176]. Furthermore, the MRC UKALL X trial provided data that 
showed girls stratified into the high-risk group with a diagnostic WCC >100x109/L, exhibited a similar prognosis to boys with a lower WCC. 
Consequently, a risk scoring system was derived, taking sex, age and WCC into 
consideration, and which demonstrated an improved discrimination between 
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standard and high-risk groups, with the latter consisting of 16% boys and 3% 
girls [176]. 
There are many frequently occurring chromosomal aberrations that act as 
prognostic markers in B cell ALL [117, 177-182] (Table 1.2).  
1.5.2. Recognition of high-risk ALL 
Relapsed ALL is very heterogeneous and still observed in over 15% of patients. 
Although many paediatric cases are successfully treated, a significant 
proportion of patients fail to regain stable remissions, with relapse rates of 2%, 
23% and 75% being observed in standard-, intermediate-, and high-risk groups, 
respectively [1]. Attempts to elucidate the prognostic value in cytogenetics of 
either diagnostic or relapsed ALL have proven difficult. This is largely due to the 
lack of primary tumour sample availability and matched diagnostic-relapse 
samples, the lack of large clinical trials, and the heterogeneic nature of relapsed 
ALL. However, recent developments in genomic array technology have allowed 
for improvements in our understanding of the genetic events that lead to relapse 
[1].  
Almost 75% of paediatric ALL cases exhibit aneuploidy or chromosomal 
rearrangements, many of which are associated with a favourable prognosis, for 
example TEL-AML1 and hyperdiploidy with >50 chromosomes. Previous 
studies using experimental models have shown that some alterations, such as 
TEL/AML1, are incapable of inducing leukaemia on their own, and support the 
notion that additional co-operating genetic alterations are needed to induce 
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overt leukaemia [183-187]. In contrast, a poor outcome is associated with MLL 
rearrangements, BCR-ABL1, and hypodiploidy.  
A significant number of paediatric ALL samples from high-risk cases do not 
harbour any of the well-known chromosomal alterations observed in ALL [67]. 
As a result, great efforts have been made in using genomic approaches such as 
array-based comparative genomic hybridisation and single-nucleotide 
polymorphism (SNP) microarrays, candidate gene sequencing, next-generation 
sequencing, transcriptome sequencing, and whole-genome sequencing to 
identify novel genetic alterations not observed by cytogenetic analysis [67, 68, 
188, 189] (See section 1.3.2.3 and 1.3.2.4).  
ALL lymphoblasts acquire fewer large structural genetic alterations compared to 
solid tumours. However, they do contain approximately 50 chromosomal 
regions that are frequently subject to alterations such as focal deletions that 
target genes encoding proteins with essential roles in cellular signalling 
pathways. Such affected pathways include lymphoid development and 
differentiation (e.g., IKZF1, PAX5 and EBF1), cell-cycle regulation and tumour 
suppression (e.g., CDKN2A, CDKN2B (INK4/ARF), TP53, PTEN), lymphoid 
signalling (CD200 and BTLA), regulation of apoptosis (BTG1) [67]. Many of the 
genes in these pathways may be targeted for mutation by a number of different 
mechanisms, namely loss-of-function and dominant negative deletions, 
translocations, and sequence mutations [67]. Recent studies have reported the 
identification of genetic alterations associated with inferior outcome to treatment 
and that may be significantly associated with an existing subtype of ALL, or 
even define entirely novel subtypes with their own distinct gene expression 
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profiles. Such novel subtypes in ALL include those harbouring rearrangements 
of the CRLF2 gene, focal deletions of ERG, and intrachromosomal amplification 
of chromosome 21 [118, 190-192]. 
BCR-ABL1 positive leukaemia 
A common feature of chronic myeloid leukaemia (CML) and a subset of ALL is 
the expression of a constitutively active form of the tyrosine kinase BCR-ABL1, 
which confers an aggressive type of leukaemia associated with a poor response 
to therapy [193]. Interestingly, it has been shown that deletions and sequence 
mutations of the lymphoid transcription factor gene IKAROS (IKZF1) are 
associated with BCR-ABL1-positive leukaemia and are capable of inducing the 
onset of leukaemia in mouse models [194]. Furthermore, lymphoid leukaemias 
with alterations in the IKZF1 gene that do not express BCR-ABL1 are also 
associated with a poor outcome, indicating a key role for IKZF1 in treatment 
failure [68]. Since IKZF1 is involved in the regulation of normal lymphoid 
development, it is thought that perhaps the loss of IKZF1 activity may lead to 
leukaemia cells adopting a phenotype akin to that of stem cells, which are 
innately more resistant to therapy [68, 190]. These studies suggest that 
targeting IKZF1 activity and its downstream pathways may allow for improved 
outcomes in patients with this subtype of ALL. 
Overall, detection of the BCR-ABL1 translocation in paediatric cases of B-
precursor ALL requires treatment intensification and consideration of treating 
the patient with monoclonal antibodies (mAbs) or tyrosine kinase inhibitors 
(TKIs) that specifically target the BCR-ABL1 fusion protein [195, 196]. 
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BCR-ABL-like ALL 
In recent years, a novel ALL subgroup was discovered which had a gene 
expression profile very similar to that of BCR-ABL1 ALL, but which did not 
express the BCR-ABL1 oncogene [68, 192]. BCR-ABL-like ALL is associated 
with a poor outcome and typically harbours alterations of the IKZF1 gene, which 
is thought to be the genetic alteration to substitute BCR-ABL1 [68].  
Studies have shown that BCR-ABL1-like leukaemias may be divided into two 
groups based on the genetic alterations, which cause constitutive activation of 
cytokine receptor and tyrosine kinase signalling [191]. Rearrangements of the 
cytokine receptor-like factor 2 (CRLF2) gene, located at the pseudoautosomal 
region of Xp/Yp, are observed in approximately half of all BCR-ABL1-like ALL 
cases [191, 192]. CLRF2 is capable of heterodimerising with interleukin 
receptor 7α (IL7R) to form the thymic stromal lymphopoietin receptor (TSLPR) 
[197]. Translocations, focal deletions, and point mutation of the CRLF2 gene 
result in deregulated expression of CRLF2 that may be detected by flow 
cytometric immunophenotyping at diagnosis [102, 190]. Almost 50% of ALL 
cases harbouring rearranged CRLF2 also have activating mutations in the 
Janus kinase genes [192]. Most mutations occur within the vicinity of the R683 
codon of the pseudokinase domain of JAK2, but may also occur in the 
pseudokinase domain of JAK1, as well as the kinase domain of JAK1 and JAK2 
[192]. The transforming capacity of CRLF2 mutations has been demonstrated in 
studies where coexpression of CRLF2 and JAK mutant alleles led to the 
transformation of cell line models [192, 198]. In addition to this, the JAK-STAT 
pathway is activated in human cells that harbour rearrangements of the CRLF2 
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gene, and is successfully inhibited with the use of selective pharmacological 
JAK inhibitors [199]. Interestingly, alterations of the IKZF1 gene have been 
shown to be associated with mutations of CRLF2 and JAK genes, and confer a 
poor treatment outcome [192, 200]. Consequently, much interest is going into 
the downregulation of the JAK-STAT pathway [201, 202], and phase I trials 
(COG ADVL1011 trial) are underway to determine whether the JAK inhibitor 
ruxolitinib could be introduced into current treatment protocols alongside 
conventional chemotherapeutic drugs currently being used to treat relapsed 
ALL [188].  
The second subtype of BCR-ABL1-like ALL cases is characterised by the 
expression of wild-type CRLF2 together with a number of genetic abnormalities 
such as the expression of fusion proteins that encode constitutively active 
tyrosine kinases (EBF1-PDGFRB, STRN3-JAK2, and BCR-JAK2), activating 
mutations in the transmembrane domain of IL7R, dysregulation of cytokine 
receptors (IGH@-EPOR), and deletions in the SH2B3 gene, encoding the 
adaptor protein Lnk that acts as a negative regulator of JAK2 [203]. Cell line 
models and primary tumours cells expressing the EBF1-PDGFRB fusion protein 
or IL7R mutant alleles are capable of inducing cellular transformation and 
activate the JAK-STAT signalling pathway [189]. Large clinical trials involving 
high-risk ALL patients have also confirmed that many of these genetic 
abnormalities occur frequently in BCR-ABL1-like ALL [188, 204].  
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Hypodiploid ALL 
Hypodiploidy in ALL is associated with an unfavourable prognosis and until 
recently not much was known about the genetics of this particular ALL subtype 
[124]. Studies using large-scale genomic profiling techniques to investigate a 
large cohort of hypodiploidy ALL cases have confirmed that near-haploid ALL 
cases exhibit a high frequency of deletions and mutations capable of activating 
the Ras signalling pathway [188]. Near-haploid (24 to 31 chromosomes) and 
low-hypodiploid (32 to 44 chromosomes) cases of ALL exhibit inactivation of 
transcription factors essential for normal lymphocyte development; features 
distinct from hypodiploid ALL. Some of these alterations involve genes in the 
IKAROS gene family, as well as genes involved in Ras signalling, such as NF1, 
KRAS, and NRAS [188]. 
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Table 1.2: Prognostic markers of high-risk ALL at presentation 
The above table summarises prognostic criteria for high-risk B-precursor ALL 
requiring more intense forms of therapy. 
 
 
 
 
• Age (<1 and years of age)
• White cell count (>50x109/L)
• Gender (Males at greater risk of poor 
treatment response)
• Cytogenetics: 
o Hypodiploidy ( 44 chromosomes)
o BCR-ABL1 gene rearrangements
o Amplified AML1 (iAMP21)
o MLL gene rearrangements
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1.6. Treatment of paediatric ALL  
Treatment of paediatric B-cell ALL typically involves the administration of 
multiple chemotherapeutic drugs in three distinct phases: the remission-
induction phase, an intensification/consolidation phase, and a 
continuation/maintenance phase. The first two phases together may last up to 
approximately 12 months, whereas the continuation phase typically lasts a 
further 2-3 years [196, 205]. Treatment is also directed towards the CNS as 
soon as possible to avoid relapses due to infiltration of leukaemic cells in this 
site [163]. 
1.6.1. Phases of chemotherapy treatment 
1.6.1.1. Remission-induction phase  
Current UK practice is such that in B-precursor ALL the first treatment phase is 
designed to reduce the initial leukaemia burden to below 1% and allow for 
normal haematopoiesis to recommence [163]. This involves the administration 
of a glucocorticoid (dexamethasone), vincristine, pegylated L-asparaginase, 
intrathecal methotrexate, and 6-mercaptopurine, typically over a period of 5 
weeks [196, 205]. Cases of ALL in the standard-risk group generally respond 
well when treated with the three-drug induction regimen (Regimen A) if it is 
followed by intensified therapy involving intrathecal methotrexate and 6-
mercaptopurine over a period of 3 weeks, whereas high-risk patients may 
receive four or more chemotherapy drugs [163].  
Responses to therapy are monitored by measuring submicroscopic ALL present 
in the bone marrow and peripheral blood of remission patients, known as 
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minimal residual disease (MRD) [206-208]. Generally, MRD is monitored 2 
weeks following the initiation of treatment. If residual lymphoblasts are above 
1%, treatment is intensified. Remission-induction therapy is largely successful, 
with 96-99% of paediatric ALL cases reaching clinical remission [163]. With 
respect to steroid drugs used to treat ALL, studies have shown that 
dexamethasone confers superior efficacy than either prednisone or 
prednisolone, since it has a longer half-life and penetrates the CNS more 
readily [209, 210]. Despite these findings, other reports also show that 
increased doses of prednisolone may be just as effective as treatment with 
dexamethasone [211]. 
1.6.1.2. Consolidation/intensification phase 
Once normal haematopoiesis is restored, the risk of relapse is reduced by 
intensifying treatment to eliminate the residual leukaemia cells that may reside 
in the bone marrow and other organs [163]. Treatment regimens in this phase 
follow on from the remission-induction phase and lasts 3 weeks. It includes the 
administration of intrathecal methotrexate on days 1, 8 and 15, the dose for 
which is dependent upon the patient’s age, together with daily oral doses of 6-
mercaptopurine [196, 205].  
Intensification therapy has proven to be very effective in the treatment of ALL 
and is a key component of current treatment protocols [163]. Additionally, a 
randomised study showed that two courses of intensification improved the 
outcome of patients compared to those patients who received only a single 
course followed by additional pulses of the glucocorticoid prednisone and 
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vincristine [212], suggesting that increasing the dose-intensity of drugs used 
during intensification therapy was far more beneficial to patients.  
The intensification phase incorporates an ‘interim maintenance I’ phase (I.M. I) 
that lasts 8 weeks and involves the administration of dexamethasone and 6-
mercaptopurine to standard-risk patients. This is followed by a single ‘delayed 
intensification I’ phase (D.I. I), serving as reconsolidation therapy, and 
consisting of the administration of 6-mercaptopurine for the duration of 7 weeks. 
Standard-risk patients that are MRD-positive at day 28 after having received 
standard therapy as part of Regimen A are transferred to Regimen C and 
receive a second 8-week round of dexamethasone and 6-mercaptopurine as 
part of ‘interim maintenance II’  (I.M. II) therapy, followed by a second round of 
delayed intensification (D.I. II) [196, 205]. 
1.6.1.3. Continuation/maintenance phase 
Patients with ALL require continuation treatment as a final phase of therapy to 
prevent relapses occurring, and so receive an additional phase of continuation 
therapy for up to 2.5 years as standard [213]. Generally, over 65% of paediatric 
ALL cases can be treated successfully within a year of therapy [214]. The key 
components of continuation therapy regimens include daily 6-mercaptopurine 
and weekly methotrexate, along with discontinuous doses of dexamethasone 
and vincristine, over a period of 112 weeks for girls and 164 weeks for boys.  
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1.6.2. Late complications and therapy-associated toxicity 
Intensive intrathecal and systemic treatment involving chemotherapeutic agents 
such as methotrexate and the glucocorticoid dexamethasone can lead to 
various complications in patients. The use of glucocorticoids may lead to short-
term complications including infection, myalgia, myopathy, hyperglycaemia, 
adrenal axis suppression and behavioural problems [215], with more severe 
and long-term side-effects of including osteonecrosis, joint collapse, and the 
requirement for complete replacement of the joint [216, 217]. Risk factors for 
developing treatment-related osteonecrosis include age between 10-20 years, 
white race, female sex, and a high body mass index [216-218]. Although the 
pathogenic events leading to glucocorticoid-induced osteonecrosis are not yet 
fully understood, it is believed that intravascular thrombotic occlusion, adipocyte 
hypertrophy, and bone marrow ischemia, as well as apoptosis of endothelial 
cells, osteoblasts, and osteoclasts may be responsible [215]. Intermittent 
administration of dexamethasone at days 1-7 and 15-21 of intensification 
treatment instead of continuous administration has been shown to reduce the 
toxic side-effects significantly [219]. However, studies are still on-going to 
determine whether or not this approach has a negative impact on maintaining 
lymphoblast counts below acceptable levels. 
Anthracyclines, such as doxorubicin and daunorubicin, may lead to severe 
cardiomyopathy that may persist for many years after treatment, especially 
when administered to female patients and at high cumulative doses [220]. 
Dexrazoxane is a drug used to counteract the negative effects associated with 
the use of anthracyclines, and has been shown to reduce cardiotoxicity without 
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compromising antileukaemic activity [221, 222]. However, current trials still limit 
the use of anthracyclines even for high-risk patients, since some cases of 
cardiotoxicity are so severe [69]. 
1.6.2.1. Stem cell transplantation 
Allogeneic haemopoietic stem-cell transplantation (SCT) is recommended for 
patients failing to respond to treatment, or that show a slow early response to 
remission-induction therapy indicated by the presence of more than 1% 
leukaemic blasts [69]. However, although SCT is a highly effective form of 
therapy, its use must be frequently reviewed as many new agents become 
available that may supersede this form of therapy in terms of efficacy, toxic 
side-effects and the ability to improve treatment outcome [223].  
Previous studies have shown that transplantation does not improve the 
outcome of patients with hypodiploid ALL [181] or MLL-rearranged ALL [109, 
182, 224], but is recommended for high-risk patients with BCR-ABL1-positive 
ALL that do not respond well to the remission-induction treatment that consists 
of intensive chemotherapy combined with a tyrosine kinase inhibitor such as 
imatinib mesylate [69]. 
1.6.3. Minimal residual disease 
Responses to therapy are monitored by measuring submicroscopic ALL present 
in the bone marrow and peripheral blood of remission patients, known as 
minimal residual disease (MRD) [206-208]. MRD measurements are used in 
conjunction with common prognostic factors to be able to stratify patients 
according to risk, and give an indication as to whether treatment intensification 
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is required [225-227].  UK protocols assess treatment response by taking bone-
marrow aspirations and performing morphological analysis at day 8, ± day 15, 
and day 28 following the start of induction therapy. MRD monitored at weeks 4 
and 11 using quantitative polymerase chain reaction (PCR)-based methods is 
also used to assess the risk of relapse [1]. Many previous studies provide 
evidence that poor clearance of leukaemic blasts from the bone marrow or 
peripheral blood is associated with a poor prognosis in ALL and that MRD 
measurements are valuable even in low-risk cases of ALL if defined by clinical 
and biologic features alone [228, 229]. Conventional techniques based on cell 
morphology lack sensitivity and accuracy in detecting leukaemic blasts and can 
only do so when the total population of leukaemic blasts constitute greater than 
5% of the total cell population (clinical remission is defined by a reduction of 
lymphoblasts below 5%)  [162, 171]. The PCR technique is able to detect 
leukaemia cells with a 100-fold increase in sensitivity over conventional 
morphology-based techniques (1 lymphoblast in 10,000 healthy cells) and is the 
preferred method for measuring MRD at very low levels (<0.01%), allowing for a 
more accurate prediction of relapse in individual ALL cases [162, 163, 230, 
231]. The detection of MRD by PCR involves the amplification of breakpoint 
fusion regions of chromosomal aberrations in B cell ALL, such as TEL/AML1, 
BCR-ABL, E2A-PBX1, and MLL fusion transcripts, which give this method its 
tumour-specificity [232]. However, some scepticism exists regarding the 
accuracy of using these markers of MRD to predict the risk of relapse, since it 
has been reported that clinical relapse did not occur for over 27 months in some 
cases that were still MRD-positive [233]. MRD may also be detected by PCR 
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amplification of antigen receptor gene rearrangement sequences in individual 
patients. The Ig and TCR gene loci contain many recombined V, D, and J gene 
segments, which when combined with random interstitial nucleotide insertions 
and deletions, provide unique tumour-specific sequences ideal for measuring 
MRD by PCR analysis [234]. Although, Ig and TCR gene rearrangements are 
ideal targets for MRD detection in individual patients, some tumours exhibit 
oligoclonality at diagnosis and may be subject to further rearrangements or 
deletions [234]. It is therefore current practice to amplify at least two sequences 
in order to avoid false negative results [39]. Over 95% of ALL patients harbour 
Ig and TCR rearrangements, namely IGH (>95%; predominantly VH-JH), IGK 
(~65%; predominantly Kde), IGL (15-20%), TCRG (~55%), TCRD (~40%), 
TCRB (~35%), and Vδ2-Jα29 (40-45%) [235, 236]. 
A second method of detecting MRD is by identifying tumour-specific 
immunophenotypes associated with ALL using multiple-channel flow cytometry. 
Abnormal phenotypes that are indicative of ALL disease, are identified using 
antibodies with specificity against surface expression of antigens such as CD19, 
CD34, TdT, CD10, CD22, CD45, CD38, and CD45 [161, 237, 238]. Flow 
cytometry allows for direct quantification of MRD as opposed to extrapolation 
from a PCR product. This method has the potential to be more accurate than 
PCR [239]. However, it does not supersede PCR techniques in terms of 
sensitivity, since flow cytometry is unable to provide consistent results when 
detecting MRD as low as 1 lymphoblast among 105 normal healthy cells. A 
further limitation with this technique is that it is dependent upon quantifying 
differences in surface antigen expression and not simply the presence or 
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absence of leukaemia-specific markers as used in PCR-based MDR detection. 
Nonetheless, large studies such as the Total Therapy Study XIII program have 
shown that MRD detection by flow cytometry holds great predictive power, 
where detectable MRD (≥0.01%) was strongly associated with higher relapse 
rates, and found to be independent of other clinical and biologic predictors of 
treatment outcome [162, 237, 240]. 
In general, studies have provided evidence to show that the persistence of MRD 
levels of 1 lymphoblast in 104 healthy cells indicates a significantly greater risk 
of a patient suffering a relapse [237, 241, 242]. Other studies have shown that 
positivity for MRD in children in clinical remission following induction therapy 
have a 5-year incidence of relapse rate of approximately 43%, increasing to 
68% if the patient continues to test positive for MRD beyond week 14 of 
maintenance therapy. This particular study also confirmed that those children 
who tested negative to MRD following induction therapy had a 5-year incidence 
of relapse rate of 10%, reducing further to 7% if those children were MRD 
negative at week 14 of maintenance therapy [240].  It is not uncommon for 
remission marrows to contain up to 1010 leukaemic blasts following induction 
therapy [243], which requires consequent consolidation and maintenance 
therapy as standard, with the intention of completely eliminating MRD.  
 
 
 
 48 
 
1.7. Apoptosis as a factor determining treatment response 
Defective regulation of apoptosis plays a fundamental role, not only in the 
development of tumours, but also their resistance to chemotherapy [244]. 
Cancer cells typically acquire multiple mutations that commonly lead to 
deregulation of signalling pathways and promote genomic instability, which in 
turn, increase the sensitivity of tumour cells to cellular stress such as that 
caused following DNA damage. Conventional chemotherapy and irradiation 
exploit this increase in sensitivity and are used with the intention of causing 
enough DNA damage to cause these tumour cells to undergo apoptosis, whilst 
attempting to minimise the damage to normal healthy cells [245]. However, 
tumour cells that acquire additional defects in the apoptotic pathways may 
become protected against cytotoxic agents and exhibit chemoresistance and 
radioresistance [245]. 
Apoptosis is a homeostatic process of programmed cellular death, which is 
activated during development and aging, and serves to maintain cell 
populations in the various tissues of the human body in a controlled manner 
[246]. Apoptosis may also be triggered by immune reactions or when 
irreparable damage is sustained to a cell through hypoxia, disease or exposure 
to harmful agents, thus acting as a defence mechanism. This prevents 
genetically damaged somatic or germ line cells from acquiring cancer-promoting 
mutations and continuing to proliferate [245].   
Previous findings in our group have shown that a subset of primary ALL 
tumours demonstrate a defect in the induction of apoptosis following exposure 
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to IR, regardless of normal p53 upregulation [247]. It was also shown that an 
association exists between in vitro resistance to apoptosis following DNA 
damage and the clinical response in vivo determined by measuring MRD. 
Furthermore, primary ALL cells that were resistant to apoptosis exhibited 
deregulated transcription of genes involved in multiple prosurvival pathways. 
When these pathways were individually targeted by pharmacological inhibition, 
this led to widely heterogeneous responses in vitro [247, 248]. Thus, an 
alternative strategy is warranted in order to counteract apoptotic resistance 
observed in ALL. 
 
1.7.1. Induction of apoptosis 
1.7.1.1. The role of tumour suppressor p53 
The p53 protein is critical to the regulation of cellular processes in response to a 
variety of intracellular and environmental stresses, such as chemotherapy, 
ultraviolet and ionising radiation, and hypoxia [249-251]. With p53 regulating 
multiple key cellular processes, it is clear to see why this protein is frequently 
inactivated by multiple mechanisms in human cancer. Mutation of the p53 gene 
is found in approximately 50% of all human cancers, and is the most common 
mechanism of inactivation [252].  Interestingly, an estimated 80% of p53 
mutations still allow a full-length p53 protein monomer to be expressed, but 
which lacks the ability to bind to DNA [253].  
Under normal conditions of cellular growth, p53 protein levels are kept low via 
interactions with its negative regulatory partner mouse double minute 2 (Mdm2). 
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The binding of Mdm2 to p53 prevents its transactivation functions and 
ubiquitinates p53, targeting it for proteosomal degradation [254]. Cellular stress 
in the form of direct DNA damage, oncogene activation, hypoxia and deprivation 
of nutrients all lead to activation and stabilisation of p53 following post-
translational modifications. When a cell is under genotoxic stress, such as that 
caused by chemotherapeutic drugs used in the clinic, stabilisation and 
activation of p53 occurs through phosphorylation of Serine-15 at the N-terminal 
region by the damage response kinases ATM and ATR, whilst checkpoint 
kinase-2 (Chk2) and checkpoint kinase-1 (Chk1) phosphorylate p53 on Serine-
20 [255]. Once activated, p53 accumulates in the nucleus and is then capable 
of regulating transcription of target genes involved in the response to DNA 
damage. Early response genes upregulated by p53 are mainly those encoding 
proteins with growth arrest and DNA repair functions, including p21, GADD45α, 
14-3-3α and MDM2 [245, 256]. If DNA damage persists and is unsuccessfully 
repaired, p53 stabilisation is maintained leading to the expression of pro-
apoptotic genes such as Bax, PUMA/NOXA and Fas/DR2 [257, 258]. 
1.7.2. The intrinsic apoptotic pathway 
A large number of non-receptor-mediated stimuli are involved in initiating 
apoptosis via the intrinsic pathway, which can be activated by intracellular 
signals in either a positive or negative way [245]. For example, negative signals 
involve the downregulation of specific growth factors, hormones and cytokines 
that inhibit programmed cell death programs and promote survival, thus 
triggering apoptosis. Other positively acting stimuli include radiation, hypoxia, 
toxins, viral infections, and free radicals [245]. Both of these types of stimuli 
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lead to changes in the inner mitochondrial membrane, which cause the opening 
of the mitochondrial permeability transition pore and a loss of the mitochondrial 
transmembrane potential. Once this occurs, two key groups of pro-apoptotic 
proteins that usually reside within the intermembrane space are released into 
the cytosol [259]. The first group of proteins include cytochrome c, 
Smac/DIABLO, and the serine protease HtrA2/Omi, which activate the caspase-
dependent mitochondrial pathway [260-263]. Cytochrome c then binds and 
activates both Apaf-1 and procaspase-9 to form a caspase-activating complex 
known as the ‘apoptosome.’ The formation of this complex causes the activation 
of caspase-9, which in turn activates downstream effector caspases-7, -6, and -
3 that cleave various substrates such as PARP1, cytokeratins, and proteins 
within the plasma membrane  [256, 264]. The second group of pro-apoptotic 
proteins consists of AIF, endonuclease G, and CAD, which are released from 
the mitochondria at a later stage of apoptosis when a cell is committed to death 
and translocate to the nucleus where they fragment DNA into pieces 
approximately 50-300 kb in size, as well as condensing peripheral nuclear 
chromatin [265-267].  
The previously described mitochondrial events are regulated by a group of 
proteins belonging to the B-cell lymphoma gene-2 (Bcl-2) family of proteins, and 
can be either pro-apoptotic (Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, and Blk) or 
anti-apoptotic (Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w, BAG, and Mcl-1). The 
expression of these proteins determines whether or not a cell commits to 
apoptotic cell death via regulation of cytochrome c release from the 
mitochondria [245]. Phosphorylation of pro-apoptotic Bad keeps this protein 
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sequestered in the cytosol bound to 14-3-3. Once Bad is unphosphorylated, it 
translocates to the mitochondria and causes the release of cytochrome c [268]. 
Bad is also capable of binding and neutralising the anti-apoptotic effects of Bcl-
XL and Bcl-2, thus promoting cell death [269]. When Bcl-2 and Bcl-XL are not 
sequestered by Bad, these proteins prevent the release of cytochrome c.  
Two additional pro-apoptotic proteins of the Bcl-2 family, Puma and Noxa, also 
play a key role in p53-mediated apoptosis. Both these proteins are upregulated 
by p53 when a cell is subjected to oncogene activation or genotoxic stress 
[245]. Overexpression of Puma in vitro has been shown to cause concomitant 
upregulation of Bax expression [270], whereas Noxa is capable of translocating 
to the mitochondria and binding to anti-apoptotic Bcl-2 family members, which 
results in the release of cytochrome c and activation of caspase-9 [271]. 
1.7.3. The extrinsic apoptotic pathway 
Apoptotic signalling by the extrinsic pathway is mediated via transmembrane 
receptors. These include death receptors belonging to the tumour necrosis 
factor (TNF) receptor gene superfamily [272], which contain cysteine-rich 
extracellular domains and a cytoplasmic domain known as the ‘death domain’ 
[273]. The death domain is essential for the transmission of apoptotic signals 
from the surface of the cell to intracellular signalling pathways. Many of the 
ligands and their corresponding receptors involved in the extrinsic apoptotic 
pathway are well characterised and include TNF-α/TNFR1 [273], FasL/FasR 
[274], Apo3L/DR3 [275], Apo2L/DR4 [276] and Apo2L/DR5 [277]. 
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Following activation of the death receptors by its corresponding ligand, the 
receptors cluster and trimerise. Adaptor proteins located within the cytoplasm 
are then recruited and bind to the receptor death domains [245]. For example, 
the adapter protein FADD binds to the Fas receptor following activation by the 
Fas ligand, whilst binding of the adapter protein TRADD and consequent 
recruitment of FADD and RIP occurs once the TNF ligand binds to the TNF 
receptor [278]. FADD then binds with procaspase-8 to form the death-inducing 
signalling complex (DISC), which leads to the activation of procaspase-8 and 
triggering of apoptosis through activation of the downstream effector caspase-3 
[245, 279].  
1.7.4. Execution of apoptosis 
Typically, cells undergoing apoptosis are subject to various biochemical 
modifications such as protein cleavage, cross-linking of proteins, DNA 
breakdown, and expression of surface markers for phagocytic recognition [280]. 
A group of highly conserved intracellular cysteine proteases known as cysteine 
aspartyl-specific proteases, or caspases, are ubiquitously expressed in most 
cell types and are key mediators of apoptosis. Caspases are expressed as an 
inactive proenzyme, which once activated, initiate a proteolytic cascade that 
serves to cleave other caspase enzymes and amplify the apoptotic signalling to 
aid rapid cell death [245]. Once activated, caspases are able to cleave protein 
at aspartic residues and cells become committed to apoptosis. There are ten 
major caspases that are grouped into three categories, namely upstream 
initiator (caspase-2, -8, -9, -10), downstream executioner (caspase-3, -6, -7), 
and inflammatory caspases (caspase-1, -4, -5) [281, 282]. The two main 
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Figure 1.2: Intrinsic and extrinsic mitochondrial apoptosis 
a)  DNA damage or endoplasmic reticulum (ER) stress are intrinsic apoptotic stimuli 
that lead to mitochondrial outer membrane permeabilisation (MOMP), and the release 
of cytochrome c. Cytochrome c then binds with APAF-1 to form the apoptosome which 
ultimately leads to the activation of caspases 9, 7 and 3. 
b) The extrinsic apoptotic pathway is activated following the ligation of death receptors 
with their corresponding ligands. This leads to the recruitment of adaptor molecules 
such as FAS-associated death domain protein (FADD) which then results in the 
dimerisation and activation of caspase 8, followed by caspase-3 and -7. (Adapted from 
Tait, W.G. & Green, D.R., Nature Reviews Molecular Cell Biology 11, 621-632, 2010) 
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pathways by which apoptosis occurs are intrinsic pathway, regulated by 
intracellular proteins, and the extrinsic pathway, which is triggered by the 
activation of Fas family of death receptors expressed on the cell surface. The 
tumour suppressor p53 is involved in triggering both these pathways; however, 
the intrinsic apoptotic pathway is its principal mechanism of action [283]. 
1.7.5. Inhibitors of apoptosis 
The c-FLIP protein is capable of inhibiting apoptotic signals mediated via the 
death receptors by directly binding to FADD and caspase-8 [284, 285]. Studies 
have shown that p53 may also play a role in the extrinsic apoptotic pathway by 
upregulation or shuttling of DR5 and Fas proteins [283, 286].  
The inhibitor of apoptosis proteins (IAPs) are a very important group of proteins 
capable of inhibiting both the intrinsic and extrinsic apoptotic pathways [287] by 
direct inhibition of caspases; some of which are nuclear factor kappa B (NFκB) 
target genes and regulate NFκB anti-apoptotic activity. Eight mammalian IAP 
family members have been identified to date, namely cellular IAP1 and IAP2 
(cIAP1 and cIAP2), X-chromosome-linked IAP (XIAP), neuronal apoptosis 
inhibitory protein (NAIP), survivin, BRUCE, livin, and testes-specific IAP (Ts-
IAP) [288]. A common feature of all IAPs is the baculoviral IAP repeat (BIR) 
domain located in the N-terminal region, which mediates the interaction with 
caspases and anti- apoptotic activity. They are approximately 80 amino acids in 
length and are able to chelate zinc ions [289]. XIAP, cIAP1, and cIAP2 inhibit 
caspase-9, -7, and -3 directly. Furthermore, it has been shown that XIAP is 
capable of promoting the degradation of inhibitor κB protein, which leads to 
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activation of NFκB and its translocation from the cytoplasm to the nucleus [290]. 
Survivin, together with the hepatitis B X-interacting protein (HBXIP), bind and 
inactivate procaspase-9, thus preventing activation of the intrinsic pathway 
[291]. 
 
1.8. The DNA damage response and treatment resistance 
Treatment of ALL relies on the stratification of patients based on prognostic 
markers such as clinical and genetic features. Furthermore, poor early blast 
clearance following remission-induction therapy is indicative of high-risk ALL 
[162]. Although major improvements in the detection and prediction of treatment 
outcome in more aggressive forms of ALL have been made over the years, not 
much was known about the molecular defects that would confer resistance and 
a poor response to therapy. Various research groups previously investigated 
differential patterns of gene expression in ALL following treatment with a single 
cytotoxic agent or a combination of drugs using gene expression arrays [292-
295]. Results from such studies provided vast amounts of information to aid the 
prediction of treatment resistance and patient prognosis in paediatric B-cell ALL; 
however, the identification of a single gene expression pattern associated with 
chemoresistance to multiple conventional cytotoxic agents used in the treatment 
of ALL has not been possible, despite many of these agents having been shown 
to exert overlapping cellular effects. This, together with the fact the multiplicity of 
genetic events observed in ALL frequently influence common signalling 
pathways, have made the discovery of novel therapeutic targets difficult [193, 
296].  
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Many chemotherapeutics drugs used to treat ALL exert their effects by inducing 
double-strand breaks (DSBs), which is an effect that can be mimicked using 
ionising radiation (IR). Using IR as a model of DNA DSBs to investigate the 
integrity of cellular responses in leukaemia cells, studies have shown that DSBs 
initiate a signalling cascade that results in the activation of both proapoptotic 
and prosurvival pathways [297, 298]. Whether or not a cell undergoes apoptosis 
is dependent upon the number of DSBs and the integrity of the DSB response 
pathway. Usually, above a certain threshold in the number of DSBs, a p53-
driven apoptotic response is initiated, and prosurvival signalling overridden. 
Thus, the integrity of the DSB response plays an important role in the formation 
and progression of lymphoid tumours, and may modulate chemosensitivity in 
ALL [299, 300]. 
1.9. Prosurvival pathways 
There are multiple molecules and pathways that modulate apoptosis. In addition 
to pro-apoptotic signalling there are also prosurvival signalling pathways, which 
create a dynamic balance of opposing signals that determine the fate of a cell.  
These pathways do not operate in isolation and a significant degree of overlap 
exists between them.  
1.9.1. The NFκB pathway 
The nuclear factor kappa beta (NFκB) protein is a transcription factor with a key 
role in regulation of the immune system by controlling the expression various 
cytokines, growth factors, and inhibitors of apoptosis [301]. However, 
pathological dysregulation of the NFκB pathway has been associated with 
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inflammatory and autoimmune diseases, as well as many cancers; particularly 
leukaemias [248]. Five mammalian NFκB family members exist: p50, p52, RelA 
(p65), c-Rel and RelB, which all have a DNA binding and dimerization domain, 
known as the Rel homology domain (RHD) [302, 303]. Through the RHD these 
transcription factors are able to form homodimers and heterodimers that 
recognise and bind to κB sites located in the promoter and enhancer regions of 
genes, thereby controlling gene expression. The RHD also allows NFκB to bind 
inhibitors of NFκB (IκB). IκB sequesters NFκB dimers in the cytoplasm, 
preventing their translocation to the nucleus [304]. The activation of NFκB 
dimers involves the phosphorylation of IκB by the IκB kinase (IKK) complex, 
which causes IκB to be targeted for ubiquitin-mediated degradation by the 26S 
proteasome [305]. This may occur in response to a wide range of stimuli and 
ultimately results in nuclear localisation of NFκB dimers, and therefore the 
expression of NFκB target genes. Unless the stimuli causing activation persist, 
NFκB provides its own negative feedback loop to terminate gene transcriptional 
activity by expressing IκBa, which results in the sequestration of NFκB subunits 
to the cytoplasm. The inhibition of apoptosis by NFκB is mediated by 
upregulation of several genes that encode anti-apoptotic proteins such as the 
IAPs, A1, TNF receptor associated factors 1 and 2 (TRAF1 and TRAF2), and 
caspase-8 FADD-like IL-1β-converting enzyme inhibitory protein (c-FLIP) [306]. 
Increased expression of the NFκB target genes cIAP1, cIAP2, TRAF1, TRAF2, 
and c-FLIP results in direct inhibition of capsase-8, whilst upregulation of XIAP 
prevents the apoptotic activity of caspase-3, -7, and -9 [307, 308]. Multiple anti-
apoptotic Bcl-2 family members such as A1, Bcl-2, and Bcl-XL are upregulated 
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by NFκB and may lead to inhibition of apoptosis by preventing cytochrome c 
release and caspase-9 activation [309, 310]. 
1.9.2. The JAK-STAT pathway 
Studies first identified the Janus kinase (JAK)-signal transducer and activator of 
transcription (STAT) pathway as a signalling pathway that mediates mammalian 
cytokine signals [311-314]. To date, seven STAT proteins (STAT1-4, 5A, 5B 
and 6) and four JAK kinases (JAK1-3 and tyrosine kinase 2 (TYK2)) have been 
identified. Activation of the canonical JAK-STAT signalling pathway involves the 
binding of a ligand, such as a cytokine, to the upstream transmembrane 
receptor. Once activated, the receptor dimerises and provides cross-activation 
of JAK kinases that are bound to the receptor. The JAK kinase then 
phosphorylates tyrosine residues located in the cytoplasmic receptor tail. 
Consequently, STAT transcription factor proteins then dock at these phosphor-
tyrosine sites, and are then phosphorylated by the JAK kinases. Phosphorylated 
STAT proteins dimerise and localise to the nucleus, where they activate 
transcription and regulate expression of their corresponding target genes [312]. 
STAT target genes include those encoding antiapoptotic factors such as the B-
cell lymphoma 2 (Bcl-2) family of proteins, genes involved in angiogenesis and 
metastasis factors such as vascular endothelial growth factor (VEGF), and 
genes involved in cell proliferation such as cyclin D1 and c-Myc [315, 316]. 
Since many of these genes are involved in proliferation and survival signalling, 
their dysregulated upregulation by STAT transcription factors is commonly 
associated with tumour-promotion. JAK-STAT signalling is also modulated by 
positive and negative regulators, which determine the magnitude and duration 
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of signals within the pathway [312, 317, 318]. Activated STAT proteins are 
capable of inducing their own expression in the form of a positive-feedback 
loop. However, negative regulators of the JAK-STAT pathway including 
suppressor of cytokine signalling (SOCS), protein tyrosine phosphatases 
(PTPs), and protein inhibitor of activated STAT (PIAS) also exist, and are 
responsible for inhibiting JAK-STAT signalling following activation [312, 317, 
318]. Studies in Drosophila have highlighted the existence of a non-canonical 
JAK-STAT signalling pathway, where unphosphorylated STAT has a role in 
directly controlling the stability of heterochromatin and regulating the activity of 
transcription machinery [319]. 
1.10. Epigenetic regulation of prosurvival gene transcription 
The term ‘epigenetics’ describes the heritable changes to a cellular phenotype 
that are a result of covalent modifications made to the nucleosome without 
altering the DNA sequence [320]. The discovery of CpG islands, 
characterisation of the human DNA methylome, and identification of novel 
histone modifications, together with the major technological advances in recent 
years, have greatly improved our understanding of epigenetics and its 
importance in maintaining normal gene expression [321]. Accumulating data 
exists to support a significant role of epigenetic modifications in ALL. For 
example, the gene encoding the negative regulator of the JAK/STAT pathway, 
SHP1, is frequently silenced by methylation in 24% of B-precursor ALL [322]. 
Additionally, studies have shown that histone acetylation plays a crucial role in 
maintaining normal regulation of the complex process of V(D)J recombination 
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during B-cell development, through a mechanism involving the IL7R/STAT5 
signalling axis and the Pax5 transcription factor [323-326].  
Chromatin is a macromolecular complex consisting of packaged DNA and 
histone proteins, and therefore contains all the heritable genetic material of 
eukaryotic cells [320]. It may be divided into two distinct regions, namely 
heterochromatin and euchromatin. Heterochromatin is typically very highly 
condensed and contains mainly inactive genes. In contrast, euchromatin 
confers a more open structure and contains the majority of active genes. Within 
chromatin, 147 base pairs of DNA are wrapped around a histone octamer 
comprising of two of each of histones H2A, H2B, H3, and H4 [320].  
The modification of DNA and histones is a dynamic process, with such changes 
being constantly made and removed by chromatin-modifying enzymes. 
Epigenetic modifications are critical to the regulation of cellular processes such 
as gene transcription, DNA repair, and replication, and it is now well known that 
deregulation of post-translational histone modifications can have serious 
consequences that contribute to many human cancers [321].  
To date, four types of DNA modifications [327, 328], and sixteen different types 
of histone modifications exist, which serve to alter the structure of chromatin, as 
well as to provide docking sites for specialised proteins that specifically 
recognise these changes [320].  
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1.10.1. Histone acetylation 
A major type of histone modification involved in modifying chromatin structure, 
DNA repair, and gene transcription is the Nε-acetylation of lysine residues. 
Acetylation functions to remove the positive charge of lysine residues, causing 
the electrostatic bonds holding histones and DNA together to weaken. 
Consequently, chromatin adopts a more ‘open’ structure associated with active 
gene transcription [320, 329, 330]. Additionally, acetylation of lysine residues 
also functions to provide the docking site required for its recognition by various 
chromatin ‘reader’ proteins containing bromodomains, and tandem plant 
homeodomain (PHD) fingers [331]. 
 
1.10.2. Histone acetylation readers and their role in regulating 
gene transcription 
The principal readers of Nε-acetylated lysine residues are a family of proteins 
containing a highly conserved binding motif known as a bromodomain. Over 40 
human bromodomain-containing proteins have been identified to date, and 
function as chromatin remodelers, transcriptional coactivators, histone 
acetyltransferases, and histone methyltransferases [332]. Until recently, 
therapeutic targeting of protein-protein interactions with small pharmacological 
inhibitors had not been possible. However, great advances in this area have 
meant that it is now possible to develop highly specific inhibitors that target the 
BET family of bromodomain proteins, consisting of BRD2, BRD3, BRD4, and 
BRDt [333, 334]. These proteins recognise epigenetic chromatin modifications, 
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such as poly-acetylated lysine residues of H3 and H4 histone tails, and play an 
essential role in the regulation of transcription and cell cycle progression [335].  
With respect to transcriptional regulation, studies have shown that BRD4 forms 
part of transcription complexes and remains bound to transcriptional start sites 
of genes expressed during the M/G1 transition, thus influencing mitotic 
progression and transcriptional elongation [336]. BRD4 recruits the positive 
transcription elongation factor complex (P-TEFb), consisting of CDK9 and cyclin 
T1 subunits, to the acetylated tails of histone H3 and H4. CDK9 subsequently 
phosphorylates the Ser2 residue of RNA polymerase II, triggering transcriptional 
elongation [337]. Despite the role in general transcription control, BRD4 activity 
seems to affect the transcription of a defined subset of growth- and survival-
promoting genes [335, 336, 338, 339]. Interestingly, the targeting of BET 
bromodomains appears to be a promising therapeutic approach following recent 
success in treating the aggressive and fatal NUT-midline carcinoma; a disease 
associated with recurrent translocations of BRD3 and BRD4 [334]. Interestingly, 
such an approach has also proven to be effective in a range of haematological 
malignancies expressing BET family proteins [340-342], with a common feature 
of these studies being the downregulation of MYC following BET inhibition. The 
c-Myc protein this gene encodes plays a fundamental role in cell cycle 
progression and survival, and is one of the most commonly dysregulated genes 
in cancer, with high expression also frequently observed in a wide range of 
haematological malignancies, including ALL [343]. Furthermore, studies in mice 
have provided striking evidence to support that BET inhibition is highly effective 
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in vivo [344, 345], and may potentially provide an alternative strategy in the 
treatment of BET protein-expressing malignancies. 
 
1.10.3. The role of PIM kinases in prosurvival gene transcription  
The PIM protein family consists of three highly conserved serine/threonine 
kinase members (PIM1, PIM2 and PIM3) [346]. The PIM1 gene was first 
discovered by cloning studies investigating retroviral integration sites in 
Moloney murine leukaemia virus (MMLV)-induced lymphomas, which showed 
that over 50% of T-cell lymphomas exhibited integration near the PIM gene 
locus and subsequent upregulation of PIM1 mRNA [347, 348]. Later studies 
using transgenic mice confirmed potent cooperating oncogenic activity between 
PIM1 and MYC [349], as well as with Bcl2, RunX2 and the E2A-PBX1 fusion 
gene [350-352]. Interestingly, MYC transgenic mice lacking the PIM1 gene 
showed that PIM2 expression was activated to compensate for PIM1 loss [353]. 
Similarly, PIM2 upregulation was found to occur as a late event in MMLV-
induced lymphomas [354] and also potently synergised with MYC [355]. 
Significant functional redundancy between PIM kinases has been shown both in 
vitro and in vivo, which is due to the high level of amino acid sequence 
homology, where PIM1 and PIM2 share 61% homology, and PIM1 and PIM3 
share 71% homology [346]. All three members of the PIM kinase family are 
ubiquitously expressed; however, their level of expression can vary between 
different cell types [356]. For example, PIM1 is most highly expressed in 
haematopoietic cells, whereas PIM2 presents at higher levels in brain and 
 65 
 
lymphoid cells, and PIM3 in breast, brain and kidney cells [356]. Through 
alternative transcription initiation, two isoforms (34 and 44 kDa) are encoded by 
the PIM1 gene that have both been shown to maintain their kinase activity 
[356]. Similarly, alternative initiation sites within the PIM2 gene have been 
reported and give rise to 3 different isoforms (34, 37 and 40 kDa), whilst only 
one protein is encoded by the PIM3 gene [357]. The PIM kinases lack a 
regulatory domain, thus they are mainly regulated at the transcriptional level 
and so are constitutively active once expressed [358, 359]. PIM1 has also been 
shown to be regulated via protein stabilisation through binding with heat shock 
proteins (HSP). For example, the binding of PIM1 protein to HSP90 leads to 
stabilisation, whereas binding to HSP70 leads to its ubiquitylation and 
proteasomal degradation [360, 361].  In contrast, protein stabilisation of PIM2 
by HSPs has not been reported.  
A wide range of cytokines and growth factors, including the interleukins and 
granulocyte-macrophage colony-stimulating factor (GM-CSF), are known to 
activate the JAK/STAT signalling pathway, which leads to rapid upregulation of 
PIM genes [346, 362-364]. Similarly, studies have shown that JAK2, BCR/ABL 
and FLT3 mutants induce the expression of PIM1 and PIM2 genes via a 
mechanism involving the activation of the NFκB prosurvival signalling pathway 
and downstream STAT transcription factors [365-368]. However, the 
relationship between PIM kinases and NFkB remains an area of debate within 
the literature, since it is not clear whether PIM is up- or downstream of NFκB 
[369, 370]. 
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Although the role of PIM kinases in B-precursor ALL has not yet been explored, 
studies have shown that PIM1 and PIM2 are frequently upregulated in several 
other human myeloid and lymphoid leukaemias, and lymphomas, such as acute 
myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), mantle cell 
lymphoma (MCL), diffuse large B-cell lymphoma (DLBLC), marginal zone 
lymphoma-MALT type (MZL-MALT), follicular lymphoma (FL), and nodal 
marginal zone lymphoma (NMZL) [357, 365, 371-375].  With respect to the 
clinical relevance of PIM kinases, high PIM2 expression is associated with 
aggressive disease in DLBLC patients [376]. Furthermore, recent studies have 
shown that PIM1 and PIM2 are also upregulated in solid tumours such as 
prostate cancer, where high levels of PIM1 protein expression (over 50% of 
prostate cancer patients) positively correlated with an inferior treatment 
outcome [357, 377].  
Studies have shown that on their own, PIM kinases only weakly transform 
mesenchymal cells to give rise to leukaemia and lymphoma [378, 379]. 
However, the synergy between PIM family members and other oncogenes such 
as MYC, results in a far greater transforming capacity [353]. Since, on its own, 
c-Myc protein overexpression leads to the induction of apoptosis, tumours must 
adapt and gain the capability to overcome this effect [353, 364]. Intriguingly, 
both PIM1 and PIM2 have been demonstrated to counteract the pro-apoptotic 
functions of c-Myc by inactivating the pro-apoptotic protein BAD through 
phosphorylation of its Ser112 residue [380]. In addition, PIM kinases 
phosphorylate c-Myc, thus increasing its stability and transcriptional activity 
[346]. Other pro-apoptotic proteins inactivated following PIM-mediated 
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phosphorylation include ASK1 and PRAS40, which are important for JNK /p38 
signalling pathways and the inhibition of mTORC1 kinase activity that regulate 
cellular growth and proliferation, respectively [381, 382]. 
More recently, PIM2 has been shown to share similar cellular functions to the 
Akt kinase downstream of the phosphatidylinositol 3-kinase (PI3K) signalling 
pathway, since both proteins regulate survival, metabolism and cell size [346, 
359, 383, 384]. Interestingly, studies have confirmed that, similar to Akt, PIM2 
promotes mRNA translation by phosphorylating and subsequently inactivating a 
ribosomal translation inhibitor known as the eukaryotic translation initiation 
factor 4E-binding protein 1 (4E-BP1) encoded by the EIF4EBP1 gene [385]. 
Furthermore, the previously mentioned phosphorylation of proapoptotic BAD by 
PIM kinases, is also observed upon activation of Akt [359]. These findings, 
together with the confirmation that PIM kinases act independently of Akt [383], 
suggest that cytokines and growth factors activate survival pathways with a 
significant degree of overlap [383].  
Intriguingly, recent studies have shown that the PIM kinases also play a role in 
regulating gene transcription by enhancing BRD4-mediated recruitment of P-
TEFb [346, 386]. More specifically, this involves the recruitment of PIM1 to E-
box DNA sequences through a direct interaction with c-Myc, which then enables 
PIM1 to phosphorylate histone H3 at Ser10 (H3S10) [386]. This allows for the 
binding of 14-3-3 proteins [387], which is then followed by recruitment of the 
acetyltransferase MYST1 that is responsible for the acetylation of histone 4 at 
Lysine 16 (H4K16) [388]. Subsequently, H4K16 provides the binding site 
required for the binding of the BET protein BRD4, which recruits P-TEFb that 
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functions to phosphorylate RNA Pol II at Ser2, thus releasing stalled RNA Pol II 
from transcriptional pause sites and promoting transcript elongation [388], as 
previously described.  
Interestingly, this highlights an alternative mechanism of Myc-regulated gene 
expression, where c-Myc promotes transcript elongation at gene promoters with 
a pre-formed transcription initiation complex, as opposed to recruiting 
transcription initiation complexes to the promoter [389]. Although it is not yet 
clear whether other PIM kinase family members regulate gene transcription in 
this way, it has been estimated that PIM1 enhances the expression of 
approximately 20% of all genes induced by c-Myc [346, 386].  
Consequently, in recent years, great effort has gone into the generation of 
pharmacological PIM kinase inhibitors [390]. One study identified the 
imidazo[1,2-b]pyridazine K00135 as a PIM kinase inhibitor, which demonstrated 
specific anti-leukaemic activity against primary AML tumour cells in vitro [391]. 
Thus, it remains to be determined whether the targeting of PIM kinases holds 
any therapeutic advantage in the treatment of B-precursor ALL. 
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1.11. Aims and objectives 
From the overview of the current status of paediatric ALL given in the 
introduction it is apparent that, despite high cure rates achieved in the last two 
decades, high levels of toxicity associated with standard chemotherapy and 
treatment resistance in a subset of patients imposes the need for new 
therapeutic approaches [1]. The results from our own laboratory suggest that 
upregulation of prosurvival pathways may represent one of the major factors in 
B-precursor ALL chemoresistance. 
Recent advances in understanding the regulation of transcription suggest two 
possibilities for the direct targeting of prosurvival cellular machinery: 
a) the inhibition of epigenetic readers as factors that recognise chromatin 
permissive for transcription  
b) the inhibition of co-factors that modify and stabilize transcription complexes. 
Therefore, the aim of my project was to use these alternative strategies to target 
prosurvival signaling in a range of B-precursor ALL tumours, and particularly 
those that exhibit treatment resistance. My approach was based on the 
hypothesis that B-precursor ALL, including high-risk ALL, can be sensitised to 
apoptosis by downregulation of survival pathway signaling via the inhibition of 
gene transcription, and that this can be achieved by targeting the BET family of 
proteins and PIM kinases. 
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Thus, the specific aims and objectives of this study were: 
• To investigate the role of BET proteins in B-precursor ALL and determine 
whether pharmacological inhibition of BET proteins leads to the 
sensitisation of tumour cells, both in vivo and in vitro.  
• To determine the effect of BET protein inhibition on gene transcription in 
pre-B ALL. 
• To characterise the cellular effects of BET protein inhibition in B-
precursor ALL. 
 
• To determine whether the PIM kinases pose as suitable candidates for 
further study, and as potential therapeutic targets in B-precursor ALL. 
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CHAPTER 2 
 
MATERIALS & METHODS 
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2. MATERIALS AND METHODS 
2.1. Primary ALL patient tumours 
The primary tumour samples used in this study were selected according to 
material availability and derived from patients enrolled in the UKALL 2003 trial, 
from the Birmingham Children’s Hospital, UK. 
Following diagnosis, stratification of paediatric B precursor ALL patients into 
three different risk groups (standard, intermediate and high risk) is defined by 
diagnostic criteria outlined in the UKALL 2003 protocol 
http://www.ctsu.ox.ac.uk/research/mega-trials/leukaemia-trials/ukall-
2003/protocol-version-7. 
The risk groups and the diagnostic features that define them are as follows: 
• Standard risk: Patients >1 and <10 years of age, with a diagnostic white cell 
count (WCC) <50x109/L, and without hypodiploidy (≤44 chromosomes), BCR-
ABL, or rearrangements of the MLL gene. 
• Intermediate risk: Patients ≥10 years of age, or that have a diagnostic WCC 
≥50x109/L, and that do not harbour lymphoblasts with BCR-ABL, hypodiploidy 
(≤44 chromosomes), or an MLL gene rearrangement. 
• High risk: All patients that exhibit a slow early response (SER) to induction 
therapy, as well as those patients harbouring lymphoblasts with BCR-ABL, 
hypodiploidy (≤44 chromosomes), an MLL gene rearrangement, or 
amplification of RUNX1 (AML1). 
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Primary ALL samples used in this study were obtained from patients during 
induction therapy. Standard risk patients were treated on Schedule A 
(dexamethasone, vincristine, pegylated L-asparaginase, methotrexate, and 6-
mercaptopurine), intermediate risk patients on Schedule B (similar to Schedule 
A, but with the addition of daunorubicin), and high risk patients on Schedule C 
(similar to Schedule B, but with the administration of higher doses of 
daunorubicin). 
Table 2.1 lists the primary ALL samples used in this study as well as available 
clinical information associated with the patients from which the samples were 
derived.  
In addition to the ALL tumours, 2 primary paediatric AML tumours (AML-1 and 
AML-2) were also included as positive controls for JQ1 anti-tumour activity. 
Clinical information for these patients can be found in Appendix 1. 
Clinical data that were available for patients used in the qRT-PCR PIM2 
expression screen can be found in Appendix 2. 
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Patient No. Age at diagnosis (years.months) 
WCC at 
diagnosis 
(x109/L) 
Clinical 
stratification Cytogenetic profile 
ALL-101 5 44.9 HIGH RISK 46 XY 
ALL-103 5.3 3.1 LOW RISK Hyperdiploid 
ALL-104 6.4 5.6 LOW RISK 46XYt(12;21) 
ALL-105 2 391.3 HIGH RISK 45xy, dic (9;20)+8, -13 
ALL-106 2.7 55.9 HIGH RISK 46XY del(1)p332p32, dup(2)q2q3),add(9)p2 
ALL-108 6.4 0.6 LOW RISK 46XY, t(12;21) 
ALL-109 13 2.7 LOW RISK 46XY 
ALL-110 2.5 7.5 HIGH RISK 46XY, t(12;21) 
ALL-111 2.7 42.9 LOW RISK 55XY, high hyperdiploid 
ALL-112 5.5 6.5 HIGH RISK Hyperdiploid 
ALL-113 1.9 10.7 HIGH RISK N/K 
ALL-114 0.7 394 Infant ALL MLL - rearrangement 
ALL-115 11 26.2 LOW RISK 47-48XX 
ALL-116 6.6 5.4 HIGH RISK 46XY, t(12;21) 
ALL-117 1.7 56 HIGH RISK 52XY,+X+4+6+7+8+21(2), 46XY(8) 
ALL-118 1 27.2 Infant ALL MLL - rearrangement 
ALL-121 2 N/K HIGH RISK Hyperdiploid 
ALL-122 3.6 3.4 HIGH RISK 46XY, t(12;21) 
ALL-123 2.6 12.1 HIGH RISK 54XX +X+4+6+14+17+18+21+21 
ALL-124 11 N/K LOW RISK 46XY, t(12;21) 
ALL-126 9 N/K Relapsed ALL Hyperdiploid 
ALL-129 2.3 87.8 N/K 47,XX,+X,t(3;22)(p25;q13)[9]/46,XX[1] 
ALL-130 7.45 40.7 N/K 55,XX,+X,ins(1;?)(q2;?),+4,+6,+10,+14,+17,+18,+21,+21[9]/46,XX[1] 
ALL-131 11 72.6 N/K t(1;19) 
ALL-132 9 24.4 N/K t(1;19) 
ALL-133 N/K N/K N/K N/K 
 
Table 2.1: Clinical information for the B-precursor ALL patients used in 
this study  
Tumours were identified by their patient number (‘Patient No.’). Data in this 
table includes the patients’ age at diagnosis, diagnostic white cell count (WCC), 
as well as details of their cytogenetic profiles. This information, together with the 
measurement of MRD at Day 28, is used to stratify patients diagnosed with B-
ALL into different risk groups and ensure they are assigned to the appropriate 
treatment regimen. (N/K = Not known; data was unavailable). 
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2.2. Tissue culture techniques  
2.2.1. Isolation and cryopreservation of mononuclear cells from 
bone marrow aspirate 
Using aseptic technique, bone marrow aspirate was carefully diluted with 10 ml 
RPMI culture medium containing L-Glutamine (Invitrogen), supplemented with 
10% foetal calf serum (Invitrogen) and 1% penicillin/streptomycin antibiotics 
(Invitrogen), all pre-heated to 37ºC in a water bath. This was then gently 
transferred to a universal tube containing 10 ml Lymphoprep (Axis-shield), 
forming two separate layers with the diluted bone marrow aspirate in the top 
layer. This was then followed by centrifugation at 1600 rpm for 25 minutes with 
no brake. The newly-formed, third middle layer containing the lymphoid 
mononuclear cells was carefully collected using a pasteur pipette, transferred to 
a new universal tube, and washed twice using supplemented culture medium at 
37ºC, centrifuging at 1600 rpm for 5 minutes on a low brake setting. Lymphoid 
mononuclear cells were counted during the second wash using a 
haemocytometer. The supernatant was discarded, leaving a pellet of lymphoid 
cells at the bottom of the universal tube. The contents of the original universal 
tube still containing the top and bottom layers were discarded, leaving behind 
residual drops of separated red blood cells. 
To prepare cells for cryopreservation, pelleted lymphoid cells were re-
suspended in cryopreservation medium at 37ºC, constituting of a mixture of 
90% foetal calf serum (Invitrogen) and 10% dimethyl sulphoxide (DMSO) 
(Sigma), at a cell density of 1.5 x 107 cells/ml. Red blood cells were also 
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prepared by re-suspending all of the red bloods cells in 1 ml cryopreservation 
medium. Cells were transferred to 1 ml Cryovials (Nunc). Vials containing 
lymphoid cells and red blood cells were appropriately labelled and placed in 
plastic containers substantially padded with cotton wool, and then stored at -
80ºC. The next day, vials were stored in the liquid nitrogen sample bank, and 
their location recorded.  
When viable cells were needed for experiments, vials containing frozen cells 
were taken from liquid nitrogen and thawed in a 37ºC water bath, before 
transferring the contents to a new universal tube, and adding 10 ml culture 
medium pre-warmed to 37ºC, one drop at a time. Cells were then centrifuged at 
1600 rpm for 5 minutes, washed in culture medium, and re-suspended at the 
required cell density. 
2.2.2. Cell line maintenance 
The following ALL cell lines were suspended in RPMI culture medium 
supplemented with 10% foetal calf serum (Invitrogen) and 1% 
penicillin/streptomycin antibiotics (Invitrogen), maintained in 75 cm2 vented cell 
culture flasks (Iwaki), and incubated in humidified incubators at 37ºC, 5% CO2: 
NALM-6 and REH were originally provided by Dr. Tony Ford (Institute of Cancer 
Research, Sutton, UK), and the NALM-17 cell line by Dr. Yoshinobu Matsuo 
(Fujisaki Cell Center, Japan). Jurkat, SD1, SUPB-15 and TOM-1 cell lines were 
obtained from DSMZ GmbH, Germany. Cells were split every 7 days at a ratio 
of 1:10. Details for the cell lines used in this study are summarised in Table 2.2.  
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Cell line 
name 
Year 
established 
Leukaemia 
type 
Sex & age at 
diagnosis 
Prognostic 
karyotype Reference 
NALM-6 1976 Pre-B cell ALL M 19 None [392] 
NALM-17 1978 Pre-B cell ALL M 9 None [393] 
REH 1975 Common-B cell ALL F 15 TEL/AML1 [394] 
SD1 1991 Pre-B cell ALL F ? BCR/ABL1 [395] 
SUPB-15 1988 Pre-B cell ALL M 8 BCR/ABL1 [396] 
TOM-1 1987 Pre-B cell ALL M 54 BCR/ABL1 [397] 
Jurkat 1977 T-ALL M 14 None [398] 
 
Table 2.2: Cell line information. 
Available information relating to the cell lines used in this study. Cell lines were 
established from leukaemia cells derived from patients diagnosed with ALL. Sex 
(M = male, F = female), age and the prognostic karyotype of each patient are 
also provided. 
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2.2.3. Chemical reagents 
The BRD4 inhibitor JQ1, and the PIM kinase inhibitor K00135 (both received as 
a 10 mM stock dissolved in DMSO), were kindly provided by Prof. Stefan Knapp 
(Structural Genomics Consortium, University of Oxford, UK). The mitotic 
inhibitor vincristine (Sigma), the topoisomerase II inhibitor daunorubicin 
(Sigma), and the synthetic glucocorticoid receptor ligand dexamethasone 
(Sigma) were dissolved in DMSO at a 10 mM stock concentration. The 26S 
proteasome inhibitor MG132 (Merck) was dissolved in DMSO at a 100 mM 
stock concentration. Aliquots of these reagents were stored at -20ºC.  
2.3. Protein chemistry techniques 
2.3.1. Extraction of total protein from viable cells 
Control and drug-treated cells were collected into separate 1.5 ml eppendorf 
tubes (Eppendorf) and centrifuged at 1600 rpm for 5 minutes at 4ºC. Culture 
medium was decanted and the pellet washed by re-suspension in ice-cold 
phosphate buffered saline (PBS). Cells were pelleted once more and PBS 
poured off, making sure to remove as much residual PBS as possible using a 
pipette. The pellet was then re-suspended in 30-60 μl UTB lysis buffer (8 M 
Urea 50 mM Tris-HCl, pH 7.5), depending on size of the pellet. Each sample 
was then subjected to a single sonication pulse lasting approximately 7 
seconds. Lysates were centrifuged at 14000 rpm for 15 minutes at 7ºC. The 
supernatants were then transferred to clean eppendorf tubes, pre-cooled on ice, 
leaving behind any cell debris. Protein samples were then snap-frozen in liquid 
nitrogen and stored at -80ºC until needed. 
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2.3.2. Total protein quantification using the Bradford assay 
Protein concentrations were determined for each sample by constructing a 
standard curve. This was done by preparing six bovine serum albumin (BSA) 
(Invitrogen) standards of increasing concentrations (0 (10 μl water), 100, 200, 
300, 400, and 500 μg/ml) and adding 10 μl of each standard in triplicate to a 96-
well flat-bottomed plate (Iwaki). The protein lysates were then loaded in 
triplicate onto the 96-well plate at a 1:10 dilution. This was done by first adding 
9 μl distilled water to an individual well, followed by 1 μl of the appropriate 
protein sample. Bradford reagent (Biorad) was then diluted 1:5 with distilled 
water, followed by addition of 200 μl of the prepared solution to each of the 
wells containing the BSA standards or protein lysate samples. After 5 minutes, 
the plate was loaded into a microplate reader (Biorad) and absorbencies 
measured at a wavelength of 595 nm. The absorbance values obtained were 
used to plot a standard curve graph with the concentration of BSA (μg/ml) on 
the x-axis and the average absorbance of the triplicate plotted on the y-axis. 
Using the mathematical equation for a straight line y=mx+c. the total protein 
concentration of each lysate was determined using the mean absorbance of the 
samples from triplicate readings (x=-c/m). Between 15 and 30 µg of protein 
were loaded for each sample. 
2.3.3. Western blotting 
2.3.3.1. SDS-PAGE 
Total protein in lysate samples was separated in an 8% polyacrylamide gel, 
consisting of 4 ml 0.1 M Tris/0.1 M Bicine (pH 8.3), 10.65 ml 30% acrylamide 
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(N, N’-methylene-bis-acrylamide) (Bio-Rad), 400 µl 10% (w/v) SDS (Sodium 
dodecyl sulphate) (Biorad), 80 µl Temed (N, N, N’. N’-tetra-methyl-
ethylenediamine) (Sigma), 200 µl 10% (w/v) APS, and 24.65 ml of sterile distilled 
water. Whilst the gel was left to set, 500 ml running buffer was prepared (0.1 M Tris 
/ 0.1 M Bicine (pH 8.3), 0.1% (w/v) SDS). 
Protein samples were prepared on ice, making sure each sample contained the 
same amount of protein. If large variations of sample volume were observed, 
samples were made up to the same volume (80 µl max.). Samples were then 
mixed with the appropriate volume of 4X Sample buffer (0.125 M Tris HCl 
pH6.8, 20% glycerol, 4% (w/v) SDS, 0.2 M DTT, 0.02% (w/v) bromophenol 
blue) and denatured for 5 minutes in a heat block at 95ºC. The samples were 
then briefly centrifuged for 5 seconds, before being loaded into the set 
polyacrylamide gel, along with a broad range protein molecular weight marker 
(Fermentas), and electrophoresed in previously prepared running buffer at 28 
mA for approximately 5 hours, or until the blue sample buffer visible within the 
gel had reached the bottom.  
2.3.3.2. Electrophoretic protein transfer 
Once electrophoresis of protein samples through the polyacrylamide gel was 
complete, protein was transferred to nitrocellulose membrane (Thermo 
Scientific) by electrophoresis at 200 mA for 16 hours in a Transphor 
electrophoresis unit (Hoefer Scientific). The transfer buffer contained 48 mM 
Tris, 390 mM glycine and 20% (v/v) methanol. Care was taken to ensure, no air 
bubbles existed between the gel and the nitrocellulose membrane, in order to 
avoid incomplete transfer of protein, and also ensure that the nitrocellulose 
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membrane was between the negatively-charged protein in the gel and the 
anode side of the transfer tank. 
2.3.3.3. Immunoblotting for transferred protein 
Once transfer of proteins was complete, the nitrocellulose membrane was 
removed from the transfer tank and left to soak in Ponceau stain (1% Ponceau 
Red in 3% (w/v) trichloroacetic acid) for approximately 2 minutes on a rocker, 
before removing the membrane from the Ponceau stain and briefly rinsing it 
with distilled water. The transferred protein bound to the nitrocellulose 
membrane was now visible as red bands, allowing for the removal of excess 
sections of membrane and cutting of the membrane into strips with a scalpel, 
depending on the size of the proteins being blotted for. Cut strips were then 
washed in Tris-buffered saline (200 mM Tris HCl, 1.36 M NaCl pH7.6, 0.1% 
Tween-20 (TBST) for 10 minutes to remove the stain, and blocked in TBST 
containing 5% milk on a rocker for 1 hour at room temperature. Blocked 
membranes were then washed in TBST for 10 minutes for a total of three 
washes, with fresh TBST wash buffer being used with each wash. At the end of 
the third wash, membranes were incubated with the primary antibody, diluted to 
the recommended concentration in TBST with 5% milk (Marvel) solution, for 1 
hour at room temperature. Antibodies recognising phospho-proteins were 
diluted to the recommended concentration in TBST with 5% (w/v) BSA 
(Invitrogen). Following incubation in primary antibody, membrane strips were 
washed in TBST for 10 minutes, three times. After the third wash, membrane 
strips were incubated in horseradish peroxidase-labelled secondary antibody 
conjugate of the appropriate anti-species, and pre-diluted to the recommended 
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concentration in TBST with 5% milk. Membranes were incubated in secondary 
antibody for 1 hour a room temperature, after which they were washed 3 times 
in TBST for 10minutes each wash. Membrane strips were briefly drained of 
excess liquid and incubated in the enhanced chemiluminescence (ECL) reagent 
(Milipore), as per manufacturer’s directions, for 1 minute. Following incubation 
in ECL, excess liquid was carefully removed from membrane strips, which were 
then placed in between two transparent acetate sheets and secured within an 
X-ray cassette with tape, whilst making sure there were no trapped air bubbles. 
The reaction between ECL substrate and the horseradish peroxidase conjugate 
leads to the production of luminol that emits light. Therefore, the ECL-treated 
membrane strips in the X-ray cassette were taken to a darkroom and exposed 
to X-ray film (Kodak) and developed in a developing system (Xograph Imaging 
Systems Compact X4). The length of time the X-ray film was exposed to 
emitted light was dependent upon the signal strength and often required 
multiple exposures to attain optimum results. Table 2.3 lists all the antibodies 
used in this study. 
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Table 2.3 Antibodies information. 
Details for the antibodies used in this study and experimental conditions under 
which they were used.  
(WB = Western blot, IF = Immunofluorescence, F = Flow cytometry, RT = Room 
temperature). 
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2.3.4. FITC Annexin V / propidium iodide flow cytometric 
analysis for the detection of apoptosis 
Cells were seeded into a 6-well plate (Iwaki) at a cell density of 1x106 cells/ml 
and exposed to 1 µM JQ1 inhibitor for 0, 24, and 48 hours (where ‘0 hours’ cells 
represented the negative control and were treated with 0.01% (v/v) DMSO 
instead of JQ1. Two additional plates were prepared in this way so as to provide 
a triplicate reading. JQ1 inhibitor was added to cells in a way that would allow 
for harvest of cells at the same time.  
At time of harvest, 2 ml of cell suspension for each treatment were transferred 
into individual flow cytometry sample tubes using a pasteur pipette. Cells were 
then washed by adding 3 ml ice-cold phosphate-buffered saline (PBS), and 
centrifuging at 2000 rpm for 5 minutes. The supernatant was then discarded, 
and cells washed with PBS once more. The required volume of 1X binding 
buffer was prepared using the 10X binding buffer contained in the apoptosis 
detection kit (BD Pharmingen) and diluting it with distilled water, after which 100 
µl 1X binding buffer was added to each tube. I then added 5 µl of FITC Annexin 
V and/or PI to the appropriate tube. Tubes were then vortexed, wrapped in 
aluminium foil and incubated for 10 minutes in the dark at room temperature. 
500 µl 1X binding buffer was then added to each tube and flow cytometry 
performed using the Beckman Coulter XL sorter. Gating of the fluorescence 
signal emitted in FITC Annexin V labelled and PI labelled cells was performed 
prior to analysis of test samples in order to be able to distinguish between the 
two different fluorophores and allow for the separation of cell populations into 
viable (FITC Annexin V and PI negative), early apoptotic (FITC Annexin V 
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positive, PI negative), and late apoptotic or dead cells (both FITC Annexin V 
and PI positive). A total of 15,000 events were collected per sample. 
2.4. Microarray study 
The microarray experiment in this study was conducted in collaboration with Dr. 
Simone Sharma at Institute of Child Health Microarray Facility, University College 
London (UCL).  
Procedures in sections 2.4.3 – 2.4.5 were performed according to instructions 
detailed in product-specific NuGen user guides 
(http://www.nugeninc.com/nugen/index.cfm/support/user-guides/). 
2.4.1. RNA extraction 
A total of 8 primary ALL tumour cells were treated with either DMSO or 1 µM 
JQ1, and then total RNA isolated using the RNeasy Mini kit (Qiagen).  
First, cells were centrifuged at 300 x g for 5 minutes and culture medium 
completely removed by careful pipetting, after which 600 µl of the supplied 
Buffer RLT was added to 0.5-1 x 107 cells. Cells were homogenised by passing 
the lysate through an RNase-free syringe fitted with a 0.9 mm syringe needle at 
least five times. One volume of 70% ethanol was then added to each lysate, 
and mixed well by pipetting. Up to 700 µl of the lysate was transferred to an 
RNeasy spin column placed in a 2 ml collection tube. The samples were then 
centrifuged at 10,000 rpm for 15 seconds, and the flow-through discarded. This 
step was repeated for the remainder of the lysate, if the sample volume 
exceeded 700 µl.  
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At this stage, the optional on-column DNase digestion using the RNase-free 
DNase kit (Qiagen) was incorporated into this protocol to eliminate genomic 
DNA contamination. This was carried out as per manufacturer’s instructions. 
Following DNase digestion, 500 µl Buffer RPE were added to each spin column 
containing the RNA samples, which were then centrifuged at 10,000 rpm for 15 
seconds. The flow-through was discarded and an additional 500 µl Buffer RPE 
were added to the spin columns, and then centrifuged at 10,000 rpm for 2 
minutes. The columns were placed in clean 1.5 ml collection tubes and 
centrifuged at full speed for 1 minute to remove any residual flow-through. The 
columns were then placed in clean 1.5 ml sample tubes (Eppendorf), and the 
RNA eluted by adding 30 µl RNase-free water directly to each column and 
centrifuging at 10,000 rpm for 1 minute, and repeating the elution step once 
more by passing the eluate through the same column. RNA samples were 
immediately placed on ice, and the RNA quality and concentration was 
determined using the ND-1000 Spectrophotometer (NanoDrop). RNA with an 
OD260nm/280nm ratio between 1.8 and 2.0 was considered of sufficient quality for 
downstream microarray applications. 
2.4.2. RNA quality control 
The 2100 Bioanalyzer (Agilent) was used to determine the integrity of RNA 
samples. The algorithm used by this machine allows for the calculation of a 
RNA integrity number (RIN), which is considered to be a reliable and 
standardised method for the assessment of RNA quality for microarray 
applications [399]. Only RNA samples with a RIN value greater than 8 were 
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deemed to be good quality RNA and chosen for use in this microarray study 
[400]. 
2.4.3. First and second strand cDNA synthesis 
A total of 40 ng RNA per sample were treated using the Ovation PicoSL WTA 
kit, which serves as a fast and simple method for preparing cDNA for whole 
genome expression analysis, optimised for analysis on Affymetrix Array Plates.  
The Ovation PicoSL WTA kit utilises Ribo-SPIA® technology to amplify cDNA 
from very small amounts of sample RNA within the picogram range, and 
consisted of three steps:  
1- Generation of first strand cDNA: The unique first strand DNA/RNA chimeric 
primers hybridise to both the 5’ end of the poly-A tail sequence and randomly 
across RNA transcripts in the sample. The reverse transcriptase (RT) enzyme 
then generates the first strand cDNA by extending the 3’ DNA end of each 
primer, producing a cDNA/mRNA hybrid molecule that contains a specific RNA 
sequence at the 5’ end of the cDNA strand that is required for the generation of 
the second strand cDNA. 
2- Generation of a DNA/RNA heteroduplex double strand cDNA (second strand 
cDNA): Priming sites for DNA polymerase to produce a second strand cDNA 
are made by fragmenting the mRNA within the cDNA-mRNA complexes 
produced in the last step. This allows for the generation of second strand cDNA 
that contains a specific complementary 5’ DNA sequence for the chimeric 
primer mix to bind to. What is produced, is a double-stranded cDNA molecule 
with a unique DNA-RNA heteroduplex at one end. 
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3- Amplification of DNA using SPIA® technology: This is a rapid DNA amplification 
process that involves the use of SPIA DNA/RNA chimeric primers RNase H and 
DNA polymerase to produce large quantities of cDNA with a sequence that is 
complementary to the mRNA in the original ALL sample. 
2.4.4. Generation of ST-cDNA  
Sense transcript-cDNA (ST-cDNA) was generated using the WT-Ovation Exon 
Module kit (NuGen), in order to render it suitable for use in the downstream 
Encore Biotin Module (NuGen). 
2.4.5. Fragmentation, labelling, and hybridisation of ST-cDNA to 
oligonucleotide probe array 
ST-cDNA was then fragmented and labelled using the Encore Biotin Module 
(NuGen). This process involved two steps, whereby cDNA was chemically and 
enzymatically fragmented into cDNA products of 50 to 100 base pairs in length, 
followed by enzymatic conjugation of a biotin-labelled nucleotide to the 3-
hydroxyl end of the fragmented cDNA. 
Subsequently, 2.5 µg of fragmented and labelled ST-cDNA were then 
hybridised to GeneChip® Human Gene 1.0 ST Arrays (Affymetrix) for 16 hours 
at 45ºC, as per NuGen’s instructions. The GeneChip® Human Gene 1.0 ST 
Arrays cover a total of 36,079 total RefSeq transcripts each. The arrays were 
then washed and stained with a fluorescent biotin-binding molecule 
(streptavidin-phycoerythrin) using the GeneChip® Fluidics Station 450 
(Affymetrix). 
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2.4.6. Oligonucleotide probe array scan 
The Human Gene 1.0 ST Arrays were then scanned using the GeneChip 
Scanner 3000 (Affymetrix), under the control of the Microarray Suite program 
(MAS 5.0). The scanner indirectly quantifies the amount of biotinylated ST-
cDNA for each probe set by using a laser to induce fluorescence of 
phycoerythrin molecules that are conjugated to streptavidin, which in turn binds 
biotin molecules. The dedicated software package measures the fluorescence 
and calculates an intensity value for each of the probe sets and using a 
statisctical expression algorithm, determines the expression level of each 
transcript within a sample. 
2.4.7. Analysis of microarray data 
Data was analysed with the help of Dr. Wenbin Wei at the School of Cancer 
Sciences, University of Birmingham. 
2.4.7.1. Normalisation of data 
Experiments involving the use of several high density oligonucleotide arrays 
often introduce variation of non-biological origin between arrays, and it is 
therefore important to remove this variation by normalisation, so that gene 
expression data may be compared between samples [401]. 
Normalisation of microarray data in this study was achieved using the default 
settings of the Robust Multichip Analysis (RMA) probe set summarisation 
algorithm available as part of the Expression Console v1.2.1 software package 
(Affymetrix).  
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2.4.7.2. Data filtration and statistical tests 
Following normalisation, data was filtered to remove any statistically 
insignificant expression values, thus making data interpretation easier. 
For univariate analysis, data was filtered in two ways: the first filtration method 
involved ordering only the DMSO-treated primary ALL tumours according to in 
vitro sensitivity to the cytotoxic effects of JQ1 (as measured in cytotoxicity assay 
experiments), and then ranking genes according to the fold difference in gene 
expression between ALL tumours most sensitive and least sensitive to JQ1. 
This was in aid of identifying genes predictive of JQ1 sensitivity.  
The second filtration method, also used as part of univariate data analysis, 
involved the ranking of genes according to fold gene expression change 
between primary ALL samples treated with either DMSO or 1 µM JQ1. 
These filtration processes were achieved using an empirical Bayes approach, 
using the Linear Models for MicroArray (LIMMA) statistical package within the 
BioConductor computer program [402]. For both filtration methods parameters 
were set to exclude genes with a p-value greater than 0.001 and a fold change 
less than 2. 
For multivariate analysis, consisting of the gene set enrichment analysis 
performed on microarray data from this study (Section 2.4.7.4), normalised 
expression data were exported to the Excel program (Microsoft) and filtered by 
removing genes that were not expressed at all or at very low levels that could 
be considered background noise. Genes with a p-value greater than 0.05 and a 
fold change less than 1.5 were excluded.  
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2.4.7.3. Gene clustering 
For the generation of heatmaps microarray data was imported from GeneSpring 
and loaded into the Cluster 3.0 computer program. Complete linkage clustering 
was then performed on the data, and then visualised as heatmaps that were 
gereated using the TreeView software program 
(http://rana.lbl.gov/EisenSoftware.htm). The heatmaps allowed for the 
visualisation of patterns of differential gene expression patterns between 
DMSO- and JQ1-treated primary ALL tumours, as well as genes that correlated 
with JQ1 EC50. 
In experiments involving PIM2, microarray data previously obtained in our lab 
[247] were re-analysed. Heatmaps allowed for the visualisation of genes that 
were expressed with a significant association to PIM2 expression.  
2.4.7.4. Gene Set Enrichment Analysis 
With the help of Dr. Wenbin Wei, Gene Set Enrichment Analysis (GSEA) [403] 
was performed on filtered microarray data and allowed for the identification of 
differentially expressed genes that belonged to, and enriched, functionally 
related gene sets representing major cellular processes and biological 
pathways.  
Using the javaGSEA Windows application (http://www.broadinstitute.org/gsea/), 
GSEA was conducted on the filtered dataset, which determined the enrichment of 
each gene in gene sets constituting the Molecular Signatures Database (MsigDB) 
1.0 gene set database. The application parameters were set to identify only those 
gene sets with a minimum of 10 genes and a maximum of 500 genes. The 
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javaGSEA application also calculated the level of significance (p-value) for each 
enriched gene set, and a false discovery rate (FDR) [403], which indicated the 
probability that an observed result was a false positive. Once GSEA was complete, 
enriched gene sets were ranked according to the p-value and FDR, and gene sets 
with a p-value less than 0.05 and an FDR rate less than 0.25 (25% chance of a 
false positive result) excluded. Using such stringent cut-off values resulted in the 
selection of only those gene sets with highly significant gene enrichment.  
2.5. Molecular genetics techniques 
2.5.1. Quantitative real-time reverse transcriptase polymerase 
chain reaction (qRT-PCR) 
2.5.1.1. cDNA synthesis 
The reverse transcription system (Invitrogen) was used to convert 1 µg total 
RNA into single-stranded cDNA.  
The first step involved placing PCR reaction tubes on ice and adding 1 µl dNTP 
mix (each of the four different dNTPs at a concentration of 10 mM) (Invitrogen), 
1 µl random primers (Promega), 1 µg of RNA, and RNase-free water (Qiagen) 
up to a total volume of 12 µl. The sample tubes were briefly vortexed and 
centrifuged, and then incubated at 65ºC for 5 minutes. 
The second step involved the addition of 1 µl Superscript II reverse 
transcriptase (Invitrogen), 1 µl RNaseOUT recombinant ribonuclease inhibitor 
(Invitrogen), 2 µl dithiothreitol (DTT) (Invitrogen), and 4 µl 5X First-Strand Buffer 
(250 mM Tris-HCl, 375 mM KCl, 15 mM MgCl2) (Invitrogen) to each sample 
tube containing 12 µl of reaction mix and RNA from the first step. Samples were 
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then incubated at 25ºC for 5 minutes, 42ºC for 50 minutes, and finally 80ºC for 
15 minutes. Synthesised cDNA was then stored at -80ºC until further use. When 
cDNA samples were needed for experiments and thawed for the first time, 
samples were diluted 1:5 with distilled water.  
2.5.1.2. Primer design 
Primers were designed for specific genes, based on the mRNA sequence for a 
given gene, using the OligoPerfect Designer online tool (Invitrogen). 
Parameters were set to generate primers with an annealing temperature of 
60ºC and maximum length of 100 bases. Lyophilised primers were reconstituted 
with sterile distilled water to a stock concentration of 200 µM. To avoid 
unnecessary freeze-thawing, primer stocks were diluted 1:10 with sterile 
distilled water. Sequences for the primers used in this study can be found in 
Table 2.4.  
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Primer name Primer sequence 
IL7R Forward 5’-AGG CAC TTT ACC TCC ACG AG-3’ 
IL7R Reverse 5’-GTT GGA AGT GAA TGG ATC GC-3’ 
BIRC3 Forward 5’-TCC GGC AGT TAG TAG ACT ATC CA-3’ 
BIRC3 Reverse 5’-GGG AAG AGG AGA GAG AAA GAG C-3’ 
EIF4EBP2 Forward 5’-GAG AAT TGC GAC GAT CCA AC-3’ 
EIF4EBP2 Reverse 5’-TCA TGA CTA TTG CAC CAC GC-3’ 
TNFSR4 Forward 5’-TTG AAT TCG AGG ATA CCG ATG-3’ 
TNFSR4 Reverse 5’-GTA ATT CAG GGA CTG GGG CT-3’ 
PPP1R13B Forward 5’-GAC AGG TTG TTT CCG GTG TT-3’ 
PPP1R13B Reverse 5’-GAC TCT CCC CGC GAT GAT-3’ 
MYC Forward 5’-AGG GAT CGC GCT GAG TAT AA-3’ 
MYC Reverse 5’-TGC CTC TCG CTG GAA TTA CT-3’ 
B-ACTIN Forward 5’-CAC CAT TGG CAA TGA GCG GTT C-3' 
B-ACTIN Reverse 5’-AGG TCT TTG CGG ATG TCC ACG T-3’ 
PIM2 Forward 5’-TGG GCA TCC TCC TCT ATG AC-3’ 
PIM2 Reverse 5’-ATT AGG GCA CAG CAG TCT GG-3’ 
 
Table 2.4: qRT-PCR primer sets used in this study.  
Primers were designed using the OligoPerfect primer design online tool 
(Invitrogen). Primers were all designed to exhibit optimum annealing at 
approximately 60ºC, in order to be most efficiently used in downstream qRT-
PCR experiments using the same protocol. 
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2.5.1.3. SYBR Green RT-PCR reaction preparation 
Control cDNA synthesised from NALM-6 cell line template mRNA was used in 
test PCR reactions to test primer sets using the FastStart Taq DNA Polymerase 
kit (Roche) with a range of annealing temperatures from 58ºC to 68ºC, as well 
as different concentrations of primers. Reactions were run on a 4% agarose gel 
and visualised in order to confirm PCR products were present, that only one 
single PCR product was made per primer set, and that a high PCR product yield 
was obtained. 
After testing the primers, PCR reactions were prepared in MicroAmp Fast Optical 
96-Well Reaction Plates (Applied Biosystems) to which 4 µl of cDNA were added 
to each well, along with 16 µl of a prepared Master mix consisting of 0.25 µl 
forward primer (250 nM), 0.25 µl reverse primer (250 nM), 10 µl Fast SYBR 
Green mix (Applied Biosystems), and 5.5 µl distilled water, giving a total volume 
of 20 µl per reaction. The reaction plate was then placed in a 7500 Fast Real-
Time PCR System  (Applied Biosystems) and thermal cycling conditions set as 1 
cycle at 95ºC for 20 seconds for activation of the DNA polymerase enzyme, 40 
cycles at 95ºC for 3 seconds for denaturation, followed by 60ºC for 30 seconds 
for annealing and extension. A heat dissociation phase was also added on to 
the end of the thermal cycling protocol within the RT-PCR system software, to 
provide a dissociation curve that measured the level of amplicons relative to a 
range of melting temperatures from 60ºC to 95ºC, and therefore confirm primer 
specificity, as characterised by a single peak above 75ºC. Ct values generated 
for each gene of interest were then normalised to the β-actin loading control 
gene, so that relative expression levels could be calculated. Fold change in 
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transcript levels of a given gene were then calculated by dividing the relative 
expression levels after drug treatment by the relative expression before drug 
treatment. 
2.6. Cell biology techniques 
2.6.1. Measurement of cytotoxicity 
Primary leukaemic cells and cell lines were seeded into opaque 96-well plates 
at a density of 5x104 cells per well, and treated with either dimethylsufoxide 
(DMSO) or increasing concentrations of JQ1 (0.001 to 10 µM), with or without 
the additional agent (dexamethasone or vincristine).  Following incubation at 
37ºC for 48 hours (primary ALL tumours) or 72 hours (cell lines), the CellTiter-
Glo Luminescent Cell Viability Assay (Promega) was used according to the 
manufacturer’s instructions to indirectly evaluate the loss of cellular viability in 
response to drug treatment based on quantitation of the amount of ATP 
released by cells following lysis using the supplied  reagents.  
In cytotoxicity experiments involving PIM inhibitor K00135, the same conditions 
were used as above, only K00135 concentrations ranging from 0.01 to 100 µM 
were used instead, unless stated. 
The Prism 4 (GraphPad) software package was used to calculate half maximal 
effective concentrations (EC50) and to analyse results by Student’s unpaired t-
test where appropriate. A p-value of <0.05 was taken as significant. 
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Calcusyn software was used to measure the degree of synergy, as indicated by 
calculated combination indices (CI), between two compounds used to treat 
tumour cells (CI<1 synergistic, CI=1 additive, CI>1 antagonistic). 
 
 
2.6.2. Fluorescent DNA fibre-labelling technique 
NALM-6 cells were pre-treated with DMSO or 1 µM JQ1 inhibitor for 1 hour and 
24 hours prior to labelling. Dual labelling of replication tracts was performed by 
pulse-labelling cell cultures in exponential growth with 25 µM chloro-
deoxyuridine (CIdU) for 20 minutes, followed by 250 µM iodo-deoxyuridine (IdU) 
for a further 20 minutes.  
To prepare DNA fibre-spreads on microscope slides, 2 ml of each cell 
suspension at a cell density of 200 cell/ml were spread on Silane-prep slides 
(Sigma-Aldrich), close to and in parallel to the label. The sample was allowed to 
evaporate until almost dry, after which 10 µl of spreading buffer (0.5% SDS in 
200 mM Tris–HCl (pH 7.4), 50 mM EDTA) was pipetted on top of the sample, 
causing cells to swell and rupture. After 10 minutes had elapsed, the slide was 
tilted at an angle of 15º to allow the cell lysate to slowly travel down the slide. 
The DNA spreads were then left to air-dry, before being fixed in 3:1 
methanol/acetic acid for 2 minutes and left to air-dry once more overnight. The 
slides were then stored at -20ºC for 24 hours. 
For immunodetection of CIdU- and IdU-labelled tracts, acid-treated fibre 
spreads were incubated with a mix of rat anti-BrdU monoclonal antibody, clone 
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BU1/75 (ICR1) (Serotec), and mouse anti-BrdU monoclonal antibody. Slides 
were fixed in 4% paraformaldehyde and incubated with a mix of AlexaFluor 555-
conjugated goat anti-rat and AlexaFluor 488-conjugated goat anti-mouse 
immunoglobulin G (IgG) (Molecular Probes). Fibres were examined using a 
Nikon Eclipse E600 microscope with a 60X lens, images recorded using the 
Volocity software package (Perkin Elmer) and the lengths of green (AlexaFluor 
488) and/or red (AlexaFluor 555) labelled patches measured using the ImageJ 
software application.  
2.6.3. Cell cycle analysis  
Staining of ALL cell line cells with PI and analysis by flow cytometry was used to 
measure the cell cycle distribution of cells treated with either DMSO or 1 µM 
JQ1 for 24 hours. This technique uses light scattering from the passing of 
sample cells through a laser, and fluorescence emitted following the excitation 
of the PI dye, which binds and intercalates into DNA, to quantify the DNA 
content in cycling cells.  
ALL tumour cells were treated in a 6-well plate (Iwaki) at a density of 2x106/ml. 
Using a Pasteur pipette, 3 ml of cell suspension were transferred to flow 
cytometry sample tubes and centrifuged at 2000 rpm for 3 minutes, and the 
supernatant discarded. Cells were then washed by re-suspending cells in 3 ml 
ice-cold PBS, before centrifuging again and re-suspending cells in 3 ml ice-cold 
70% ethanol/PBS, drop-by-drop whilst gently vortexing. At this stage cells were 
either stored at -20ºC for up to a week or used immediately.  
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Ethanol-fixed samples were stained on the day of cytometric analysis, by first 
centrifuging cells at 2000 rpm for 5 minutes at 4ºC, re-suspending the formed 
pellet in 3 ml ice-cold  PBS, and then centrifuging cells once more before re-
suspending pellets in a 1 ml PI/RNase solution (25 µg/ml PI, 0.1 mg/ml RNase). 
PI-satined cells were then wrapped in aluminium foil and incubated in the dark 
at room temperature. Samples were then analysed using an Accuri C6 Flow 
Cytometer (Becton Dickinson) with an excitation wavelength of 488 nm. Using 
the latest version of WinMDI, the proportion of cells in the G1, S, and G2 
phases of the cell cycle were determined. 
2.6.4. Bromodeoxyuridine (BrdU) incorporation cell 
proliferation assay 
NALM-6 cells were treated with either DMSO or 1 µM JQ1 for 24 hours. 3x106 
NALM-6 cells were pulse-labelled with 10 µM BrdU (Sigma-Aldrich) for 20 
minutes prior to harvesting cells at the 24 hour timepoint, washed in PBS, and 
then fixed in 80% ice-cold ethanol overnight at -20ºC. Cells were then incubated 
in 15 mM pepsin for 20 minutes at 37ºC, before being pelleted and incubated 
with 2 N HCl for 20 minutes at room temperature. The pellet was then washed 
in buffer Bu (0.1% FCS, 0.1% Tween 20, 0.1 M Hepes in PBS) and incubated 
with mouse anti-BrdU antibody, clone Bu20a (Dako) diluted to 1:50 in buffer Bu 
for 45 minutes. Cells were then centrifuged and re-suspended in anti-mouse-
FITC antibody (Vector laboratories) diluted at 1:50 with buffer Bu. To stain total 
DNA, cells were pelleted and re-suspended in PBS containing 25 µg/ml 
propidium iodide (Sigma-Aldrich) and 50 µg/µl RNase (Sigma-Aldrich), before 
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performing analysis of samples by flow cytometry using an Accuri C6 Flow 
Cytometer (Becton Dickinson). 
2.7. ALL xenograft mouse model studies 
Two in vivo experiments were performed in this study. Animals were treated in 
accordance with UK Home Office guidelines, Schedule 1 
(http://www.legislation.gov.uk/ukpga/1986/14/pdfs/ukpga_19860014_en.pdf). 
In the first experiment 1x106 NALM-6 cells were injected subcutaneously into 16 
NOD/Shi-scid/IL-2Rγnull (NOG) mice. Upon evidence of visible tumours, animals 
received either 50 mgkg-1 JQ1 (n=8) or vehicle alone (10% (w/v) 2-hydroxy-
propyl-β-cyclodextrin) (Sigma-Aldrich) (n=8) via intra-peritoneal (IP) injection for 
5 days per week for a period of 2 weeks. Tumour volume was measured 
manually thrice weekly using a calliper.  
In the second experiment, a xenograft model of a primary B precursor ALL 
tumour (ALL 105) was created by the intravenous injection of 1x106 cells via the 
tail vein. Once levels of human CD45 reached 1% in the peripheral blood, mice 
received either 50 mgkg-1 JQ1 (n=7) for 5 days per week over a period of 4 
weeks, or vehicle alone (n=7).  The proportions of cells positive for hCD45, 
hCD10, hCD19, and hCD34 were assessed on weekly blood samples. At the 
end of drug treatment spleens were harvested and tumour burden determined 
by spleen size. In addition, percentages of hCD45+CD34+CD19+CD10+, 
hCD45+CD34+CD19+CD10-, and hCD45+CD34-CD19+CD10 subpopulations 
were calculated from the proportion of gated live cells, and compared between 
the vehicle-treated and JQ1-treated animals.  
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3. RESULTS I: TARGETING BET PROTEINS IN PRE-B ALL  
3.1. Sensitisation of ALL tumour cells to the BET 
bromodomains inhibitor JQ1 
Although remarkable improvements in the treatment of B precursor ALL have 
been made over the past few decades, a significant number of patients still 
suffer from disease relapse and toxicity associated with the use of conventional 
chemotherapeutic agents. This highlights the highly heterogenous nature of 
ALL, where variable treatment responses are observed and resistance to 
treatment sometimes ensues. It is therefore clear to see that the requirement 
exists for a novel, more targeted approach in treating these patients.  
The bromodomain-containing BRD4 protein is a member of the BET family of 
proteins, and has recently emerged as novel therapeutic target in malignancies 
such as AML and NUT-midline carcinoma [344]. Studies have shown that BRD4 
forms part of transcription complexes and remains bound to transcriptional start 
sites of genes expressed during the M/G1 transition of the cell cycle, thus 
promoting mitotic progression and transcriptional elongation [336]. 
Taking these findings into consideration, I aimed to explore the possibility of 
targeting BET proteins in ALL, including BRD4 that has previously been 
implicated in the pathophysiology of haematopoietic malignancies, using the 
highly specific pharmacological inhibitor JQ1, as an alternative strategy to 
downregulating multiple prosurvival signaling pathways and cellular processes, 
and thereby sensitising tumours to apoptosis. 
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3.1.1 Expression of BRD4 in ALL cell lines and primary tumours 
To establish whether or not pharmacological inhibition of BRD4 was a feasible 
approach, I began by determining the protein expression levels of BRD4 in 
lysates prepared from a panel of 6 ALL cell lines, representing diverse disease 
subtypes. These included BCR-ABL1+ ALL (SD1, SUPB-15, and TOM-1), 
apoptotic-resistant BCR-ABL1- ALL (NALM-6, REH), and apoptotic-sensitive 
ALL (NALM-17). I also tested a panel of 10 primary ALL tumours (ALL-103, 
ALL-104, ALL-105, ALL-106, ALL-108, ALL-109, ALL-110, ALL-111, ALL-112, 
and ALL-113) of which 5 were low-risk MRD (ALL-103, ALL-104, ALL-108, ALL-
109 and ALL-111) and 5 were high-risk MRD (ALL-105, ALL-106, ALL-110, 
ALL-112 and ALL-113). I used SDS-PAGE followed by the Western-blotting 
technique to visualise BRD4 protein.   
I observed high levels of 152 kDa BRD4 protein expression across all ALL cell 
lines and primary tumours analysed, irrespective of their phenotype (Figure 3.1a 
& b). Although it was not possible to improve the western blot due to restricted 
primary tumour material, BRD4 expression did not appear to correlate with 
clinical features (age, WCC, cytogenetic abnormalities, or risk stratification) that 
were associated with the patients from which these tumours were derived 
(Table 2.1).  
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Figure 3.1: Expression of BRD4 protein in ALL cell lines and 
primary tumours. 
 
Whole protein lysates were prepared from 6 ALL cell lines and 10 
primary ALL tumours and probed for 152 kDa BRD4 protein expression 
by Western blotting. Β-actin was used as a loading control.  
 
a) High levels of BRD4 expression are seen across all ALL cell lines in 
this panel, namely NALM-6, NALM-17, REH, SD1, SUPB-15 and TOM-1.  
 
b) Although some degree of inter-patient variability in the level of BRD4 
expression exists, all primary ALL tumours express BRD4 protein. 
Tumour cells treated with 1 µM JQ1 for 6 hours do not show any 
significant decrease in BRD4 expression relative to β-actin. 
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3.1.2 In vitro cytotoxic effects of JQ1-mediated inhibition of 
BET proteins in ALL cell lines and primary tumours 
Since all the ALL cell lines and primary tumours analysed expressed high levels 
of BRD4 protein (Figure 3.1), I decided to use a luminescent ATP-based 
cytotoxicity assay to measure the effect of JQ1 treatment on cell viability. The 
panel of cell lines tested were SUPB-15, SD1, REH, TOM-1, Jurkat and NALM-
6.  Cell viability was measured 72 hours following exposure to increasing 
concentrations of JQ1 inhibitor only. I also addressed JQ1-mediated cytotoxicity 
in a panel of 25 non-cycling primary B precursor ALL tumours that included 
representatives of low-risk and high-risk MRD phenotypes, infant and relapsed 
ALL, as well as non-tumour PBMC obtained from 3 healthy donors. Since 
recent studies demonstrated potent sensitisation of primary AML tumours 
following BRD4 inhibition [344], I also tested for JQ1 cytotoxicity in 2 primary 
AML tumours.  
In all the ALL cell lines tested, I found that JQ1 led to an impressive decrease in 
cell viability at 72 hours (Figure 3.2a), with EC50 values ranging from 0.17–1.00 
µM (Table 3.1). Interestingly, treatment of primary ALL tumours with a cytotoxic 
dose of 1 µM JQ1 inhibitor did not have an impact on BRD4 expression levels, 
which was consistent with the JQ1 mechanism of action involving the inhibition 
of BRD4 activity as opposed to decreasing its expression. 
In contrast to ALL cell lines that were uniformly sensitive, incubation of primary 
ALL tumours with 1 µM JQ1 demonstrated a moderate to substantial loss of cell 
viability following 48 hours (Figure 3.2b). I calculated that 36% (9/25) of primary  
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Figure 3.2:  JQ1-induced cytotoxicity in a panel of ALL cell lines and a 
range of primary tumours. 
Effects of JQ1 treatment on cell viability were measured using a luminescent 
ATP-based cytotoxicity assay. 
a) Cell lines NALM-6, NALM-17, REH, SD1, SUPB-15 and TOM-1 incubated 
with 1 µM JQ1 for 72hr show a dramatic loss of viability. Assays were 
performed in triplicate. Data are presented as mean ± SEM; n=3. 
b) Compared to PBMC obtained from two healthy individuals, representative 
primary ALL and AML tumours show a differential loss of viability upon 48hr 
incubation with 1 µM JQ1. Data are presented as mean ± SD. 
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ALL tumours showed EC50 values < 1 µM (2 high-risk MRD, 4 low-risk MRD, 1 
infant ALL, and 2 tumours with unknown risk stratification), which was a 
cytotoxic dose comparable to that observed in ALL cell lines (Table 3.2).  
Furthermore, I also noticed that primary tumours with an EC50 value between 1 
and 10 µM, for which I had complete clinical information, were all MRD high-risk 
ALL tumours. Interestingly, lower sensitivity to JQ1 was observed in 16% (4/25) 
of primary ALL tumours, where EC50 values were >10 µM (Table 3.2). Of these 
JQ1-resistant tumours, one was high-risk ALL (ALL-123), and three were low-
risk ALL (ALL-103, ALL-109, ALL-124).  
I calculated the mean EC50 for all primary tumours and control PBMC treated 
with JQ1, and found that high-risk ALL tumours had a lower mean EC50 of 5.63 
± 5.32 µM, compared to low-risk ALL tumours with a mean EC50 of 7.58 ± 6.31 
µM (Table 3.2). This suggested JQ1 cytotoxic activity favourably targeted high-
risk ALL tumours, which are those derived from patients that frequently exhibit 
chemoresistance and are deemed as having an unfavourable clinical prognosis.  
Infant ALL tumours (ALL-114 and ALL-118) were also sensitive to JQ1-
treatment (0.17 and 2.0 µM, respectively). Infant ALL is characterised by 
potential chemoresistance, frequently occurring rearrangements of the Mixed-
Lineage Leukaemia (MLL) gene, and a poor clinical prognosis [404, 405]. Since 
MLL fusion proteins activate the transcription of several oncogenes through 
binding with BRD4 [406], and the JQ1 inhibitor has been shown to exert potent 
anti-leukaemic activity against MLL-rearranged AML [344], it is possible that 
JQ1 is also effective in eliminating infant ALL tumour cells. 
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Cell line median JQ1 EC50 (±SD) (µM) 
SUPB-15 0.237 (±0.019) 
SD1 0.173 (±0.023) 
REH 1.004 (±0.012) 
TOM-1 0.398 (±0.019) 
Jurkat 0.326 (±0.006) 
NALM-6 0.552 (±0.021) 
   
 
 
 
Table 3.1: Half-maximum-effect concentrations (EC50) calculated for a 
panel of ALL cell lines treated with JQ1 inhibitor. 
JQ1 EC50 values (±S.D.) were calculated for SUPB-15, SD1, REH, TOM-1, 
Jurkat, and NALM-6 using the Prism 4 software package (GraphPad Inc.), 
which were derived from data values obtained for each cell line in cytotoxicity 
experiments following 72h incubation of cells with a log-scale range of JQ1 
concentrations.  
EC50 values for JQ1-treated ALL cell lines were generally in the low nanomolar 
range (0.173-1.004 µM).  
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Table 3.2: Half-maximum-effect concentrations (EC50) calculated for a 
panel of primary leukaemia tumours treated with JQ1 inhibitor. 
Calculated EC50 values were derived from cytotoxicity experiment data, where primary 
tumours were treated with a range of log-scale JQ1 concentrations for 48h. 
ALL tumours, particularly those derived from high-risk patients, were sensitised to 
clinically achievable JQ1 concentrations (JQ1 EC50 <10 µM). Primary AML tumours 
were used as a positive control and were also sensitised to JQ1. 
Healthy PBMCs were not sensitised to JQ1 and showed high JQ1 EC50 values. 
Patient JQ1 EC50 (µM) Sub-group mean                            JQ1 EC50 ± SEM (µM)
ALL-101 1.80
ALL-105 0.11
ALL-106 5.83
ALL-110 3.38
ALL-112 4.30
ALL-113 0.72
ALL-116 5.82
ALL-117 5.75
ALL-121 2.81
ALL-122 1.45
ALL-123 34.17
ALL-126 1.47
ALL-103 23.08
ALL-104 0.18
ALL-108 0.73
ALL-109 20.22
ALL-111 0.79
ALL-115 0.49
ALL-114 0.17
ALL-118 2.00
ALL-129 0.12
ALL-130 1.45
ALL-131 2.64
ALL-132 1.17
ALL-133 0.42
AML-1 0.06
AML-2 3.72
 PBMC-1 886.08
 PBMC-2 10107000.00
 PBMC-3 303.49
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The healthy PBMCs did not exhibit a significant loss of cell viability even with 10 
µM JQ1 (Figure 3.2b), whereas both primary AML samples (AML-1 and AML-2) 
showed a significant loss of viability with a mean EC50 of 1.89 ± 1.49 µM (Table 
3.2).  
These results indicate that JQ1 activity has a profound impact on the viability of 
multiple ALL cell lines and primary ALL tumours in vitro, regardless of their 
phenotype. This data also suggests that JQ1 is capable of sensitising high-risk 
ALL more potently than low-risk ALL. The observation that primary AML 
tumours are highly sensitive to the effects of JQ1 treatment in the results I 
reported, is supported by published data demonstrating the in vivo anti-tumour 
activity of JQ1 in an AML xenograft model [344]. Finally, results showing that 
JQ1 treatment does not exert cytotoxic effects in healthy control PBMCs, are 
indicative of JQ1 activity being tumour-specific and potentially safe to test in 
animal studies. 
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3.1.3 Combined in vitro cytotoxic effects of JQ1 together with 
conventional chemotherapeutic agents in ALL cell lines and 
primary tumours. 
Since treatment with JQ1 alone induced substantial in vitro cytotoxic effects in 
ALL cell lines and a large panel of ALL tumours, I decided to investigate the 
combined cytotoxic effects of JQ1 together with conventional cytotoxic agents 
used to treat ALL, namely dexamethasone, vincristine, and daunorubicin.  
I treated REH, TOM-1, and NALM-6 cells with a subcytotoxic dose of JQ1 (0.1 
µM) in combination with log scale increments in drug concentration of each of 
the conventional cytotoxic agents named above, ranging from 0.0001 to 10 µM, 
and measured cell viability at 72 hours using the ATP-based cytotoxicity assay.  
Notably, treatment of TOM-1 cells with the JQ1/dexamethasone combination 
showed enhanced cytotoxicity compared to dexamethasone treatment alone 
(Figure 3.3), and was highly synergistic with dexamethasone concentrations 
ranging from 0.0001 to 0.1 µM (Table 3.3).  
In contrast, I observed no increased cytotoxicity in REH cells when 0.1 µM JQ1 
was combined with increasing concentrations of dexamethasone (Figure 3.4). 
There was no dose-dependent response following dexamethasone treatment, 
therefore use of the Calcusyn software package to calculate synergistic effects 
was not possible, since a dose-effect curve is a requirement. This may have 
been due to the fact REH cells are known to lack expression of the 
gonadotrophin receptor via which dexamethasone exerts its cytotoxic effects 
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[407]. I did not observe any synergistic effects in REH cells treated with a 
combination of JQ1 with either vincristine or daunorubicin (data not shown). 
Similarly, treatment of NALM-6 cells with the JQ1/dexamethasone combination 
also led to greatly enhanced cytotoxic effects compared to dexamethasone 
treatment alone (Figure 3.5), and exhibited the greatest cytotoxic response to 
dexamethasone compared to REH and TOM-1. Furthermore, I observed highly 
synergistic effects across all the different concentrations of dexamethasone I 
used to treat NALM-6 cells (ranging from 0.0001 to 10 µM) (Table 3.3).  
Given that combined JQ1/dexamethasone treatment appeared to induce the 
greatest sensitisation of ALL cell lines (TOM-1 and NALM-6) to dexamethasone 
(Figures 3.3 & 3.5) in comparison to combinations with either vincristine or 
daunorubicin, and the availability of primary tumour material was limited to be 
able to test multiple drug combinations, I selected dexamethasone as the drug 
to test for synergistic effects in combination with 0.1 µM JQ1 in three 
representative primary ALL tumours (ALL-129, ALL-130, and ALL-132). I did 
this by measuring cell viability at 48 hours after drug treatment using the ATP-
based cytotoxicity assay.  
I found that the JQ1/dexamethasone treatment combination led to increased 
sensitisation to dexamethasone in all three primary ALL tumours (ALL-129, 
ALL-130 and ALL-132), when compared to tumour cells treated with 
dexamethasone alone (Figure 3.6-3.8). I observed the greatest sensitisation in 
ALL-129 and ALL-130, with the greatest differential in surviving cell fractions 
being at lower concentrations of dexamethasone, ranging between 0.0001 and 
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0.01 µM. Furthermore, I confirmed that treatment with the JQ1/dexamethasone 
combination demonstrated highly synergistic effects in all three primary ALL 
tumours using concentrations of dexamethasone ranging between 0.0001 and 1 
µM (Table 3.4). 
These results indicate that JQ1 activity leads to increased in vitro sensitisation 
of ALL cell lines and primary tumours to conventional chemotherapeutic agents 
used in the clinic. 
3.1.4 Summary 
In conclusion, I showed that BRD4 protein is expressed at high levels in multiple 
ALL cell lines and primary ALL tumours. I also showed that treatment of both 
cell lines and primary tumours with JQ1 induced cytotoxicity, irrespective of the 
phenotype or associated risk stratification. Furthermore, the data I have 
reported shows there may be potential benefits from treating ALL tumours with 
a combination of JQ1 with chemotherapeutics such as dexamethasone. This 
data supports the rationale for further work to elucidate the mechanism of JQ1-
mediated cytotoxicity in ALL, and determine whether or not these anti-tumour 
effects are translatable in an in vivo model of ALL. 
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Figure 3.3: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in the TOM-1 cell line 
Cell viability was measured in triplicate using a luminescent ATP-based 
cytotoxicity assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitises TOM-1 cells (72h incubation), with a surviving fraction of 0.59 
at 0.1 µM JQ1.  
b) Treatment of TOM-1 cells with the JQ1/dexamethasone drug combination led 
to significant synergistic cytotoxicity.  
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Figure 3.4: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in the REH cell line 
Cell viability was measured in triplicate using a luminescent ATP-based cytotoxicity 
assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitised REH cells (72h incubation), with a surviving fraction of 0.76 at 0.1 µM 
JQ1.  
b) REH cells are resistant to the cytotoxic effects of dexamethasone. Subsequently no 
synergistic effects were observed following treatment with a combination of 
JQ1/dexamethasone. 
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Figure 3.5: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in the NALM-6 cell line 
Cell viability was measured in triplicate using a luminescent ATP-based 
cytotoxicity assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitises NALM-6 cells (72h incubation), with a surviving fraction of 
0.48 at 0.1 µM JQ1.  
b) Treatment of NALM-6 cells with the JQ1/dexamethasone drug combination 
led to significant synergistic cytotoxicity.  
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Table 3.3: Combination indices for JQ1 and dexamethasone in TOM-1 and 
NALM-6 cell lines. 
Combination indices (CI) were calculated using the Calcusyn software 
(Biosoft™), in line with the Chou and Talalay drug interations mathematical 
model [408]. 
The CI is a measure of drug interaction, with CI>1, CI=1 and CI<1 representing 
antagonistic (*), additive (**) and synergistic (***) effects, respectively. 
Synergistic cytotoxic effects were observed in TOM-1 cells treated with 0.1 µM 
JQ1 together with 0.0001-0.1 µM dexamethasone. 
Synergistic cytotoxic effects were observed in NALM-6 cells treated with 0.1 µM 
JQ1 together with 0.0001-10 µM dexamethasone. 
Dexamethasone (µM) Combination Index Synergism
JQ1 (0.1 µM) JQ1 (0.1 µM)
TO
M
-1
0.0001 0.44 ***
0.001 0.34 ***
0.01 0.25 ***
0.1 0.53 ***
1 4.43 *
10 36.77 *
N
AL
M
-6
0.0001 0.33 ***
0.001 0.31 ***
0.01 0.26 ***
0.1 0.18 ***
1 0.17 ***
10 0.19 ***
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Figure 3.6: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in ALL-129 primary tumour cells. 
Cell viability was measured in triplicate using a luminescent ATP-based 
cytotoxicity assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitises ALL-129 tumour cells (48h incubation), with a surviving 
fraction of 0.37 at 0.1 µM JQ1.  
b) Treatment of ALL-129 cells with the JQ1/dexamethasone drug combination 
led to significant synergistic cytotoxicity using 0.0001-10 µM dexamethasone. 
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Figure 3.7: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in ALL-130 primary tumour cells. 
Cell viability was measured in triplicate using a luminescent ATP-based 
cytotoxicity assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitises ALL-130 tumour cells (48h incubation), with a surviving 
fraction of 1.06 at 0.1 µM JQ1.  
b) Treatment of ALL-130 cells with the JQ1/dexamethasone drug combination 
led to significant synergistic cytotoxicity using 0.0001-1 µM dexamethasone. 
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Figure 3.8: In vitro cytotoxic effects of combined treatment with JQ1 and 
dexamethasone in ALL-132 primary tumour cells. 
Cell viability was measured in triplicate using a luminescent ATP-based cytotoxicity 
assay. Data are presented as mean ± SEM; n=3. 
a) JQ1 sensitises ALL-132 tumour cells (48h incubation), with a surviving fraction of 
1.26 at 0.1 µM JQ1.  
b) Treatment of ALL-132 cells with the JQ1/dexamethasone drug combination led to 
significant synergistic cytotoxicity using 0.0001-0.1 µM dexamethasone. 
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 Dexamethasone (µM) 
Combination Index  Synergism 
 
JQ1 (0.1 µM) JQ1 (0.1 µM) 
A
LL
-1
29
 
0.0001 0.266 *** 
0.001 0.001 *** 
0.01 0.211 *** 
0.1 0.135 *** 
1 0.210 *** 
10 0.838 *** 
A
LL
-1
30
 
0.0001 0.066 *** 
0.001 0.001 *** 
0.01 0.069 *** 
0.1 0.168 *** 
1 0.192 *** 
10 1.143 * 
A
LL
-1
32
 
0.0001 0.112 *** 
0.001 0.141 *** 
0.01 0.469 *** 
0.1 0.342 *** 
1 1.286 * 
10 15.398 * 
 
Table 3.4: Combination indices for JQ1 and dexamethasone in primary 
ALL tumours. 
Combination indices (CI) were calculated using the Calcusyn software 
(Biosoft™), in line with the Chou and Talalay drug interactions mathematical 
model [408]. 
The CI is a measure of drug interaction, with CI>1, CI=1 and CI<1 representing 
antagonistic (*), additive (**) and synergistic (***) effects, respectively. 
Synergistic cytotoxic effects were observed in ALL-129 tumour cells treated with 
0.1 µM JQ1 together with 0.0001-10 µM dexamethasone. 
Synergistic cytotoxic effects were observed in ALL-130 tumour cells treated with 
0.1 µM JQ1 together with 0.0001-1 µM dexamethasone. 
Synergistic cytotoxic effects were observed in ALL-132 tumour cells treated with 
0.1 µM JQ1 together with 0.0001-0.1 µM dexamethasone. 
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3.2 Gene expression profiling and transcriptional biomarkers of 
JQ1 sensitisation 
Although the bromodomain-containing protein BRD4 has been shown to play a 
key role in regulating cell growth and proliferation, the underlying mechanisms 
by which it regulates transcription of genes involved in cell growth had, until 
recently, remained largely unknown. We now understand that whereas most 
transcription factors such as RNA polymerase II, Oct1, Pax 3, and E2F1 
dissociate from chromosomes during mitosis, causing global transcription to 
cease, BRD4 protein remains bound to mitotic chromosomes to provide cellular 
‘memory’ to daughter cells [336]. This allows for the reloading of RNA 
polymerase II and many other transcription factors onto chromosomes, and re-
initiation of inherited patterns of gene expression following mitosis. Studies in 
NIH3T3 and MEF cells have shown that knockdown of the BRD4 gene using 
specific shRNA leads to a block at G1 and therefore cell cycle arrest, and that 
BRD4 knockdown significantly reduces the expression of cell cycle genes, such 
as cyclin D1 and cyclin D2 [335].  
Data to support alternative roles for BRD4 and the regulation of transcription of 
genes independent of cell cycle regulation are relatively limited. However, a 
recent study has provided evidence that Lys310-acetylated NFκB recruits BRD4 
in a complex with p-TEFb, which consists of CDK9 and cyclin T1, and RNA 
polymerase II to form the transcription machinery complex required for the 
expression of various pro-inflammatory NFκB genes, frequently associated with 
the aetiology of many cancers [409]. Our laboratory has previously published 
data confirming the deregulation of apoptotic pathways in primary ALL tumours, 
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partly attributed to the upregulation of multiple prosurvival signaling pathways 
such as the NFκB pathway [247, 248]. Taking all these reported findings into 
consideration, together with the fact that I showed JQ1-mediated BRD4 
inhibition to not only be cytotoxic to proliferating cell lines, but also to largely 
non-cycling primary ALL tumour cells in vitro, I hypothesised that BRD4 also 
regulates the expression of genes involved in prosurvival signaling and 
inhibition of apoptosis in ALL, and not only genes associated with cell-cycle 
progression. 
To test my hypothesis and further investigate the mechanism of JQ1-mediated 
cytotoxicity in ALL, I decided to make use of global gene expression microarray 
technology to identify the effect that BRD4 inhibition has on gene transcription 
in 8 primary ALL tumours before and after 6 hour exposure to 1µM JQ1, using 
Affymetrix GeneChip Human Gene 1.0 ST Arrays. I decided to use a 6 hour 
JQ1-exposure time point since I was only interested in the changes in 
expression of primary response genes, and wanted to reduce the likelihood of 
secondary response gene activation. 
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3.2.1 RNA quality control 
Before starting the microarray experiment I needed to assess the integrity and 
quality of the RNA extracted from primary ALL tumour cells, to ensure that 
results obtained were reliable and truly representative of gene expression 
patterns within sample tumour cells. I made use of the Agilent 2100 Bioanalyser 
system to assess RNA quality, which is based on the RNA Integrity number 
(RIN), determined by the 2100 Expert system software. High RIN values 
represent good quality RNA, which is seen as two distinct bands (representing 
28S and 18S eukaryotic ribosomal subunits) and as two distinct peaks on the 
electropherogram (Figure 3.9b). It has been shown that RNA samples with RIN 
values below 7 are likely to reflect RNA degradation (Figure 3.9). Thus, I used 
carefully extracted RNA with RIN values greater or equal to the recommended 
value of 8 [400]. A total of 8 primary ALL tumour samples were selected for this 
microarray study (ALL-101, ALL-103, ALL-104, ALL-105, ALL-106, ALL-108, 
ALL-109 and ALL-113), which represented a spectrum of different sensitivity to 
JQ1 based on EC50 values obtained in in vitro cytotoxicity experiments.  
The primary RNA I extracted proved to be high quality, which increased the 
likelihood of successful microarray hybridisations and the collection of high 
integrity data from which to investigate the effects of JQ1-mediated BRD4 
inhibition on gene transcription in primary ALL (Figure 3.10 and 3.11). 
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Figure 3.9: Interpretation of data generated by the Agilent 2100 bioanalyser in the 
assessment of RNA quality. 
This system uses voltage-induced size separation in gel-filled channels and microcapillary 
electrophoresis to separate RNA and allow for the assessment of RNA quality. The system 
generates an electropherogram, and then uses an algorithm to calculate an RNA integrity 
number (RIN) [399, 410]. RNA samples with RIN values below 7 are of insufficient quality for 
downstream microarray applications, and a RIN value of 8 or greater is recommended [400]. 
a) Good quality gel-separated RNA is visualised as two distinct bands, comprising of 28S and 
18S ribosomal RNA r(RNA) species, with high RIN values. 
b) A typical electropherogram of good quality RNA is shown as two single peaks for 18S and 
28S rRNA, and high RIN values. (M = marker, FU = fluorescence units) 
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Figure 3.10: Quality assessment of primary ALL RNA samples using the 
Agilent 2100 bioanalyser: Gel electrophoresis. 
RNA extracted from 16 primary ALL tumour samples (8 control DMSO-treated 
and 8 1µM JQ1-treated samples) was gel-electrophoresed by the bioanalyser. 
Two distinct 18S and 28S rRNA bands were observed for all tumour RNA 
samples, with no observable degradation. 
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Figure 3.11: Quality assessment of primary ALL RNA samples using the 
Agilent 2100 bioanalyser: Electropherogram and RIN calculation. 
Laser-induced fluorescence of RNA is detected by the bioanalyser, and 
generates an electropherogram (plotted as fluorescence over time), which is 
used to calculate the RIN value for each RNA sample. 
Aside from the marker peak on the far left of each electropherogram, two 
distinct 18S and 28S rRNA peaks were observed for each RNA sample. 
All RNA samples (DMSO- and JQ1-treated) showed RIN values greater than 8 
and were of very high quality for downstream microarray experiments. 
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3.2.2 Analysis of single gene expression changes in primary 
ALL tumours following BRD4 inhibition 
Univariate analysis of microarray results is used to explore the most significant 
changes in the expression of individual genes between two different treatment 
conditions. I used the univariate analysis approach to investigate which genes 
were most differentially expressed in 8 primary ALL tumours upon inhibition of 
BRD4 following 6 hour exposure to the cytotoxic concentration of 1 µM JQ1, 
compared to the same tumours treated with DMSO. With the assistance of the 
bioinformatics expert, Dr. Wenbin Wei, array data were analysed using the 
Affymetrix Expression Console with the default settings of “Default: RMA-
Sketch”. I then identified genes most differentially expressed, with p-values less 
than 0.001 and a fold change greater than 2 using the limma analysis package 
[402]. 
With expression data filtered using the above mentioned statistical parameters, 
I identified a total of 96 differentially downregulated genes in JQ1-treated 
tumour cells (Figure 3.12). Downregulated genes included those involved in the 
inhibition of apoptosis such as BIRC3, which is an NFκB target gene encoding 
cIAP2 protein, commonly overexpressed in haematological malignancies and 
implicated in caspase inhibition [343, 411, 412]. The FAIM3 gene, encoding the 
anti-apoptotic factor Toso, was also significantly downregulated by JQ1 and is 
known to inhibit and regulate death receptor signaling [413]; an apoptotic 
pathway shown to be upregulated in lymphoblasts treated with anthracyclines 
commonly used to treat ALL [414]. Intriguingly, and consistent with recently 
published data [345], I found that JQ1 also caused downregulation of the IL7R  
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Figure 3.12: Global gene expression profiling to investigate the effects of 
JQ1 on gene transcription in primary ALL tumours 
Transcript expression heat-map was generated using dChip (http://www.dchip.org/) 
with the default settings, and shows a selected subset of genes downregulated or 
upregulated in 8 primary ALL tumours following 6 hour exposure to 1 µM JQ1.  
Downregulated genes include those belonging to multiple pro-survival signaling 
pathways such as NFκB and JAK/STAT, as well as c-Myc target genes and members 
of the interleukin gene family.  
Each column represents a different patient sample and each row represents a single 
gene. Colour changes within a row indicate expression levels relative to the average of 
the same population. Red indicates up-regulation, blue down-regulation. 
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gene, which was the third most differentially expressed gene among JQ1-
treated primary ALL tumours (3.91-fold decrease, p<0.001). The IL7R gene 
encodes the interleukin-7 receptor (IL-7R), which mediates prosurvival 
signalling via the JAK/STAT pathway and has been shown to be constitutively 
expressed in B-cell precursor ALL [197]. For a fully functional cytokine receptor 
to form, IL-7R must heterodimerise with either the IL-2R γ (IL2RG) subunit to 
form the IL-7 receptor, or with the cytokine receptor-like factor 2 (CRLF2) to 
form a receptor for thymic stromal lymphopoietin (TSLP), both of which are 
involved in abnormal activation of the STAT5 transcription factor [415, 416] . 
Furthermore, CRLF2 deregulation is observed in up to 10% of paediatric ALL 
and is associated with an unfavourable prognosis [192].  
Another cytokine receptor gene, IL2RA, encoding a protein subunit of the cell 
surface receptor complex to which the cytokine IL-2 binds has been shown to 
activate the JAK-STAT signalling pathway [417]. The IL2RA gene was also 
significantly downregulated following JQ1 treatment in all primary ALL tumours 
tested, suggesting that JQ1 targets multiple points in JAK/STAT pathway.  
Additionally, I found that the SENP1, ALKBH8, and CARD6 genes were also 
downregulated in JQ1-treated primary ALL, and encode proteins frequently 
associated with the promotion of cancer cell survival [418-422], as well as the 
MYC gene commonly overexpressed in haematological malignancies and key 
to cell proliferation [343, 412].  
I found that 127 genes were significantly upregulated following treatment of 
primary ALL cells with JQ1 inhibitor (Figure 3.12). These included the 
 131 
 
EIF4EBP2 gene, encoding a protein involved in the regulation of mTor signaling 
through repression of growth-promoting mRNA translation [423], as well as the 
PAIP2B gene, with a role in inhibiting translation of mRNA. The PPP1R13B 
gene was also upregulated following JQ1 treatment, and encodes the ASPP1 
protein. Interestingly, ASPP1 cooperates with p53 to induce apoptosis and is 
associated with a poor prognosis in ALL patients that lack its expression [424]. 
In summary, univariate analysis of microarray data in this experiment revealed 
that JQ1-mediated BET protein inhibition in primary ALL led to downregulation 
of genes involved in apoptosis inhibition and survival, as well as the 
upregulation of genes with a role in apoptosis induction and translational 
repression.  
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3.2.3 Microarray validation of differential responses in primary 
ALL tumours at 6 hours following JQ1-mediated BRD4 
inhibition using qRT-PCR 
Due to the nature of microarray studies, involving the measurement of 
expression levels of thousands of genes all at the same time, there is potential 
for false positive results, which imply a given gene is up- or downregulated 
following a particular treatment, when in fact it is not. For the same reasons as 
to why it is necessary to repeat experiments, and apply statistical significance 
tests to data, the validation of microarray data using a different experimental 
technique provides confidence that an observed result is not a false positive. 
To validate the differential responses observed in the microarray in this study, I 
selected 6 candidate genes (TNFSF4, IL7R, BIRC3, MYC, EIF4EBP2, and 
PPP1R13B) and decided to use qRT-PCR as the method of validation, since it 
is a highly sensitive and efficient technique. I selected TNFSF4 because this 
gene exhibited the greatest average differential response between untreated 
and JQ1-treated cells, and the highest statistical rank in the microarray analysis, 
with a 4.82-fold decrease in transcript expression (p<0.01). The IL7R gene also 
ranked highly with respect to statistical analysis, playing a major role in 
precursor B cell proliferative signaling and being directly involved in the 
activation of the JAK-STAT pathway [425]. BIRC3 is the NFκB target gene 
encoding the antiapoptotic cIAP2 protein [426]. MYC was selected since it is 
commonly overexpressed in leukaemia and potently drives cell proliferation. 
Recent studies have also confirmed that downregulation of BRD4 activity leads 
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to reduced expression of c-Myc protein in AML [344]. EIF4EBP2 is the gene 
encoding the 4EBP2 protein that is responsible for inhibiting growth-promoting 
mTOR signaling [427], whilst PPP1R13B encodes the ASPP1 protein implicated 
in the regulation of the apoptotic function of the TP53 tumour-suppressor gene 
in ALL and is associated with a poor prognosis when expressed at abnormally 
low levels [424]. Changes in expression of the above mentioned genes after 6 
hour exposure to 1 µM JQ1, measured by qRT-PCR, were generally consistent 
across tumours in the microarray, and have functions relevant to cell survival 
and apoptosis. Thus, JQ1-mediated modulation of the expression of all 6 genes 
might explain JQ1-induced cytotoxicity observed in ALL cells. 
I used 10 primary tumours (ALL-119, ALL-120, ALL-121, ALL-122, ALL-123, 
ALL-124, ALL-125, ALL-126, ALL-127, and ALL-128) for RT-PCR validation that 
were not used in the microarray, in order to confirm whether or not the changes 
in gene expression following JQ1 treatment observed in the microarray results 
were reproducible by RT-PCR. 
After RT-PCR quantification of selected gene mRNA transcripts in primary 
tumours, I found that there were uniform patterns of differential expression 
similar to those seen in the microarray data. IL7R, BIRC3, TNFSF4 and MYC 
were significantly downregulated following 6 hour JQ1 exposure, whilst 
EIF4EBP2 and PPP1R13B were significantly upregulated (Figure 3.17). 
In summary, the RT-PCR results I obtained suggest that changes in gene 
expression following JQ1 treatment are reproducible irrespective of the method 
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used or the primary tumour analysed, and therefore that results derived from 
the analysis of my microarray data are reliable. 
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Figure 3.17: Validation of microarray data using the qRT-PCR technique 
RNA was extracted from 10 primary tumours (ALL-119, ALL-120, ALL-121, ALL-122, 
ALL-123, ALL-124, ALL-125, ALL-126, ALL-127, and ALL-128) that were not included 
in the microarray experiment. 
Microarray results were validated by qRT-PCR using primer sets recognising TNFSR4, 
EIF4EBP2, BIRC3, PPP1R13B, MYC and IL7R mRNA. Ct values were normalised to 
β-actin mRNA. Graphs represent mRNA levels in DMSO- and JQ1-treated tumours. 
Pre-treatment of primary ALL tumours with 1 µM JQ1 leads to the differential 
expression of all selected validation genes in a similar fashion to that observed in the 
microarray experiment. 
p<0.01 p<0.01 
p<0.01 
p<0.01 
p<0.01 
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3.2.4. GSEA analysis of differentially regulated signaling 
pathways in primary ALL tumours following JQ1-mediated BET 
protein inhibition 
Multivariate analysis of microarray data is an approach used to assess whether 
or not there are synchronised changes in the expression of multiple genes 
belonging to common signaling pathways. As a wealth of expression data is 
generated from a microarray study, multivariate analysis can help identify which 
signaling pathways are affected by a particular treatment. Thus, I decided to 
use this method to analyse my microarray data to provide further insight as to 
the cellular signaling pathways being modulated in primary ALL tumours 
following treatment with JQ1 inhibitor. 
More specifically, I used gene set enrichment analysis (GSEA) [403] to look for 
concordant expression changes among genes grouped according to the 
biological pathway or function they are associated with; otherwise known as 
‘gene sets’. An advantage of this method of analysis over analysis on an 
individual gene level is that GSEA does not depend upon important individual 
genes standing out, but instead can detect modest yet consistent changes in 
gene expression within gene sets. This approach prevents the overlooking of 
differentially expressed genes even if only a selection of genes within a gene 
set is actually significant [428].  
With this in mind, the GSEA software package I used allowed me to rank all the 
genes according to their significance level (with respect to the differential 
expression observed when comparing genome-wide expression profiles of 
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DMSO- and JQ1-treated ALL tumours), and then calculating an enrichment 
score (ES) for each biological pathway, which is dependent upon the 
significance ranking of the member genes in that pathway. In other words, this 
establishes the proportion of genes that are significantly under- or 
overexpressed within their respective gene sets. This proportion is considered 
to be significant if the calculated false discovery rate (FDR) is less than 25% 
[429], or if the p-value is less than 0.05 [430, 431]. Use of the FDR value to 
determine significance is usually more stringent than use of the p-value; 
however, I decided to use both the FDR and p-value to determine the 
significance of differentially regulated gene sets. 
I aimed to identify biological processes or signaling pathways that were 
differentially regulated in primary ALL tumours following JQ1 treatment. Using 
GSEA I identified 771 out of 1886 gene sets that were downregulated following 
exposure to 1 µM JQ1, of which 172 gene sets were significantly downregulated 
exhibiting an FDR < 25%. %. Consistent with previous univariate analysis, I 
identified  gene sets representing the prosurvival signaling pathways NFκB and 
JAK-STAT, as well as the c-MYC pathway and multiple cytokine signaling 
pathways (IL2, IL7, IL10, and IL17) (Table 3.5; Figure 3.13 and 3.14). The 
‘BRCA/BRCA1 pathway’ and ‘cell proliferation’ gene sets were also 
downregulated, but marginally failed to meet the significance criteria, with them 
having a significant p-value but not FDR. GSEA also identified 1115 out of 1886 
gene sets to be upregulated following JQ1 treatment, of which 175 gene sets 
were significantly enriched at FDR < 25%. Noticeably, a significant proportion of 
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gene sets upregulated included those involved in gluconeogenesis, glycolysis, 
and Hif1a signaling.  
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Table 3.5: GSEA pathways downregulated in primary ALL tumours 
following JQ1 treatment. 
GSEA of microarray expression data obtained from 8 primary ALL tumours 
incubated with either DMSO or 1 µM JQ1 for 6 hours show that, in addition to 
the MYC pathway, JQ1-treatment leads to the downregulation of multiple 
cytokine and prosurvival signaling pathways, including the NFκB and JAK-STAT 
pathways, which are significant at FDR <0.25 (25%). 
Gene set / pathway name
Number of genes 
in pathway
NOM P FDR q
IL17 PATHWAY 13 0 0.010
CELL SURFACE RECEPTOR LINKED 
SIGNAL TRANSDUCTION
121 0 0.010
NFkB PATHWAY 106 0 0.080
INFLAMMATORY RESPONSE 
PATHWAY
29 0.002 0.020
CYTOKINE CONNECTION 15 0.02 0.100
IL7 PATHWAY 16 0.014 0.100
MYC PATHWAY 43 0.004 0.079
IL10 PATHWAY 13 0.039 0.140
IL2RB PATHWAY 34 0.012 0.140
STRESS SPECIFIC 44 0.012 0.150
CELL ADHESION 132 0.006 0.150
IL1 PATHWAY 62 0.014 0.170
JAK/STAT SIGNALING PATHWAY 150 0.01 0.200
VEGF 23 0.05 0.220
BRCA/BRCA1 PATHWAY 93 0.02 0.264
CELL PROLIFERATION 196 0.01 0.270
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Figure 3.13: GSEA of the NFκB and JAK-STAT pathways in primary ALL tumours 
in response to JQ1 treatment. 
Both the prosurvival signaling a) NFκB and b) JAK-STAT pathways are significantly 
downregulated (FDR <25%) in primary ALL tumours cells exposed to 1µM JQ1 for 6 
hours. 
NFκB pathway
JAK-STAT pathway
a) 
b) 
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Figure 3.14: GSEA of the MYC and Surface receptor signaling pathways in 
primary ALL tumours in response to JQ1 treatment. 
Both the a) MYC and b) Surface receptor signaling pathways are significantly 
downregulated (FDR <25%) in primary ALL tumour cells exposed to 1µM JQ1 
for 6 hours. 
 
MYC pathway
Surface receptor 
signaling pathway
b) 
a) 
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3.2.5 Identification of biomarkers predictive of JQ1 sensitivity 
and resistance 
Cytotoxicity data presented in section 3.1.1 show that, although primary ALL 
tumours ubiquitously express the BET protein BRD4 and a large proportion of 
ALL tumours are sensitised to the cytotoxic effects of JQ1 treatment, a 
considerable number of tumours still exhibit moderate sensitisation or 
resistance to BET inhibition. 
Upon consideration of the above observations, I proceeded to identify a way by 
which to predict tumour response to JQ1, so that unnecessary administration of 
this inhibitor to ALL patients most unlikely to respond would be avoided as this 
would only increase the risk of toxic side-effects, without providing any 
therapeutic advantage. 
Subsequently, I decided to look for biomarker genes predictive of JQ1 
sensitivity using the microarray data I had previously obtained (section 3.2.2). 
With the help of Dr. Wenbin Wei, I ranked primary ALL tumours according to 
JQ1 EC50 values from cytotoxicity experiments in section 3.1.2 and, using 
normalised and filtered gene expression values derived from untreated tumours, 
selected those genes most significantly associated with JQ1 EC50 using 
Spearman's rank correlation coefficient statistical analysis (coefficient ≥0.6; 
p<0.05) (Figure 3.15). 
Of these genes, I found that expression of the PLAUR and REL genes showed 
a strong positive correlation with JQ1 EC50 values in primary ALL tumours 
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(Figure 3.16), where the highest expression levels were observed in those 
tumours most resistant to the cytotoxic effects of JQ1 treatment.  
The PLAUR gene encodes the receptor for urokinase plasminogen activator 
(uPAR), which is anchored to the cell surface and is frequently overexpressed 
in human cancers [432-434]. The uPAR plays a role in the urokinase-catalysed 
activation of plasminogen, which results in extracellular matrix degradation and 
facilitates tumour invasion [435]. Furthermore, studies have shown that uPAR 
expression is associated with blast cell dissemination to the peripheral blood 
and inferior treatment outcome in AML [436]. 
The REL gene encodes c-Rel, which belongs to the rel subfamily of NFκB 
transcription factors, and is frequently overexpressed in Hodgkin’s lymphoma 
(HL) and non-Hodgkin’s B-cell lymphomas (NHLs) [437], and promotes B-cell 
proliferation and survival [438].   
Given their close association with JQ1 resistance in primary ALL tumours, 
quantification of either PLAUR or REL gene transcripts could be used to predict 
tumour sensitivity to JQ1. Importantly, this could be quickly determined using 
the qRT-PCR technique, which would require a very low number of cells from a 
biopsy.  
I next decided to perform GSEA on the EC50-ranked microarray data derived 
from untreated primary tumours, in a bid to identify biological processes or 
signaling pathways that may be upregulated and contributing to the resistance 
to JQ1 observed in a subset of tumours.  
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Figure 3.15: Transcriptional biomarkers predictive of JQ1 sensitivity and 
resistance in primary ALL 
The Affymetrix Expression Console™ software was used to normalise microarray gene 
expression values from untreated primary ALL tumours that were ranked according to 
JQ1 EC50 values derived from in vitro cytotoxicity experiments. 
ALL tumours are ranked from low to high EC50 values (green to red), seen on the top 
row of the above heatmap.  
The heatmap shows a subset of genes that positively correlate with JQ1 EC50 using 
Spearman’s rank correlation coefficient (coefficient ≥0.6; p<0.05), and may allow ALL 
tumour sensitivity to treatment with JQ1 to be predicted. 
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Figure 3.16: The PLAUR and REL genes as biomarkers predictive of JQ1 
sensitivity 
Primary ALL tumours analysed in the JQ1 microarray were ranked according to 
JQ1 EC50 values derived from in vitro cytotoxicity experiments.  
Expression levels of the a) PLAUR and b) REL genes in DMSO-treated tumours 
were plotted as mRNA expression relative to transcript levels in ALL-105 
tumour cells, which expresses the lowest level of each biomarker gene and is 
most sensitive to the cytotoxic effects of JQ1. 
Expression of PLAUR and REL genes negatively correlates with JQ1 sensitivity. 
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I found that 721 of 1335 gene sets were differentially upregulated in JQ1-
resistant primary tumours in comparison with JQ1-sensitive tumours. Of these, 
121 gene sets were significant (FDR <25%; p<0.05) and included gene sets 
representing NFκB, RAS and NOTCH prosurvival signaling pathways, as well 
as pathways that regulate cytokine signaling and gene transcription (Table 3.6).  
Since RAS and NOTCH pathways are upregulated in untreated JQ1-resistant 
primary ALL tumours, and I did not observe their downregulation in tumours 
following JQ1 treatment, it is possible that cross-talk from RAS and NOTCH 
signaling pathways may be promoting ALL tumour cell survival and contribute 
towards JQ1-resistance [439-441].   
In addition, two gene sets representing pathways that regulate the ribosome 
and ribosomal protein expression were also upregulated in JQ1-resistant 
tumours (Figure 3.15).  
Overall, the PLAUR and REL genes appear to be suitable candidate biomarker 
genes predictive of JQ1 sensitivity in B-precursor ALL. Furthermore, JQ1 
resistance may be mediated via the upregulation of multiple converging 
prosurvival signaling pathways and expression of ribosomal proteins involved in 
protein translation. 
3.2.6. Summary 
In conclusion, microarray data presented in this section were generated using 
high quality primary RNA samples, and qRT-PCR validation results were 
concordant with the changes in gene expression observed in the microarray. 
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The inhibition of BET proteins induced gene expression changes in primary ALL 
tumours that would be expected to favour the induction of apoptosis. This 
involved the downregulation of multiple prosurvival pathways, such as the NFκB 
and JAK-STAT signaling pathways.  
Importantly, the PLAUR and REL genes were identified as potential biomarker 
genes predictive of B-precursor ALL tumour sensitivity to JQ1. 
Overall, these results support my hypothesis in that targeting the BET family of 
proteins poses as an alternative strategy by which to inhibit prosurvival gene 
transcription to promote the induction of apoptosis in pre-B ALL.  
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Table 3.6: GSEA pathways upregulated at baseline level in primary ALL 
tumours most resistant to JQ1 activity 
Gene expression data was obtained from 8 DMSO-treated primary ALL tumours 
ranked according to JQ1 EC50.  
GSEA was performed on microarray gene expression data to identify pathways 
most strongly associated with JQ1 EC50 using Spearman’s rank correlation 
coefficient (coefficient ≥0.6; p<0.05). 
Multiple prosurvival pathways (including RAS and NFκB pathways), gene 
transcription pathways, and ribosome metabolism and assembly pathways are 
upregulated in primary ALL tumours with the highest JQ1 EC50 values (most 
resistant to JQ1 activity). These pathways are significant at FDR <0.25 (25%) 
and a nominal p-value (NOM P) <0.05. 
Gene set / pathway name Number of genes in pathway NOM P FDR q
RIBOSOME ASSEMBLY 67 0.000 0.002
TNFα-MEDIATED NFKB SIGNALING 18 0.000 0.021
RIBOSOMAL PROTEINS 81 0.000 0.029
TACI GENE EXPRESSION SIGNATURE 
(Moreaux et al. 2004) 288 0.000 0.032
RAS ONCOGENIC SIGNATURE 199 0.000 0.035
NFKB SIGNALING 88 0.005 0.085
TRANSCRIPTION FACTORS 56 0.000 0.110
GENE TRANSCRIPTION 63 0.011 0.143
CYTOKINE-CYTOKINE RECEPTOR 
INTERACTION 197 0.006 0.156
CELL COMMUNICATION 99 0.006 0.188
NOTCH SIGNALING PATHWAY 37 0.025 0.191
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3.3. Cellular effects of JQ1 on ALL tumour cells 
I proceed to elucidating some of the cellular effects by which cytotoxicity is 
exerted in ALL tumour cells following JQ1-mediated BET inhibition (Section 
3.1.2). 
Since I showed in section 3.1.1 that the BET protein family member BRD4 is 
frequently expressed in B-cell precursor ALL, and other studies have confirmed 
BRD4 plays a crucial role in positively regulating the expression of genes 
involved in growth and cell cycle progression [442], I began by investigating the 
effects of JQ1 treatment on the cell cycle of cycling ALL tumour cells (section 
3.3.1).  
Based on data from cell cycle analysis experiments that hinted towards a JQ1-
mediated impact on S-phase tumour cells, as well as the reported findings that 
BRD4 interacts with the RFC-140 essential for DNA replication [443], and plays 
a distinct role in Merkel cell polyomavirus (MCV) DNA replication [444], I also 
investigated the impact of JQ1 on the DNA replication process in ALL (section 
3.3.2). 
Finally, I investigated the effects of JQ1 treatment on apoptosis in ALL tumour 
cells, in order to gain a better understanding of how ALL tumour cells are 
eliminated.  
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3.3.1. Investigating JQ1-mediated effects on the cell cycle and 
c-Myc downregulation.   
I decided to use propidium iodide staining and flow cytometry to obtain cell 
cycle profiles for TOM-1, SUPB-15, SD1, and NALM-6 ALL cell lines following 
24 hour treatment with either DMSO or 1 µM JQ1. I found that JQ1 treatment 
led to a consistent accumulation of cells in the G1 phase of the cell cycle in all 
cell lines compared to control (Figure 3.18). This was accompanied by a 
marked reduction in S-phase cells in the SUPB-15, SD1, and NALM-6 cell lines. 
However, there was no reduction in the proportion of cells in the G2 phase of 
the cell cycle. Taking these observations into consideration, it is possible that 
JQ1 activity may be affecting cell cycle proteins regulating transition to the G2 
phase, as well as clearly inducing G1 arrest. The significant reduction in the 
proportion of S-phase cells is of particular interest and may be indicative of an 
impact on the DNA replication process. Furthermore, since the S-phase 
population of cells are not completely reduced, it was important to investigate 
whether DNA replication is still active within these cells (section 3.3.2).  
The c-Myc protein is tightly regulated throughout the cell cycle and plays a vital 
role in the facilitation of G1/S progression through the induction of G1 
cyclin/CDK kinase activity [445, 446]. Thus, downregulation of c-Myc is 
commonly associated with cell cycle arrest and the accumulation of cells in the 
G1 phase of the cell cycle [445]. A wide range of haematological malignancies 
exhibit deregulated expression of c-Myc, including B- and T-ALL, AML, chronic 
lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B-cell lymphoma, 
multiple myeloma, and Burkitt lymphoma, with previous studies showing that  
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Figure 3.18: Cell cycle analysis in DMSO- and JQ1-treated ALL cell lines  
ALL cell lines TOM-1, SUPB-15, SD1 and NALM-6 were treated with either DMSO or 
1µM JQ1 for 24 hours. Cells were then analysed by FACS using the PI dye to stain 
total DNA content. Graphs are plotted as cell count over PI stain intensity.  
G1-arrest is shown in all ALL cell lines tested following JQ1 treatment. 
A reduction of S-phase cells is also shown in SUPB-15, SD1 and NALM-6 cell lines. 
DMSO 1 µM JQ1
TOM-1
SUPB-15
SD1
NALM-6
G1
S G2
PI
Cell 
count
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overexpression of c-Myc in many of these diseases is associated with a poor 
clinical prognosis [447]. Consequently, a pharmacological strategy to 
downregulate c-Myc expression and activity is long sought after but not yet 
available. 
In recent years, c-Myc has been implicated as a downstream target of BRD4 
[339, 442]. Additionally, treatment of leukaemic cells with JQ1 in the context of 
AML led to rapid, marked reductions of Myc at both the transcriptional and 
protein levels. Taking these findings into consideration, together with the 
observation that JQ1 treatment induces potent G1-arrest, and that data from my 
microarray experiment shows MYC transcripts were downregulated in primary 
ALL tumours following exposure to JQ1, I decided to further investigate the 
regulation of Myc expression in ALL.  
Using the preB-ALL NALM-6 cell line, I quantified MYC mRNA levels by RT-
PCR at 6 and 24 hours after initial exposure of cells to 1 µM JQ1. I found that at 
6 hours MYC transcript levels were reduced by approximately 30% compared to 
control DMSO-treated NALM-6 cells (Figure 3.19a). However, at 24 hours MYC 
transcript levels had increased again, this time exhibiting a 20% reduction 
compared to control. This was unexpected since studies have shown MYC 
transcript levels to be substantially downregulated by lower concentrations of 
JQ1 up to at least 48 hours in multiple AML cell lines [344]. I then decided to 
use Western blotting to see how JQ1 affected c-Myc protein expression in a 
panel of ALL cell lines. Interestingly, exposure to 1 µM JQ1 led to complete 
downregulation of c-Myc protein at 24 hours across all cell lines tested and was 
maintained up to at least 96 hours (Figure 3.19b).  
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Figure 3.19: Myc downregulation in ALL cell lines following JQ1 treatment  
a) NALM-6 cell were treated with either DMSO or 1µM JQ1 for 6 and 24 hours. Total 
RNA was extracted from samples and Myc mRNA was measured by qRT-PCR.  
JQ1 induces transient downregulation of Myc mRNA (6hr) at the transcriptional level, 
before increasing again after 24hr exposure to JQ1. 
b) TOM-1, NALM-6, REH and SUPB-15 cells were treated with 1µM JQ1 for 0 (DMSO 
control), 24, 48, 72 and 96 hrs. Protein lysates were analysed by Western blotting, 
where samples were probed for c-Myc and β-actin (loading control). 
1µM JQ1-treatment leads to complete and sustained downregulation of c-Myc protein 
by 24hr in all ALL cell lines analysed. 
 
a) 
b) 
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Since Myc expression at the transcriptional level did not mirror expression at the 
protein level in ALL cell lines, and c-Myc protein downregulation following 24 
hour exposure to 1 µM JQ1 was a common feature, I decided to investigate 
whether or not JQ1-mediated c-Myc protein downregulation was due to 
modulation of protein stability and the targetting of c-Myc for proteasomal 
degradation. This idea is consistent with the fact BRD4 has previously been 
reported to regulate the stability of the papillomavirus-encoded E2 protein [448]. 
I treated NALM-6 and TOM-1 cells with either DMSO (control), the 26S 
proteasome inhibitor MG132 (10 µM) alone, JQ1 (1 µM) alone, or a MG132/JQ1 
combination for 24 hours, and then assessed the levels of c-Myc protein 
expression by Western blotting. I found that in both ALL cell lines, treatment 
with JQ1 alone caused complete reduction of c-Myc, as was expected; 
however, treatment with the MG132/JQ1 combination completely abrogated 
JQ1 activity with respect to c-Myc downregulation (Figure 3.20). This suggests 
that the MG132 inhibitor prevents proteasomal degradation of c-Myc protein in 
ALL tumour cells exposed to JQ1, and that JQ1 is capable of modulating the 
stability of c-Myc protein via a post-translational mechanism involving the 26S 
proteasome, thus highlighting a role for BET proteins in the reguation of cellular 
proteins at the post-translational level, in addition to the transcriptional level. 
In summary, JQ1 treatment leads to cell cycle G1 arrest in all ALL cell lines 
tested and it is possible that JQ1 activity has an impact on DNA replication 
machinery. Treatment with JQ1 also induces modest and temporary 
downregulation of MYC at the transcriptional level, but instead appears to 
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mainly exert the observed loss in c-Myc protein expression by regulating protein 
stability at the post-translational level.  
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Figure 3.20: MG132-mediated inhibition of the proteasome abrogates 
downregulation of c-Myc protein by JQ1 
NALM-6 and TOM-1 cells were either untreated, treated with 10 µM MG132 
only, 1 µM JQ1 only, or treated with an MG132/JQ1 inhibitor combination for 
24hr. Protein lysates were analysed by Western blotting, where samples were 
probed for c-Myc and β-actin (loading control). 
Treatment of ALL tumour cells with 1 µM JQ1 leads to complete downregulation 
of c-Myc in both cell lines, whereas treatment with either MG132 or MG132/JQ1 
combination does not. This suggests JQ1-mediated c-Myc protein 
downregulation is dependent upon activity of the proteasome. 
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3.3.2 Investigating the effects of JQ1 exposure on the DNA 
replication process 
Each time a eukaryotic cell divides, accurate replication of the complete 
genome must be precisely coordinated in order to maintain genome integrity. 
The origins of replication are the sites at which multiple proteins assemble in an 
ordered manner during late mitosis and early G1 to form the pre-replicative 
machinery, giving rise to replication forks [449]. Abnormal modifications to this 
highly organised process may lead to unscheduled DNA synthesis and genomic 
instability; thus promoting tumorigenesis [450]. Studies have shown that c-Myc 
plays an important role in DNA replication origin initiation via a non-
transcriptional mechanism involving the direct interation with minichromosome 
maintenance (MCM) proteins that constitute the pre-replicative complex crucial 
to the regulation of replication origins [451, 452]. Furthermore, it has also been 
reported that the BET protein BRD4 directly interacts with the largest subunit, 
RFC-140, that constitutes part of the highly conserved five-unit replication factor 
C (RFC) complex essential for DNA replication [443]. Interestingly, the role of 
BET proteins in replication is not only restricted to mammalian cells. A recent 
study has shown that BRD4 interacts with the MCV Large T antigen (LT) and is 
critical for successful viral DNA replication of the MCV genome [444].  
Upon consideration of the above mentioned observations, it is possible that JQ1 
activity has an impact on the DNA replication process in ALL cells. This was 
also supported by the observation that transcription of the CLSPN gene 
encoding the protein Claspin was upregulated in the microarray in primary ALL 
tumours treated with JQ1 (Figure 3.12), since Claspin is a critical mediator of 
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the DNA-damage response pathway [453]. The Claspin protein is expressed 
following increased levels of stress and blocks in DNA replication, and is 
responsible for the phosphorylation and consequent activation of Chk1, which in 
turn activates the S-phase checkpoint [454]. 
The significant reduction in the proportion of S-phase cells following JQ1 
treatment of ALL cell lines I previously showed (Figure 3.18), also suggests a 
specific effect on replication. In light of this observation, I was particularly 
intrigued to investigate the status of replicative activity in the very small 
proportion of remaining S-phase cells, despite being treated with JQ1, as active 
replication in these cells might indicate JQ1-resistant ALL clones capable of re-
expansion.  
I therefore decided to test my hypothesis that JQ1-induced cytotoxic effects 
observed in proliferating ALL cells are partly due to a direct impact on DNA 
replication, rather than just consequences of cell cycle arrest. I did this by using 
a fluorescent DNA fibre-labelling technique and the BrdU incorporation assay to 
investigate the effects of JQ1 on replicating NALM-6 cells.  
The DNA fibre-labelling technique involves the use of halogenated nucleotide 
analogues that are incorporated into newly synthesised DNA of proliferating 
cells. Once extracted DNA fibres are stained with specific antibodies conjugated 
to either red or green fluorescent dyes, they can be visualised by fluorescent 
microscopy. With the use of dedicated computer software, this approach allows 
for the identification and quantification of ongoing replication forks, fork 
terminations, new origins of replication, as well as the determination of the 
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direction and the rate at which replication forks progress [455] (See Appendix 
8.6 for schematic showing possible replication structures).  
I began by investigating fork progression rates, derived from the measurement 
of the fluorescent red and green portions of each individual DNA fibre within the 
captured photographic images. I decided to treat NALM-6 cells with 1 µM JQ1 
for a short exposure time of 1 hour, insufficient to induce G1/S cell cycle arrest, 
so as to exclude the possibility that any replication effects I observed using a 
longer exposure time would not be attributable to cell cycle effects. Upon 
measuring the individual fibres extracted from NALM-6 cells treated with either 
DMSO or 1 µM JQ1 for 1 hour, I found that treatment of cells with JQ1 led to 
greatly decreased fork progression rates compared to control cells (Figure 
3.21a). This indicated that JQ1 may have a direct effect on the DNA replication 
process and that it was unlikely that the effects observed after just 1 hour were 
due to JQ1-mediated downregulation of genes involved in cell cycle 
progression.  
I then investigated the effect of JQ1 on fork progression rates at a 24 hour 
timepoint, since this was the same timepoint at which I observed a significant 
reduction in the proportion of S-phase NALM-6 cells by PI/FACS cell cycle 
analysis (Figure 3.18). I found that 24 hour exposure to 1 µM JQ1 also caused a 
decrease in fork progression rates compared to control cells (Figure 3.21b).  
To further confirm that the observed reduced rates of fork progression were due 
to the inhibition of replication in S-phase cells and not derived from a JQ1-
mediated effect on the G1/S checkpoint and reduced entry to the S-phase, I 
 160 
 
used the BrdU incorporation assay to quantify the level of BrdU uptake by S-
phase NALM-6 cells following exposure to increasing concentrations of JQ1. I 
found that JQ1 treatment did not affect the entry of cells into the S-phase of the 
cell cycle, but did reduce the proportion of S-phase cells in a dose-dependent 
manner (Figure 3.22).  
I next wanted to gain further insight into the type of replication structures that 
were present in NALM-6 cells treated with 1 µM JQ1 by quantifying the total 
number of 1st label origins, 2nd label origins, 1st label terminations/stalled forks, 
and 2nd label terminations. I found that 24 hour exposure of NALM-6 cells to 1 
µM JQ1 led to greater than 13% increase in the proportion of DNA fibres 
characteristic of stalled replication forks compared to DMSO-treated cells 
(Figure 3.23). No significant changes were observed for the other types of 
replication structures. 
The data presented in this section lend support toward my hypothesis that JQ1 
activity has a direct effect on DNA replication. I showed that treatment of a 
proliferating ALL cell line with JQ1 led to reduced fork progression rates and an 
increase in the frequency of stalled replication fork structures, as a result of 
increased replication stress. Finally, BrdU incorporation assay data also 
indicates that the observed JQ1-mediated effects on replication are 
independent of G1/S checkpoint control. 
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Figure 3.21: Effect of JQ1 treatment on DNA replication fork progression 
in ALL tumour cells 
NALM-6 cells were pre-treated with either DMSO (control) or 1 µM JQ1 for 1hr and 24hr. 
Cells were then labelled with CldU (first label/red fluorescent dye) and IdU (second 
label/green fluorescent dye) for 20 minutes each. Photographs were taken of visualised 
replication fibres in each treatment. Individual fibres were measured using ImageJ 
software, and distribution of fork speeds calculated.  
a) Treatment of NALM-6 cells with 1 µM JQ1 for 1hr causes a reduction in replication fork 
progression, as demonstrated in analysis of both CIdU and IdU labels. 
b) Treatment of NALM-6 cells with 1 µM JQ1 for 24hr causes a reduction in replication fork 
progression, as demonstrated in analysis of the IdU label. This is not demonstrated by 
analysis of the CIdU label. 
These results, involving a short 1hr incubation of cells with JQ1 inhibitor, suggest JQ1 
activity has a direct impact on DNA replication fork progression in NALM-6 cells. 
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Figure 3.22: JQ1 treatment induces specific reduction of replicating S-
phase cells 
BrdU incorporation by FACS analysis shows a normal S-phase cell distribution in 
NALM-6 cells (DMSO-treated control), which reduces in intensity when treated with 
increasing concentrations of JQ1. This suggests JQ1 specifically targets DNA 
replication. 
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Figure 3.23: JQ1 causes DNA replication stress in S-phase ALL tumour 
cells 
NALM-6 cells were pre-treated with either DMSO (control) or 1 µM JQ1 for 24hr and 
pulse-labelled with CldU (red) and IdU (green) for 20 minutes each. 
a) JQ1-treated DNA replication fibre (right) shows reduced incorporation of 
CIdU, and complete lack of IdU incorporation, compared to replication fibres 
extracted from DMSO-treated NALM-6 cells (left) that incorporated both dyes.  
This indicates JQ1 perturbs replication fork progression. 
b) Four different replication structures could be derived from the measurement 
of both CIdU and IdU stained replication fibres. 
Treatment of cells with JQ1 causes an increase (~13%) in the proportion of 1st 
label terminations, which represent stalled replication forks.  
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3.3.3 Effect of JQ1 on apoptosis in ALL tumour cells 
Most therapeutic agents kill tumour cells via the induction of apoptosis, and the 
knowledge we have acquired regarding programmed cell death has allowed for 
the design of novel agents that specifically target malignant cells for killing more 
efficiently. The induction of apoptosis is considered to be an ideal mechanism of 
killing for novel agents, since apoptotic cells are removed in a very controlled 
manner via phagocytosis, as opposed to necrotic cell death, where cells lyse 
and release their contents into the extracellular space, triggering an 
unfavourable inflammatory response [245]. 
 
Our group previously reported that apoptotic resistance observed in primary 
ALL tumours in vitro following DNA damage correlates with high-risk patient 
stratification and a poor clinical response in vivo, indicating that overcoming this 
apoptotic resistance with novel agents could potentially improve the treatment 
outcome of high-risk patients [247]. Our group also reported that despite a 
normal damage-induced upregulation of p53 in the primary tumours tested, 
those resistant to apoptosis exhibited upregulation of multiple prosurvival 
pathways [248]. Deregulation of prosurvival pathways is often associated with 
the abnormal expression of antiapoptotic proteins such as Mcl-1, Bcl-2, as well 
as many of the IAP family members. Mcl-1, is a known therapeutic target in 
acute and chronic lymphoid malignancies [456], and is upregulated in many 
cases of relapsed ALL [457]. Deregulated expression of Bcl-2 is also reported to 
correlate with a poor response to chemotherapy in AML and CLL [458, 459]. 
The BIRC3 gene encodes the antiapoptotic protein cIAP2, which is frequently 
 165 
 
overexpressed in Hodgkin lymphoma and many haematological malignancies 
including ALL [460, 461]. Overexpression of survivin, an antiapoptotic protein 
encoded by the BIRC5 gene, has been reported in primary ALL tumours and is 
associated with high risk of clinical relapse [462].  
 
Taking the above reported findings and the importance of understanding a 
therapeutic agent’s mechanism of cell killing, particularly when combined with 
other agents, I first determined whether or not JQ1 induced killing by apoptosis. 
I  used Annexin V / PI staining and flow cytometric analysis, and found that 
incubation of NALM-6 cells with 1 µM JQ1 for 72 hours revealed a differential 
increase (~11%; p < 0.01)  in the percentage of apoptotic cells compared to 
DMSO-treated control cells (Figure 3.24a). I then used the Western blotting 
technique to confirm this observation by treating preB-ALL cell lines with 1 µM 
JQ1 and probing for PARP1, procaspase-3 and procaspase-7 over a 96 hour 
timecourse. I found that JQ1 treatment led to cleavage of full-length PARP1, 
procaspase-3 and procaspase-7 proteins, as seen in the BCR-ABL1+ SUPB-15 
cell line at 72 hours, and in the REH cell line at the later timepoint of 96 hours 
(Figure 3.24b). Since procaspase-3 and -7 require cleavage in order to act as 
the effector caspases of apoptosis and induce cleavage of substrates such as 
PARP1, these results indicate that the cytotoxic effects of JQ1 activate the 
apoptosis pathway. The delayed onset of apoptosis seen in REH when 
compared to SUPB-15 may be a reflection of the less prominent JQ1 cytotoxic 
effects observed in experiments using ATP-based cytotoxicity assays.  
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Next, I wanted to further investigate the mechanism of apoptosis induction 
following JQ1 treatment in ALL cell lines by measuring p53 expression levels in 
the NALM-6 cell line with wild-type p53. I used Western blotting to measure the 
level of total p53 in NALM-6 cells treated with 1 µM JQ1 over a 72 hour 
timecourse. In this experiment I also included DMSO-treated NALM-6 cells as a 
negative control, and NALM-6 cells treated with 100 nM daunorubicin as a 
positive control for p53 upregulation and activation. I found that treatment with 
JQ1 did not cause upregulation of p53 protein throughout the timecourse, as 
seen in the DMSO control, and in contrast to the cells treated with the DNA-
damaging agent daunorubicin, where p53 upregulation occurred at 6 hours 
post-treatment and persisted up to 72 hours (Figure 3.25a).  
 
Subsequently, I tested for phosphorylation of p53 at Ser15, which is a 
phosphorylation site targeted by the mediators of the DNA damage response, 
ATR and ATM [463]. Phosphorylation of p53 at Ser15 leads to p53 
transactivation and p53-mediated transcription of genes involved in cell cycle 
arrest such as CDKN1A that encodes the p21 protein, as well as other genes 
involved in DNA repair and apoptosis [464-466]. Whereas treatment with 
daunorubicin led to phospho-p53 (Ser15) upregulation at 6 hours through to 72 
hours exposure (Figure 3.25a), I found that JQ1 and DMSO did not lead to the 
phosphorylation of p53 (Ser15). Similarly, JQ1 and DMSO failed to induce p21 
upregulation, whereas exposure to daunorubicin led to moderate p21 
upregulation after 6 hours, the levels of which continued to increase, peaking at 
48 hours, before decreasing again at 72 hours post- treatment (Figure 3.25a). 
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These results suggest that JQ1 induces via p53-independent apoptosis in ALL 
cells.  
 
Thus, to further elucidate the p53-independent mechanism of apoptosis induced 
in JQ1-treated NALM-6 cells, I decided to probe for four key anti-apoptotic 
proteins, Bcl-2, Mcl-1, BIRC3 (cIAP2), and BIRC5 (survivin) and look for any 
changes in expression of these proteins following JQ1 treatment. I found that 
following 24 hour exposure of NALM-6 cells to 1 µM JQ1, Mcl-1 expression 
levels decreased steadily until 96 hours and that no significant change was 
observed in the expression levels of Bcl-2 and cIAP2 (Figure 3.25b). However, 
the expression of survivin was completely lost within 48 hours of incubation with 
1 µM JQ1.  
Since I did not observe any significant impact of JQ1 on the transcription of 
BIRC5 in the microarray data, I addressed the possibility that the loss of survivin 
protein expression was due to protein degradation. Using Western blotting I 
measured the levels of survivin in NALM-6 cells treated with either DMSO, 1 µM 
JQ1, 10 µM MG132, or a combination of JQ1/MG132. I found that JQ1 
treatment alone caused complete downregulation of survivin, compared to no 
change in expression in cells treated with DMSO or MG132 alone (Figure 3.26). 
In contrast, treatment of NALM-6 cells with JQ1 combined with the proteasome 
inhibitor MG132 completely abolished the ability of JQ1 to downregulate 
survivin, as was seen with c-Myc protein expression.  
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3.3.4 Summary  
Taken together, in terms of cellular killing, I found that JQ1 treatment of ALL cell 
lines induced p53-independent apoptosis that involved the downregulation of 
the antiapoptotic protein survivin by modulating the stability of this protein at the 
post-translational level. 
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Figure 3.24: JQ1 induces caspase-dependent apoptosis in ALL tumour cells 
a) Annexin V/PI staining and FACS analysis shows differential induction of apoptosis in 
NALM-6 cells treated with 1 µM JQ1 over a 72h incubation period compared to DMSO-
treated control cells. 
b) Western blotting shows the induction of apoptosis in ALL cell lines SUPB-15 and 
REH as measured by cleavage of proteins PARP1, procaspase-3 and -7 over a 96hr 
incubation period with 1 µM JQ1. Actin was probed for as a loading control. 
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Figure 3.25: Induction of apoptosis by JQ1 involves a p53-independent 
mechanism 
a) Western blotting shows no evidence of either p53 upregulation, p53 phosphorylation 
or significant p21 upregulation in NALM-6 cells incubated with 1 µM JQ1 over 72hr. 
Treatment with the DNA-damaging agent daunorubicin (100 nM) induces expression of 
both total and phosphorylated p53, as well as the expression of the p53 target p21. 
b) Western blot shows that 24hr exposure of NALM-6 cells to 1 µM JQ1 leads to the 
downregulation of Mcl-1 protein expression levels, which decrease steadily until 96 
hours. The expression of survivin was completely lost within a 48hr incubation with 1 
µM JQ1. No significant change was observed in the expression levels of Bcl-2 and 
cIAP2 protein. Actin was used as a loading control. 
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Figure 3.26: Co-treatment of ALL tumour cells with JQ1 and the 
proteasome inhibitor MG132 abrogates JQ1-mediated downregulation of 
survivin  
JQ1 abolishes protein expression of survivin in NALM-6 cells, which is rescued 
following combined JQ1/MG132 treatment. This suggests the downregulation of 
survivin expression following JQ1 treatment is at the post-translational level. 
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3.4. Investigation of JQ1 activity in an ALL xenograft model 
 
Many murine models have been developed to aid our understanding of human 
cancer development and responses to novel therapies before they reach the 
clinic.  One of the most commonly used models is the human tumour xenograft, 
whereby human tumour cells are transplanted under the animal’s skin or into 
the organ type from which the human tumour cells originated from [467]. The 
recipient mice must be immunocompromised so that the human tumour cells 
are not rejected by the host immune system. Efforts to develop mouse strains 
with increased capacities for enhanced human tumour engraftment have led to 
the discovery and use of severe combined immunodeficiency (SCID) mouse 
strains. The NOG (NOD/Shi-scid/IL-2Rγnull) mouse is a more recently 
developed generation of SCID mice, accepting heterologous cells far more 
easily than other immunodeficient murine models such as the nude mouse and 
NOD/SCID mouse, since NOG mice have dyfuctional macrophage and dendritic 
cells, and lack T-, B- and NK-cell activity [468]. Depending on the number of 
cells injected, leukaemia cells typically engraft over a period of 8 weeks, in 
which time in vivo responses to specific therapies may be tested [469]. The 
greatest advantage of using a human tumour xenograft model is that tumours 
will consist of human and not mouse tumour cells, therefore maintaining the 
original human tumour’s molecular features including chromosomal 
abnormalities, whilst providing a more realistic representation of how effective 
the therapy would be if given to the patient [469, 470]. Indeed, studies looking at 
whether or not results from tumour xenograft models translated to responses 
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observed in the respective patients revealed a very high degree of predictive 
power both in the response to chemotherapeutic agents and resistance in 
patients [471]. Therefore, it is not surprising that cancer therapeutic agents are 
rarely clinically approved unless shown to exhibit anti-tumour activity in a 
preclinical in vivo mouse model [470]. 
Additional aspects to consider, when using murine models to investigate 
leukaemia, are that exposure to some drugs may impose selective pressure on 
leukaemic subclones or may target specific immunophenotypic subpopulations 
of cells more than others, causing a shift in the expression of 
immunophenotypic markers [472]. This phenomenon is sometimes observed in 
the clinic and creates difficulties in the monitoring of MRD to promptly predict 
the risk of relapse in patients receiving treatment [473, 474]. The CD34 marker 
is an antigen expressed in human haematopoietic stem cells and progenitor 
cells, with expression decreasing as the cell differentiates. Important studies in 
ALL have provided evidence to support the existence of disease-propagating 
pre-leukaemic stem cells that evolve through the acquisition of additional 
genetic abnormalities [475-478]. This is also supported by studies in paired 
relapse and diagnostic primary ALL samples, which provide evidence for the 
selection of leukaemic stem cells with acquired additional abnormalities [80, 
479].  
In hindsight, the fact that the proportion of leukaemic subpopulations are subject 
to change and the evolving pre-leukaemic stem cell is likened to a constantly 
moving therapeutic target [480], highlights the importance in monitoring 
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subpopulations by measuring expression of surface markers when testing 
therapeutic agents in animal studies.  
 
Since JQ1 exhibited potent anti-tumour activity in xenograft models of AML and 
NUT midline carcinoma, and I observed JQ1 cytotoxic effects against ALL in 
vitro, I decided it was appropriate to begin testing the efficacy of JQ1 in vivo 
using the ALL xenograft mouse model our group has developed. 
 
To address JQ1 activity in vivo, I performed two separate experiments using 
ALL xenograft models; one using an in vitro JQ1-sensitive ALL cell line, and the 
other using a JQ1-sensitive primary ALL tumour. 
 
3.4.1 Investigating JQ1 activity in a NALM-6 xenotransplant 
model 
The first experiment involved the subcutaneous injection of NALM-6 cells into a 
cohort of 16 NOG mice. Once tumours were visible, with the help of a colleague 
from our group (Tracey Perry), animals received either 50mgkg-1 JQ1 (n=8) or 
vehicle alone (n=8) via intra-peritoneal (IP) injection for 5 days per week, for a 
period of 2 weeks. The tumour volume was then measured manually three 
times a week using callipers.  
I found that animals receiving JQ1 showed a significant reduction in tumour 
growth over a 10-week period compared to animals treated with vehicle over 
the same period of time (Figure 3.27) (p<0.05) 
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Figure 3.27: JQ1 prevents proliferation of ALL tumour cells in vivo  
An unpaired, 2-tailed t-test was used to compare the differences between vehicle (n=8) 
and JQ1 treated animals (n=8), with error bars representing the standard deviation.  
 
a) Subcutaneous NALM-6 tumours show a significant impairment in growth when 
treated with 50mg/kg JQ1 over a 2 week time period compared to tumours treated with 
vehicle. This was significant at p<0.05 
b) The difference in tumour size is shown in the photograph of two representative 
animals, treated with vehicle (left) and 50mg/kg JQ1 (right). 
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(control)
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3.4.2 Investigating JQ1 activity in ALL-105 xenotransplant 
model 
The second experiment involved the development of a xenograft model of an 
apoptotic-resistant, MRD high-risk, but JQ1-sensitive primary B precursor ALL 
(ALL-105), in a cohort of 14 NOG mice. Once animals had been injected with 
ALL-105 primary tumour cells (again with the kind help of Tracey Perry), the 
level of engraftment was monitored by measuring the percentage of human 
CD45 (hCD45) cells by weekly blood sampling and flow cytometric analysis. 
Once the levels of hCD45 reached 1%, treatment commenced. After 4 weeks of 
treatment with either JQ1 or vehicle, flow cytometric analysis was used to 
measure the overall tumour load in the spleens of engrafted animals, as well as 
the frequency of specific ALL progenitor populations. 
Furthermore, I found that engrafted spleens from animals treated with JQ1 
showed a significant reduction in tumour load compared to spleens from 
animals treated with vehicle (p<0.001). This was represented by a reduction in 
mean spleen weight, and reduction in spleen size in JQ1-treated animals 
(Figure 3.29).   
I found that the level of hCD45-positive cells in all animals treated with vehicle 
exceeded the recommended experimental endpoint of 25% hCD45 by 28 days, 
whereas levels of hCD45 in samples taken from animals receiving JQ1 
treatment were maintained below 25% throughout a period of 49 days (the end 
of the experiment) (Figure 3.28).  
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flow cytometric analysis revealed three ALL subpopulations in the engrafted 
leukaemia, CD34+CD19+CD10-, CD34+CD19+CD10+ and CD34-
CD19+CD10+, that had the capacity to proliferate in vivo. Although the 
malignant origin was uncertain, a small percentage of CD34-CD19+CD10- cells 
were also detected in engrafted spleens. I observed a JQ1-induced reduction in 
all three ALL progenitor subpopulations, with the greatest reduction being 
exerted on CD34+CD19+CD10+ subset of ALL cells (Figure 3.30).  I observed 
a slight increase in the frequency of CD34-CD19+CD10- cells in JQ1-treated 
animals in comparison to vehicle-treated animals, suggesting either differentially 
lower sensitivity of mature progenitors or differentiation of blast cells induced by 
JQ1. 
 
Finally, I found that the mean body weight of animals treated with JQ1 did not 
significantly differ from those receiving vehicle during a 28 day period and did 
not exceed the recommended experimental endpoint of 15% loss in body 
weight (Figure 3.31). This indicated that the JQ1 compound was well tolerated 
by the animals and did not cause a significant deterioration in their health. 
3.4.3 Summary 
In conclusion, the data obtained from these animal studies confirmed that JQ1 
confers anti-tumour activity in vivo. This was demonstrated by a clear reduction 
of tumour growth and leukaemia burden in JQ1-treated animals compared to 
those treated with vehicle. Data analysis also revealed that JQ1 eliminates all 
ALL progenitor subpopulations, with the greatest effect seen in 
CD34+CD19+CD10+ cells. 
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Figure 3.28: JQ1 prevents proliferation of apoptosis-resistant primary ALL 
tumour cells in vivo  
 
a) Graph shows %hCD45 in vehicle-treated ALL-105 engrafted NOG mice. All 
vehicle-treated mice exceeded the experimental endpoint of 25% hCD45 by 28 
days.  
 
b) Graph shows %hCD45 in ALL-105 engrafted NOG mice treated with JQ1. 
The level of %hCD45 was maintained below 25% throughout a period of 49 
days. 
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Figure 3.29: JQ1 treatment leads to reduced leukaemic burden in an ALL 
xenograft mouse model (ALL-105) 
 
In a xenograft of a representative apoptosis-resistant primary ALL-105, animals 
treated with JQ1 (n=7) showed a significant reduction in tumour load compared 
to spleens from animals treated with vehicle (n=7). 
 
This was represented by a reduction in mean spleen weight (p<0.001) (left), 
and reduction in spleen size (right) in JQ1-treated animals. The spleen size of 
the animals treated with JQ1 was representative of the spleen size seen in 
healthy control mice.  
 
An unpaired, 2-tailed t-test was used to compare the differences between 
vehicle and JQ1 treated animals, with error bars representing the standard 
deviation. 
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Figure 3.30: JQ1 eliminates multiple ALL subpopulations in vivo 
Flow cytometric analysis of murine spleens engrafted with ALL-105 reveals that 
JQ1-treated animals show reduction in ALL subpopulations: 
CD34+CD19+CD10-, CD34+CD19+CD10+ and CD34-CD19+CD10+, and a 
relative increase in the CD34-CD19+CD10- population. 
An unpaired, 2-tailed t-test was used to compare the differences between 
vehicle and JQ1 treated animals, with error bars representing the standard 
deviation. 
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Figure 3.31: JQ1 is well tolerated in an ALL xenograft mouse model 
NOG mice engrafted with ALL-105 and treated with either vehicle or JQ1 were 
weighed on days 0, 14, 21 and 28.  
Total body weight of mice receiving either treatment did not fluctuate 
significantly or reduce by 15% (experimental endpoint). This suggests JQ1 is 
well tolerated in vivo. 
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CHAPTER 4 
Results II: The PIM2 kinase as a candidate 
for further study  
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4. RESULTS II: THE PIM2 KINASE AS A CANDIDATE 
FOR FURTHER STUDY  
 
4.1. Investigation of PIM kinases as potential targets in the 
treatment of precursor B-cell ALL 
PIM kinases are expressed in a wide range of leukaemia and lymphomas, and 
have been positively associated with a poor treatment prognosis [481-484]. 
However their role in precursor B-cell ALL has not yet been explored. 
As described in section 1.10.3, recent studies have demonstrated that the PIM 
kinases play an important role in the regulation of gene transcription by 
promoting specific histone acetylation events required for the docking of BET 
proteins, such as BRD4, to histones within transcriptionally active chromatin 
[386, 387]. This in turn allows for the recruitment of the P-TEFb complex, which 
is essential for the release of RNA polymerase II from promoter-proximal pause 
sites and subsequent transcript elongation [388].  
In light of my results described in Chapter 3 that show BET proteins are 
associated with the transcriptional upregulation of multiple prosurvival pathways 
in ALL, I hypothesised that PIM kinases serve as an alternative means by which  
prosurvival signalling pathways are kept switched on and that consequently, 
targeting PIM kinases can induce apoptosis in ALL tumour cells. 
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Indeed, in support of this hypothesis, further analysis of the microarray results 
presented in this study, in which I ranked the fold-change in gene expression 
(as opposed to basal expression levels) in JQ1-treated primary ALL tumours 
according to EC50 values derived from in vitro cytotoxicity experiments, showed 
that upregulation of the PIM2 gene in response to JQ1 treatment was strongly 
associated with JQ1-resistant tumours (Appendix 3). This suggests that PIM 
proteins might compensate for the pharmacological inhibition of BET protein 
activity, and confer resistance to JQ1. 
I therefore proceeded to investigate whether PIM kinases were important in the 
pathogenesis of B-ALL, and posed as a viable therapeutic target for future 
studies.  
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4.1.1. Method validation for the screening of primary ALL 
tumours for PIM expression 
I first wanted to identify the most practical method by which to measure the 
frequency of PIM kinase expression in primary pre-B ALL tumours, whilst using 
a limited amount of primary tumour material. 
Since I had access to RNA samples extracted from a cohort of 68 primary ALL 
tumours, and PIM expression is reported to be regulated at the transcriptional 
level [385, 485], I decided to validate the qRT-PCR technique for the indirect 
screening of primary ALL tumours for PIM protein expression.  
I began by testing the primers I designed to detect PIM1 and PIM2 transcripts 
on a panel of 7 primary ALL RNA samples (ALL-201, ALL-204, ALL-210, ALL-
213, ALL-217, ALL-232 and ALL-240). I did not measure PIM3 transcript levels 
as this gene is not associated with haematopoiesis.  
I found that for each RNA test sample, the primer sets for both PIM genes 
amplified a single product at the expected molecular weight (Figure 4.1 a & b). 
Sequencing of the amplified PCR products also confirmed that they aligned to 
PIM1 and PIM2 mRNA sequences. These results showed that the PIM primer 
sets were specific and could be used in further experiments. 
Using qRT-PCR and Western blotting, I then decided to test whether PIM gene 
expression correlated with PIM protein expression levels in a panel of 7 
leukaemia cell lines (REH, NALM-17, SD1, Kasumi, Jurkat, CEMC1 and K562). 
In contrast to the REH, NALM-17, Jurkat and CEMC1 cell lines that did not 
express PIM, I found that both PIM1 and PIM2 were expressed at the RNA and 
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protein level in Kasumi, SD1 and K562 cell lines (Figure 4.2 a & b). I detected 
two PIM1 protein isoforms (33 kDa and 44 kDa) and three PIM2 isoforms (34, 
38 and 40 kDa), with the 38 and 40 kDa PIM2 isoforms being expressed at 
higher levels to that of the 34 kDa isoform. Although studies have shown that 
both PIM1 isoforms retain kinase activity, the kinase activity of PIM2 isoforms 
has been shown to negatively correlate with molecular weight, with the largest 
40 kDa isoform showing the least kinase activity [380]. Since each of the PIM 
isoforms retains kinase activity, I wanted each isoform to be detected in the 
qRT-PCR PIM expression screen; thus I made sure to design primers that 
amplified regions of the PIM genes that were common to all PIM1 and PIM2 
isoforms. 
Importantly, I observed a correlation between PIM2 mRNA and protein 
expression in leukaemia cell lines (Figure 4.2 a & b).  In contrast, PIM1 mRNA 
expression did not correlate with PIM1 protein expression, since the difference 
in PIM1 protein expression in SD1 and K562 cell lines was not proportionate to 
the difference observed at the mRNA level in the same cell lines. This suggests 
that post-translational modification of PIM1 and modulation of its stability may 
be occurring, as is described in the literature [361].  
Taken together, these results confirm that measurement of PIM2 mRNA by 
qRT-PCR is a suitable method by which to indirectly and efficiently measure 
PIM2 protein expression, as opposed to the measurement of PIM1, which may 
prove to be inaccurate given the regulatory post-translational mechanisms of 
PIM1 protein expression. 
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Figure 4.1: Confirmed specificity of PIM1 and PIM2 primer sets 
PCR reactions were set up to test the a) PIM1 and b) PIM2 primer sets. cDNA 
synthesised from total RNA samples from a panel of 7 primary ALL tumours 
(ALL-201, ALL-204, ALL-210, ALL-213, ALL-217, ALL-232 and ALL-240) was 
used to prepare the PCR reactions. Reactions were prepared using the 
FastStart PCR system (Roche) and were set to 45 amplification cycles, with an 
annealing temperature of 60°C.  
The primer sets used to amplify the PIM1 and PIM2 target sequence produced 
a single product in all the RNA samples tested, with products being of the 
expected size. 
a) 
b) 
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Figure 4.2: Correlation between PIM mRNA expression and protein 
expression 
a) cDNA was synthesised from total RNA extracted from a panel of 7 leukaemia cell lines 
(Kasumi, Jurkat, CEMC1, REH, NALM-17, SD1 and K562). Graph represents PIM1 and PIM2 
mRNA expression relative to the expression levels in normal B-cells as quantified by qRT-PCR.  
Ct values were normalised to β-actin mRNA 
b) Graph represents PIM1 and PIM2 protein expression levels in the same panel of cell lines as 
above, detected by Western blotting. PIM kinase isoforms were also detected. Actin was used 
as a loading control. 
A correlation between mRNA and protein expression exists for PIM2 but not PIM1. 
a) 
b) 
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4.1.2. PIM expression screen of a cohort of primary ALL tumour 
samples  
I showed in section 4.1.1. that measurement of PIM2 RNA expression by qRT-
PCR can be used to indirectly measure PIM2 protein levels, given that PIM2 
protein is constitutively active once expressed and is not regulated by post-
translational modification [380]. I therefore proceeded to screening a cohort of 
68 primary ALL tumour RNA samples for PIM2 expression. 
Using the level of PIM2 RNA expression in that of the PIM-expressing cell line 
K562 as a marker for high expression, I found that PIM2 was highly expressed 
in 17/68 (25%) RNA tumour samples (Figure 4.3). In addition, I screened a 
small independent cohort of primary ALL tumours for PIM2 protein by Western 
blotting and confirmed that PIM2 was highly expressed in 2/7 (28.6%) (Figure 
4.4), which corroborates the calculated frequency of PIM2 overexpression in B-
precursor ALL derived from qRT-PCR data. However, it is likely that more 
tumours express significant levels of PIM2 protein, since the calculated 
frequencies of high PIM2 expression are based on a comparison to K562 that 
expresses high levels of this kinase.  
I next wanted to see if PIM2 expression could be associated with clinical 
features in pre-B ALL. I decided to designate ALL tumours as PIM-2 positive 
and PIM2-negative if they expressed ≥50% or <50% PIM relative to K562, 
respectively. Using the available clinical information corresponding to the cohort 
of 68 RNA samples analysed, I found that there was no association between 
PIM2 expression and patient age or gender. I also found no difference in the 
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cytogenetic repertoire between PIM2-positive and PIM2-negative tumours, 
suggesting that PIM2 expression was not associated with cytogenetic features 
conferring a poor treatment prognosis. 
To determine whether PIM2 expression influenced patient response to 
treatment, I checked whether PIM2 expression influenced patients’ responses 
at Day 8 of treatment with respect to blast clearance. I found that there was a 
positive trend between PIM-2 positive tumours and poor blast clearance (Figure 
4.5, top)  
I then looked at whether PIM2 expression influenced MRD at Day 28 of 
treatment and found that PIM2-positive tumours were associated with positive 
MRD (Figure 4.5, bottom), suggesting that PIM2 expression may be associated 
with chemoresistance.   
Overall, PIM2 appears to be overexpressed in over a quarter of primary ALL 
tumours and may influence chemoresistance in vivo.  
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Figure 4.3: qRT-PCR screen for PIM2 expression in a large cohort of pre-B 
ALL tumours  
A large cohort of primary ALL tumour RNA samples (n=68) were screened for PIM2 
expression by qRT-PCR. Graph represents PIM2 mRNA expression relative the 
expression K562.  
This shows PIM2 is overexpressed in 17/68 (25%) of B-precursor ALL tumours. 
 
 192 
 
 
 
 
 
 
 
Figure 4.4: PIM2 is expressed at the protein level in primary pre-B ALL 
tumours  
Western blotting was used to screen for PIM2 protein in a panel of primary ALL 
tumours (n=7). Actin was used as a loading control. 
PIM2 protein is expressed in 2/7 (28.6%) of primary ALL tumours. 
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Figure 4.5: Influence of PIM2 expression on patient response to treatment  
A positive trend towards an association between high-PIM2 expression and poor early 
response to treatment at day 8 is shown (top) (11.8 vs. 22.2%; p=0.5906).  
A positive trend towards an association between high-PIM2 expression and MRD 
positivity at day 28 is shown (bottom) (45.5% vs. 64.7%; p=0.3340). 
Due to the small number of tumour sample for which clinical information was available, 
statistical significance was not observed. However, this may be improved by extending 
this cohort in further studies. 
(GER, good early response; PER, poor early response; MRD, minimal residual 
disease) 
GER
PER
Blast clearance (Day 8)
Low PIM2 High PIM2 
MRD neg.
MRD pos.
MRD (Day 28)
Low PIM2 High PIM2 
88.2%
11.8%
77.8%
22.2%
54.5%
45.5% 35.3%
64.7%
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4.1.3 In vitro cytotoxic effect of K00135-mediated inhibition of 
PIM kinases in ALL cell lines and primary tumours 
Since a significant proportion of primary ALL tumours overexpressed PIM2, I 
decided to use a luminescent ATP-based cytotoxicity assay to investigate the 
effect of PIM kinase inhibition on the cell viability of a panel of leukaemia cell 
lines (SD1, REH, Jurkat and K562) using the PIM inhibitor K00135 [391]; an 
imidazo[1,2-b]pyridazine derivative kindly provided to me by our collaborator 
Prof. Stefan Knapp. Cell viability was measured 72 hours following exposure to 
increasing concentrations of the K00135 inhibitor alone.  
I also addressed K00135-mediated cytotoxicity in a panel of 11 primary B-
precursor ALL tumours that were identical to some of the tumour samples 
tested in JQ1 experiments (Section 3.1.2), but independent of the primary ALL 
tumour cohort screened for PIM2 expression by qRT-PCR in section 4.1.2. 
Additionally, I tested for cytotoxic effects of K00135 on healthy non-tumour 
PBMCs, to determine whether any observed cytotoxic effects were tumour-
specific. 
I found that the treatment of the PIM1- and PIM2-expressing SD1 ALL cell line 
with K00135 induced cytotoxic effects in a dose-dependent manner (EC50 5.4 
µM) (Figure 4.6; Table 4.1). Similarly, the induction of cytotoxicity was observed 
in K562 cells (EC50 19.3 µM), which were much less sensitive to the effects of 
K00135 treatment when compared to SD1 cells, despite the K562 cell line 
exhibiting the greatest PIM kinase overexpression of the leukaemia cell lines I 
tested (Figure 4.2b). As expected, the NALM-17 cell line that expressed very 
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low levels of PIM protein, was not sensitised following K00135 treatment (EC50 >100 µM). However, REH and Jurkat cell lines, which did not express any 
detectable PIM proteins (Figure 4.2a & b), appeared to be sensitised to K00135 
treatment (REH EC50 10.2 µM and Jurkat EC50 4.6 µM). This suggests that 
K00135-induced cytotoxicity observed in the leukaemia cell lines not expressing 
PIM protein may be due to off-target effects, despite the K00135 inhibitor having 
been shown to exert selective antileukaemic activity in several AML cell lines 
and primary AML tumours [391].  
With respect to primary ALL tumours, I found that treatment of tumour cells with 
K00135 over a 48 hour incubation period led to dose-dependent induction of 
cytotoxicity, with a range of sensitivity to K00135 being observed (Figure 4.7; 
Table 4.2). Three tumours (ALL-103, ALL-104 and ALL-111) demonstrated 
increased sensitivity to K00135 compared to the rest of the tumours tested in 
this panel, with 30% (3/10) tumours showing EC50 values <5 µM, compared to 
70% (7/10) tumours that had EC50 values >5 µM. Importantly, similar treatment 
of healthy PBMCs did not demonstrate sensitivity to K00135 (EC50 >10 µM).  
As primary tumour material was limited, I aimed to make good use of the 
information I had already obtained from previously analysed tumours. Thus, I 
referred to the microarray data from my studies involving JQ1 to derive PIM2 
basal expression levels in the primary tumours I had treated with K00135 
(Figure 4.8), since K00135-treated tumours were largely the same primary ALL 
tumours I had used to test for JQ1 cytotoxicity and I had also confirmed in 
section 4.1.1. that PIM2 transcript levels correlate with PIM2 protein levels.  
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Intriguingly, I found that at a clinically achievable concentration of 1 µM K00135, 
ALL-103 tumour cells, which expressed one of the highest levels of PIM2 in this 
panel of ALL tumours (table 4.2), was the most sensitive to the cytotoxic effects 
of K00135. In contrast, the primary ALL tumour with the lowest expression of 
PIM2 (ALL-106) was the least K00135-sensitive tumour of all the tumours 
analysed. A further observation was that ALL-105 expressing high levels of 
PIM2 was not sensitised to K00135, suggesting some tumours may be 
inherently resistant to the effects of PIM kinase inhibition.  
Overall, the specificity with which K00135 targets PIM kinases in the leukaemia 
cell lines I tested remains largely unknown, since I observed cytotoxic effects of 
K00135 in two ALL leukaemia cells lines not expressing PIM kinases. This may 
be due to cross-reactivity of K00135 with one other kinase (CLK1), as has been 
reported [486]. However, similar to BET inhibition, Pim kinase inhibition by 
K00135 induces differential cytotoxicity in primary ALL tumour cells compared 
to normal healthy PBMCs. Importantly, some primary tumours also appear to be 
resistant to K00135 treatment, despite expressing high levels of PIM2. 
 
 
 
 
 197 
 
 
 
 
Figure 4.6: K00135-induced cytotoxicity in a panel of leukaemia cell lines  
Effects of K00135 treatment on the cell viability of B-precursor ALL cell lines 
REH, NALM-17, Jurkat, and SD1 were measured at 72hr using a luminescent 
ATP-based cytotoxicity assay. The CML cell line K562 is confirmed as being 
sensitive to the cytotoxic effects of PIM-inhibition [487], and was therefore 
included as a positive control. Assays were performed in triplicate. Data are 
presented as mean ± SEM; n=3. 
Apart from the NALM-17 cell line, which shows resistance to the cytotoxic 
effects of K00135, ALL cell lines (REH, Jurkat, SD1) show increased 
sensitisation to K00135 compared to the CML K562 cell line.  
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Table 4.1: Half-maximum-effect concentrations (EC50) calculated for a 
panel of leukaemia cell lines treated with K00135 inhibitor  
JQ1 EC50 values were calculated for REH, NALM-17, Jurkat, SD1, and K562 
using the Prism 4 software package (GraphPad Inc.), which were derived from 
data values obtained for each cell line in cytotoxicity experiments following 72hr 
incubation of cells with a log-scale range of K00135 concentrations.  
With the exception of NALM-17 cells, which show overt resistance to K00135 
(EC50 398.4), ALL cell lines are sensitised to the cytotoxic effects of K00135 
EC50 4.6-10.2 µM), with K562 positive control cells being less sensitive to 
K00135-induced cytotoxicity (EC50 19.3 µM). 
 
 
 
 
 199 
 
 
Figure 4.7: K00135-induced cytotoxicity in a panel of primary ALL tumours  
Effects of K00135 treatment on the cell viability of B-precursor ALL cell lines 
REH, NALM-17, Jurkat, and SD1 were measured using a luminescent ATP-
based cytotoxicity assay. 
Compared to PBMCs obtained from healthy individuals (n=3), representative 
primary ALL tumours show a differential loss of viability upon 48hr incubation 
with 0.1 and 1 µM JQ1. Data are presented as mean ± SD. 
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Table 4.2: Half-maximum-effect concentrations (EC50) calculated for a 
panel of primary ALL tumours treated with K00135 inhibitor. 
Calculated median EC50 values were derived from cytotoxicity experiment data, 
where primary tumours were treated with a range of log-scale K00135 
concentrations for 48hr. 
Compared to PBMCs obtained from healthy individuals (n=3), a total of 7 
representative primary ALL tumours (ALL-103, ALL-104, ALL-108, ALL-109, 
ALL-110, ALL-111 and ALL-113) show a differential loss of viability following 
48hr exposure to K00135 (EC50 values <10 µM). 
A total of 3 primary ALL tumours (ALL-105, ALL-106 and ALL-112) exhibit 
resistance to the cytotoxic effects of K00135 (EC50 >40 µM), with ALL-105 
showing the greatest resistance (EC50 4892 µM). 
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Figure 4.8: PIM2 expression in primary ALL tumours analysed in 
cytotoxicity experiments involving the K00135 inhibitor 
PIM2 expression levels in tumours tested for sensitivity to K00135-induced 
cytotoxicity (section 4.1.3) were derived from JQ1 microarray data presented in 
section 3.2.2, as these were the same tumours. 
The graph represents PIM2 mRNA expression relative to expression levels in 
ALL-106. Tumours are arranged from low to high PIM2 expression.  
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4.2. Identification of gene expression patterns associated with 
PIM2 expression in primary B-precursor ALL tumours 
As previously described in section 1.10.3, studies have shown that the PIM1 
kinase promotes transcriptional pause release of stalled RNA Pol II, through a 
mechanism involving the BET protein BRD4 [488].  The role of other PIM kinase 
family members in regulating transcription has not yet been elucidated. 
However, given the high degree of amino acid sequence homology between 
PIM1 and PIM2 [362], it is possible that PIM2 may influence the expression of a 
distinct subset of genes. 
Furthermore, results from cytotoxicity experiments (section 4.1.3.) indicate that 
the PIM inhibitor K00135 leads to differential sensitisation of a subset of primary 
ALL tumours, and that in the majority of tumours this effect depends on PIM2 
expression. Thus, I decided to investigate the transcriptional profiles of primary 
ALL tumours associated with high and low levels of PIM2 expression to identify 
potential PIM2-regulated genes and pathways.  
I did this by reanalysing microarray data previously obtained from our lab from 
22 individual primary ALL tumours, which harboured a range of cytogenetic 
features and included several tumours derived from patients in the high-risk 
stratification group. With the help of a statistician (Dr. Wenbin Wei), I ordered 
tumours according to their baseline level of PIM2 gene expression, and then 
selected the top 100 genes most significantly associated with PIM2 expression 
using the Spearman’s rank correlation coefficient [489]. 
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Using this approach, I found that high PIM2 expression was associated with the 
upregulation of 33 genes, including multiple NFκB transcription factor target 
genes (XIAP, TNFAIP3, NLRP3 and CD48), as well as TIMP1, HYOU1 and 
UBA1 (Figure 4.9). 
The NFκB target gene XIAP encodes a member of the IAP family of apoptotic 
inhibitors [490], and is frequently overexpressed in a variety of malignancies, 
including leukaemias and lymphomas [491, 492]. It has been shown to be one 
of the most potent suppressors of apoptosis induced by a wide range of agents, 
such as TNF, TRAIL, Fas-L, staurosporine, paclitaxel and etoposide [493, 494]. 
Furthermore, the expression of XIAP has been shown to correlate with a poor 
clinical outcome in DLBCL [491]. 
Another gene associated with the overexpression of PIM2 was the tissue 
inhibitor of metalloproteinase 1 (TIMP1) gene, which is a STAT3 target gene 
that has been shown to be overexpressed in a spectrum of tumour types, and is 
frequently associated with an aggressive clinical phenotype [495-500]. 
The hypoxia up-regulated 1 (HYOU1) gene was also positively associated with 
PIM2 expression and has previously been shown to be overexpressed in 
prostate cancer and confer chemotherapeutic resistance via a mechanism 
involving the inhibition of caspase-dependent apoptosis [501, 502]. 
Upregulation of the UBA1 gene encoding the ubiquitin-activating enzyme UBA1 
(E1) was another gene I found to be associated with high PIM2 expression. The 
E1 enzyme initiates the multi-step proteasomal pathway of protein degradation 
by conjugating a single ubiquitin molecule to proteins, which are then further 
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ubiquitinated by other ubiquitin-conjugating enzymes, and consequently 
degraded [503, 504]. Whereas polyubiquitinated proteins are destined for 
proteasomal degradation, monoubiquitination of proteins has been shown to 
regulate gene transcription and DNA repair [505, 506]. Interestingly, recent in 
vivo studies using an AML primary xenograft mouse model have demonstrated 
that E1 activity is significantly upregulated and that its inhibition leads to 
targeted malignant cell death and delayed tumour growth [507]. 
I also identified a significant association between the downregulation of 67 
genes and high PIM2 expression (Figure 4.10). These included DNA repair 
genes such as MLH3 and XRCC2, which encode protein key to the regulation of 
mismatch repair (MMR) and homologous recombination (HR), respectively. 
Studies have shown that downregulation of the MLH3 gene is observed in 
hereditary nonpolyposis colorectal cancer (HNPCC), ALL, CLL and malignant 
lymphoma [508-514], and is associated with an increased rate of spontaneous 
mutation and instability of microsatellites [515]. With respect to the XRCC2, a 
lack in XRCC2 gene expression is associated with fragmentation of the 
centrosome and increased genomic instability [516]. Furthermore, decreased 
expression of this gene has been shown to promote tumourigenesis following 
DNA damage, as other less accurate DNA repair mechanisms are activated 
instead, introducing a higher rate of misrepaired DNA lesions [517]. Thus, 
XRCC2 is recognised as a tumour suppressor gene.  
Interestingly, I found that high PIM2 expression was associated with 
downregulation of the POLH gene encoding DNA polymerase eta (Pol η) that is 
also involved in the accurate repair of DNA, particularly translesion synthesis of 
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DNA damage caused by ultraviolet radiation [518]. Subsequently, decreased 
Pol η expression is linked to an increased risk of malignant melanoma [519].  
Intriguingly, studies have also confirmed an association between deficiencies in 
Pol η and hypermutation occurring during immunoglobulin class switch 
recombination [520]. In addition, Pol η is targeted to stalled replication 
machinery and forms a complex with proliferating cell nuclear antigen (PCNA) 
and replication factor C (RFC) [521]; the latter of which is known to interact with 
the BET protein BRD4, as mentioned in section 1.10.3.  
In addition, I found that downregulation of the RPL5 gene correlated with high 
PIM2 expression, of which the ribosomal protein product has been shown to 
block cell growth by enhancing tumour suppressor p53 activity in response to 
ribosomal stress during protein synthesis [522]. 
Next, I decided to use GSEA on the same microarray data to identify subtle 
associations between biological signalling pathways and PIM2 expression in B-
precursor ALL tumours [403]. I identified 38 gene sets upregulated in PIM2-
expressing ALL tumours that were significantly enriched at a false discovery 
rate (FDR) <25%.  
This included gene sets representing pathways that regulate gene transcription, 
the cell cycle, DNA replication, ribosome assembly, protein translation, 
proteasomal degradation and PI3K/Akt prosurvival signaling (Table 4.3).  
Intriguingly, with regards to gene transcription, the expression of PIM2 was 
significantly associated with the upregulation of several basal transcription 
factor genes. The basal transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF 
 206 
 
and TFIIH) are proteins essential to RNA Pol II-mediated gene transcription and 
form protein complexes that constitute the pre-initiation complexes at gene 
promoters [523-527]. The basal transcription factors then promote the binding of 
RNA Pol II to DNA, and also ensure that promoter escape and entry into the 
transcript elongation phase takes place [523, 527, 528]. 
Furthermore, GSEA highlighted multiple pathways encompassing the DNA 
replication process. For example, tumours expressing high levels of PIM2 were 
associated with the upregulation of pathways that regulate interaction of the 
origin recognition complex (ORC) with replication origins, which are where DNA 
replication initiates from during the S-phase of the cell cycle [529, 530]. I will 
therefore be interesting to confirm whether PIM2 has a direct impact on DNA 
replication in future studies. 
In contrast, I did not identify any statistically significant gene sets that negatively 
correlated with PIM2 expression. 
Overall, the results I obtained from reanalysis of microarray data previously 
obtained in our lab suggest a link between PIM2 expression and the 
upregulation of prosurvival (NFκB and PI3K signaling) and anti-apoptotic 
pathways. Furthermore, results indicate PIM2 is positively associated with the 
expression of genes involved in the regulation of gene transcription, cell 
proliferation, DNA repair, DNA replication and protein translation. However, at 
this stage it is not possible to specify whether these pathways are up- or 
downstream of PIM2 activity.  
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Particularly interesting, is the observation that many of the pathways and 
biological processes associated with PIM2 expression, such as upregulated 
NFκB pathway activity and anti-apoptotic pathway signaling, gene transcription 
and DNA replication, overlap with those downregulated following the inhibition 
of BET proteins, suggesting this overlap may be contributing to the resistance to 
K00135 and JQ1 observed in some tumours. 
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Figure 4.9: Re-analysis of global gene expression data identifies a positive 
correlation between the expression of a specific subset of genes and PIM2 
expression in primary ALL tumours 
Microarray data previously obtained in our lab [247] was re-analysed to look for 
associations between PIM2 expression and specific genes in pre-B ALL. A total of 22 
tumours were ordered from low to high PIM2 gene expression (PIM2 gene indicated by 
arrow). 
Transcript expression heat-map was generated using dChip (http://www.dchip.org/) 
with the default settings, and shows a subset of genes with the strongest positive 
correlation with PIM2 expression, determined using Spearman’s rank correlation 
coefficient statistical analysis (coefficient ≥0.6; p<0.05). 
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Figure 4.10: Re-analysis of global gene expression data identifies a 
negative correlation between the expression of a specific subset of genes 
and PIM2 gene expression in primary ALL tumours 
Microarray data previously obtained in our lab [247] was re-analysed to look for 
associations between PIM2 expression and specific genes in pre-B ALL. Tumours were 
ordered from low to high PIM2 gene expression (PIM2 gene indicated by arrow). 
Transcript expression heat-map was generated using dChip (http://www.dchip.org/) 
with the default settings, and shows a subset of genes with the strongest negative 
correlation with PIM2 expression, determined using Spearman’s rank correlation 
coefficient statistical analysis (coefficient ≥0.6; p<0.05). 
           
  
PIM2
GPX1
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Table 4.3: GSEA pathways positively associated with PIM2 gene 
expression in primary ALL tumours 
GSEA results were obtained from the re-analysis of gene expression data 
previously obtained in our lab [247], and derived from the analysis of 22 DMSO-
treated primary ALL tumours. Tumours were ranked in order of low to high PIM2 
expression.  
Spearman’s rank correlation coefficient was used to identify pathways and 
biological processes most strongly associated with PIM2 expression (coefficient 
≥0.6; p<0.05). 
The pathways listed above are significant at FDR <0.25 (<25%). 
 
Gene Set Size FDR q-val
ORC1 REMOVAL FROM CHROMATIN 62 0.02
CELL CYCLE CHECKPOINTS 102 0.03
CDT1 ASSOCIATION WITH THE CDC6 ORC ORIGIN COMPLEX 51 0.04
CDC20 PHOSPHO APC MEDIATED DEGRADATION OF CYCLIN A 59 0.06
AUTODEGRADATION OF CDH1 BY CDH1 APC 53 0.07
CELL CYCLE MITOTIC 283 0.09
CD28 DEPENDENT PI3K AKT SIGNALING 17 0.11
PROTEASOME PATHWAY 19 0.11
p53-INDEPENDENT DNA DAMAGE RESPONSE 43 0.11
EIF PATHWAY 15 0.17
BASAL TRANSCRIPTION FACTORS 31 0.21
PEPTIDE CHAIN ELONGATION 83 0.23
GTP HYDROLYSIS AND JOINING OF THE 60S RIBOSOMAL 
SUBUNIT 103 0.23
RIBOSOME 85 0.24
VIRAL MRNA TRANSLATION 83 0.25
PROTEIN TRANSLATION 117 0.25
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4.3. Cellular effects of K00135 on ALL tumour cells 
4.3.1. Investigating the effect of K00135 on c-Myc expression 
As mentioned in Chapter 1, the c-Myc transcription factor plays a major role in 
the regulation of cell proliferation, growth and differentiation, and is deregulated 
in a wide range of leukaemias and lymphomas [343]. Importantly, studies using 
bitransgenic mice overexpressing either PIM1 or PIM2 together with MYC led to 
mice succumbing to precursor B-cell lymphoma in a very short period of time, 
demonstrating the strong synergy between these two oncogenes [379]. Further 
studies showed that PIM2 greatly enhances c-Myc transcriptional activity by 
stabilising c-Myc protein via a mechanism involving phosphorylation of c-Myc 
Ser 329 [531]. 
Taking the above into consideration, together with the fact that PIM kinases 
have been shown to enhance BRD4-mediated gene transcription by forming a 
complex with c-Myc [346], I decided to use Western blotting to measure the 
level of c-Myc protein in K00135-sensitive ALL tumour cells and determine the 
effect of K00135-mediated PIM kinase inhibition on c-Myc expression. Using the 
K562 CML cell line as a positive control, I found that treatment of the PIM-
expressing pre-B ALL cell line SD1 and K562 with 1 µM K00135 led to complete 
downregulation of c-Myc protein by 72 hours post-treatment in both cell lines 
(Figure 4.11a).  
I next proceeded to test primary ALL tumour cells treated with K00135 for the 
effect on c-Myc expression, as was observed in cell lines. Thus, I selected 
primary ALL tumour ALL-103, which overexpressed PIM2 as shown in Figure 
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4.8. On this occasion, I used a range of increasing concentrations of K00135 
inhibitor and a fixed 48 hour timepoint at which to harvest the cells, since 
primary tumour cells are less resilient than cell lines and exhibit a significant 
loss of viability at timepoints beyond 48 hours of in vitro culture. I found that 
ALL-103 primary tumour cells also overexpressed c-Myc protein, which was 
completely downregulated in tumour cells treated with 1 µM K00135 (Figure 
4.11b).  
In summary, similar to BET protein inhibition, treatment of PIM-expressing ALL 
tumour cells with the PIM inhibitor K00135 leads to a loss of c-Myc protein 
expression. 
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Figure 4.11: Myc downregulation in ALL tumour cells following K00135 
treatment  
Protein lysates were analysed by Western blotting, where samples were probed for c-
Myc and β-actin (loading control). 
a) SD1 and K562 cells were treated with 1µM K00135 for 0 (DMSO control), 24, 48 and 
72hrs.  
Treatment with 1µM K00135 leads to complete downregulation of c-Myc protein by 
72hr in both leukaemia cell lines analysed. The K562 cell line was used as a positive 
control for PIM kinase inhibitor activity. 
b) PIM2-expressing ALL-103 primary tumour cells were treated with increasing 
concentrations of K00135 inhibitor (0, 0.1, 0.5 and 1 µM).  
Treatment of ALL-103 tumour cells with 1 µM K00135 leads to complete 
downregulation of c-Myc protein.  
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4.3.2. Effect of K00135 on apoptosis 
As previously mentioned, PIM2 has been shown to inhibit apoptosis and 
caspase activation by phosphorylating the pro-apoptotic protein BAD on 
Ser112, confirming that PIM2 is a prosurvival kinase [380]. Since PIM kinases 
are upregulated by JAK/STAT and NFκB pathway signaling, and our group has 
previously shown that the NFκB pathway is frequently upregulated in apoptotic-
resistant, I decided to test B-precursor ALL tumour cells (ALL-103) for an effect 
on apoptosis following treatment with the PIM kinase inhibitor K00135. 
I did this by treating ALL-103 tumour cells with increasing concentrations of 
K00135 (0, 0.1, 0.5 and 1 µM) for 24 hours, and then using the Western blotting 
technique  to probe for cleaved procaspase-7 and PARP1 protein as an 
indicator of apoptosis induction. I found that the degree of cleavage of these 
proteins increased in a dose-dependent manner, where treatment with 1 µM 
K00135 led to an almost complete cleavage of procaspase-7 and PARP1 
proteins (Figure 4.12a). 
Interestingly, I found that K00135 treatment of SD1 cells led to the cleavage of 
PARP1, which also coincided with the downregulation of proapoptotic BAD 
phosphorylation on Ser112 (Figure 4.12b). This observation was in line with a 
study that showed this effect in the FDC-P1 mouse myeloid cell line [380], but 
was an effect not yet reported within the context of ALL.  
In summary, the above observations indicate that pharmacological inhibition of 
PIM2 leads to the induction of caspase-dependent apoptosis in primary ALL 
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tumour cells, and that this might involve the downregulation of Bad Ser112 
phosphorylation.  
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Figure 4.12: K00135 induces caspase-dependent apoptosis in ALL tumour 
cells 
a) Western blotting shows dose-dependent induction of apoptosis in ALL-103 
primary tumour cells treated with K00135 as measured by the cleavage of 
PARP1 and procaspase-7 proteins. Actin was probed for as a loading control. 
b) Western blotting shows induction of apoptosis over a period of 72hr in SD1 
cells exposed to 1 µM K00135 as measured by the cleavage of PARP1 and 
downregulation of proapoptotic BAD phosphorylation on Ser112. Actin was 
probed for as a loading control. 
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5. DISCUSSION I: INHIBITION OF BET PROTEINS AS 
AN ALTERNATIVE STRATEGY FOR THE 
SENSITISATION OF HIGH-RISK B-PRECURSOR ALL 
 
5.1 Treatment resistance in B precursor ALL and the 
requirement for more targeted treatments  
As pointed out in the introduction, paediatric B precursor ALL is currently a 
highly curable disease, with long-term disease-free survival rates of over 80% 
being achieved in children [69]. However, despite major improvements in the 
treatment of this disease in previous years, treatment resistance in a significant 
number of patients together with general long-term toxic effects from currently 
used therapies are still observed [532]. Thus, alternative targeted therapeutic 
approaches are needed if we are to overcome these problems within the clinic. 
In my thesis I have addressed regulators of transcription and epigenetic readers 
as therapeutic targets. The therapeutic potential of pharmacologic inhibition of 
bromodomains has only recently been explored in haematological malignancies 
such as AML, demonstrating striking anti-tumour effects [344]. In addition, 
although recently cytotoxic effects were demonstrated in ALL cell lines, this 
approach has not been tested in a wide range of primary ALL tumours and little 
is known of the cellular effects following bromodomain inhibition [345].  
In this study, I investigated the inhibition of bromodomains in B-precursor ALL 
as a potential novel strategy for the sensitisation of primary ALL tumours, 
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including high-risk ALL tumours that are frequently associated with resistance to 
therapy. I utilised the thieno-triazolo-1,4-diazepine, JQ1, which binds specifically 
and competitively to the acetyllysine binding pocket of the conserved 
bromodomain and extra-terminal domain (BET) protein family (BRD2, BRD3, 
BRD4, BRDT). Data published by our collaborator Prof. Stefan Knapp shows 
that, of the BET protein family members, JQ1 binds to the bromodomains of 
BRD4 with the greatest affinity [334]. I investigated JQ1-mediated cytotoxicity 
and also attempted to characterise transcriptional changes and cellular effects 
in ALL tumour cells in response to JQ1 treatment. Finally, I addressed the 
efficacy of JQ1 in eliminating leukaemia cells using the in vivo ALL xenograft 
developed by our group. 
5.2 A role for JQ1-mediated BET bromodomains inhibition in B 
precursor ALL 
Previous findings have shown that BET proteins are frequently expressed in 
aggressive diseases such as AML and NUT midline carcinoma, and that 
treatment of these malignancies with the BET protein inhibitor JQ1 successfully 
leads to their elimination [334, 344]. Data presented in this study suggests that 
this may also be a promising avenue in the treatment of B-ALL. Results 
presented in Chapter 3 show that a wide range of ALL cell lines and primary 
tumours express the BET protein family member BRD4 and that tumour cells 
treated with JQ1 can be successfully sensitised irrespective of the cellular 
phenotype or patient risk stratification. Furthermore, all primary ALL tumours 
express BRD4 and the level of BRD4 expression does not appear to influence 
JQ1 sensitivity. Furthermore, BRD4 is not downregulated upon treatment with 
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JQ1. This latter observation is in keeping with the fact JQ1 does not alter 
transcriptional regulation of BRD4 but instead blocks any protein activity 
downstream of BRD4 [334]. Data in Chapter 3 also demonstrate that several 
high-risk primary ALL tumours are highly sensitive to JQ1 in vitro activity at 
submicromolar concentrations, as are ALL cell lines harbouring cytogenetic 
features associated with poor prognosis and aggressive disease such as BCR-
ABL1. Indeed positive results were obtained testing JQ1 in vivo using a 
xenograft model of high-risk ALL, as is further discussed in section 3.4. 
Together these findings address the current complications associated with 
therapy-resistant high-risk ALL, and instil confidence in the further development 
of JQ1 as a compound with potential inclusion in clinical trials. At this point, it is 
not possible to infer whether or not the cytotoxic effects of JQ1 treatment 
observed in this study are a consequence of the sole inhibition of BRD4 since 
BET bromodomains exhibit high sequence conservation, and all inhibitors 
developed to date exhibit some degree of inhibitory activity toward other BET 
protein family members [334]. However, published data highlights the structural 
basis for potent and specific activity of JQ1 towards BRD4 in particular [334], 
and an RNA interference (RNAi) screen targeting multiple chromatin regulators 
in an AML mouse model also identified BRD4 as being key to disease 
maintenance [344]. This provides indirect evidence that the cytotoxic effects 
observed in JQ1-treated ALL tumour cells are primarily due to inhibition of 
BRD4 activity. Additionally, some crossover in inhibition may have a desirable 
effect on tumour cells, since other members of the BET family of proteins are 
also implicated in tumorigenesis [340, 533]. 
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Results from in vitro cytotoxicity experiments show that ALL cell lines are all 
sensitive to the cytotoxic effects induced by JQ1. In contrast, primary ALL 
tumours treated with JQ1 showed a wide range of responses. Cell lines are 
immortal and continually proliferating unlike isolated primary tumour cells, and 
so it is possible that this is reflected in the degree of sensitivity to JQ1, since the 
cytotoxic effects of JQ1 have been shown to be partly due to its impact on cell 
cycle progression [340]. Primary ALL tumour cells obtained from patients’ bone 
marrow do not proliferate in standard culture. Thus, it may be possible that 
those primary ALL tumours sensitised by JQ1 in vitro, respond as a result of 
alternative cellular effects exerted by JQ1 other than on the regulation of the cell 
cycle, which may not be as prominent. Therefore, a possibility remains that, if 
primary ALL tumour cells were induced to proliferate in vitro, they would show 
similar degrees of JQ1 sensitivity to the ALL cell lines. Another alternative 
explanation may be that tumour cells showing a lack of response to JQ1 are not 
dependent upon BET protein-regulated pathways for their survival. For 
example, primary AML tumour cells I tested were highly sensitive to JQ1 
treatment, whereas healthy peripheral blood mononuclear cells (PBMCs) were 
not, further supporting the tumour-specificity of the JQ1 inhibitor and the 
unlikelihood of off-target effects leading to undesirable toxicity. 
Treatment of ALL cell lines with a combination of JQ1 together with 
conventional chemotherapeutic agents dexamethasone, vincristine, or 
daunorubicin produced variable results, where the combination of JQ1 with 
dexamethasone led to greatly enhanced sensitivity in cell lines TOM-1 and 
NALM-6, which was in contrast to the response observed following treatment of 
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these cell lines with either JQ1/vincristine or JQ1/daunorubicin combinations. 
These synergistic effects of combined JQ1/dexamethasone treatment were also 
observed in several representative primary ALL tumours.  
Microarray results presented in Chapter 3 demonstrate that JQ1-mediated 
inhibition of BET proteins leads to the downregulation of prosurvival pathways, 
including the NFκB pathway (section 3.2.4) previously reported by our group to 
be frequently upregulated in treatment-resistant preB-ALL [248]. Studies using a 
human lung carcinoma cell line have also reported that BRD4 binds to 
acetylated RelA, and coactivates the transcriptional activity of NFκB [338]. In 
addition, the mechanism of apoptosis-induction by dexamethasone could be 
partly explained by its ability to upregulate IκB; an inhibitory protein that 
sequesters the NFκB transcription factor in the cytoplasm, preventing the 
expression of NFκB target genes [534, 535]. It is therefore possible that the 
synergistic cytotoxic effects observed in ALL tumour cells treated with the 
JQ1/dexamethasone combination are due to modulation of the NFκB pathway 
by each of these drugs, in a disease where NFκB activity is frequently 
upregulated.  
It may be possible that the lack of synergistic effects observed in ALL cell lines 
treated with JQ1 in combination with either vincristine or daunorubicin was due 
to the mechanism of cytotoxicity induction by both vincristine and daunorubicin 
being largely dependent upon proliferation, and may therefore be counteracted 
by JQ1 inhibitory activity on the cell cycle. However, this does not explain the 
similar absence of synergism observed in non-cycling primary tumours. 
Nevertheless, the JQ1/dexamethasone combination may have positive 
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implications in the clinic if the synergistic effects translate in vivo, since it may 
be possible to eliminate ALL blasts more effectively, as well as lower the dose 
of dexamethasone given to a patient, and therefore the risk of toxic side-effects. 
At this point it is worth noting that response to glucocorticoids remains one of 
the most powerful predictors of outcome in ALL [536] and therefore, 
development of compounds such as JQ1 that can manipulate this effect is 
highly desirable. 
Interestingly, dexamethasone failed to induce cytotoxicity in the REH cell line. 
Unsurprisingly, combined treatment with JQ1 did not exhibit synergistic 
cytotoxicity. This can be explained by the fact that REH does not express GR 
[407], which is required for dexamethasone to bind to in order for cytotoxicity to 
be induced. Limited evidence exists to suggest a GR-independent mechanism 
of action exists for dexamethasone, but  this aspect remains largely 
inconclusive [537]. 
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5.3 Microarray analysis reveals differentially expressed genes 
belonging to apoptotic, prosurvival, and protein translation 
pathways in JQ1-treated primary ALL tumours 
Since results presented in section 3.2  show that ALL tumour cells respond well 
to the cytotoxic effects of JQ1, and JQ1 inhibits BET proteins that play a crucial 
role in the epigenetic control of gene expression, I decided genome-wide 
expression analysis using microarray technology would be the best approach to 
investigate transcriptional responses in a panel of primary ALL tumours 
following JQ1 treatment. Furthermore, the full set of genes which BRD4 
regulates has not been thoroughly investigated, and has not been extensively 
looked at in primary ALL. A panel of primary tumours with a range of 
cytogenetic abnormalities and sensitivity to JQ1 were selected for inclusion in 
the microarray experiment, so that the transcriptional responses observed were 
not just characteristic of a particular cellular phenotype, but instead factored in 
the biological heterogeneity of ALL. Stringent statistical parameters were set to 
filter for the most significant and uniform differentials in gene expression across 
the ALL tumour panel. This, together with rigorous quality control of RNA and 
the experimental procedure, ensured that observed JQ1-induced expression 
changes were most likely to be genuine and reproducible. 
Microarray data show that the MYC gene is significantly downregulated in 
primary ALL following JQ1 treatment (section 3.2). This is a very important 
result, since MYC plays a central role in cell cycle progression and survival 
[343, 412] and is one of the most deregulated oncogenes in cancer, including 
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several different haematological malignancies [343]. For these reasons, a drug 
that downregulates MYC expression has long been sought after in the treatment 
of MYC-expressing tumours. JQ1 appears to be a promising candidate to fulfil 
this task, since it not only downregulates MYC at the transcript level, but also 
shows striking downregulation of c-Myc protein (section 3.3). 
Other genes found to be consistently downregulated by JQ1 activity include 
SENP1, ALKBH8, and CARD6, which are all associated with a role in tumour 
cell survival [420-422].  
Results in Chapter 3 also show that 127 genes were significantly upregulated in 
primary ALL tumours following JQ1 treatment. These included genes with a role 
in the inhibition of the mTor growth-promoting signaling pathways (EIF4EBP2) 
[427] and mRNA translation (PAIP2B) [538], as well as enhancement of the 
apoptotic signaling (PPP1R13B) [539]. The JQ1-mediated upregulation of the 
PPP1R13B gene is particularly interesting from a clinical standpoint, since this 
gene encodes ASPP1 protein capable of stimulating the apoptotic function of 
the p53 tumour suppressor, but also triggering apoptosis independently of p53 
via interactions with both p63 and p73 [539]; a feature of ASPP1 that could 
potentially be of use in the targeting of tumours harbouring mutant p53. 
Furthermore, decreased levels of ASPP1 have been shown to confer a poor 
prognosis in patients with ALL [424].  
From the microarray data in this study, it is evident that the inhibition of BET 
proteins has great impact on the expression of genes involved in multiple 
cellular processes and signaling pathways. Since JQ1 has such a profound 
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cytotoxic effect on ALL cell lines and primary tumours in vitro, it is likely that 
tumour cell death is induced following JQ1-mediated modulation of transcription 
of genes involved in apoptosis, proliferation, survival and cellular growth. This is 
not surprising given that BRD4 recruits the positive transcription elongation 
factor b (P-TEFb) complex to gene promoters, leading to the phosphorylation of 
RNA polymerase II and stimulating transcriptional elongation [442, 540]. The 
fact JQ1 has such a broad effect on gene transcription in primary ALL may 
account for the multiple JQ1-induced cellular effects observed in this study 
(section 3.3).  
 
GSEA results in (section 3.2.4) show that JQ1 activity causes significant 
downregulation of multiple prosurvival signaling pathways, including the NFκB 
pathway that is capable of exerting prosurvival effects and countering apoptotic 
signaling. NFkB target genes in this gene set that were differentially expressed 
in primary ALL tumours following JQ1 treatment included IL7R, IL6, IL8, and 
STAT5A. The impact JQ1 had on this pathway was of particular interest, since 
our group had previously reported that the NFκB pathway was upregulated in 
primary ALL tumours that were resistant to DNA damage-induced apoptosis in 
vitro [248].  
GSEA results also indicate that JQ1 activity leads to the downregulation of the 
JAK-STAT pathway in primary ALL. This holds great potential in the treatment 
of particular subsets of ALL, such as BCR-ABL-positive ALL and BCR-ABL-like 
ALL, which are known to exhibit increased JAK-STAT pathway activation and 
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demonstrate poor treatment outcome [191]. Although the BCR-ABL1 oncogene 
itself activates the JAK-STAT pathway, almost half of all BCR-ABL-like ALL 
tumours that do not express BCR-ABL1 harbour rearrangements of the CRLF2 
gene that are frequently associated with activating mutations within JAK genes 
[190]; again demonstrating a poor response to treatment. Furthermore, 
approximately 10% of all cases of ALL harbour JAK mutations, some of which 
harbour IKZF1 gene alterations that are associated with a poor clinical outcome 
[190].  
Interestingly, upon consideration of GSEA results, it is possible that the 
observed downregulation of JAK-STAT and NFκB pathways might be largely 
attributable to the significant impact JQ1 has on the IL-7R gene, since the IL-7R 
belongs to the same signalling axis, and is an important upstream regulator of 
JAK-STAT and NFκB activity.  
The Myc pathway was also shown to be downregulated by JQ1 activity, which 
coincided with the observation that the MYC gene itself is downregulated in 
JQ1-treated primary ALL tumours in this study. Indeed, results support the 
downregulation of the Myc pathway, since c-Myc protein is also completely 
downregulated. Since MYC is central to cell proliferation, an impact on the cell 
cycle of ALL tumour cells was predicted and confirmed in cell cycle analysis 
experiments (section 3.3.1).  
Given that GSEA shows the ability of JQ1 to downregulate major prosurvival 
pathways in primary ALL tumours (section 3.2.4), a possibility remains that the 
primary tumours that failed to respond to JQ1 treatment in cytotoxicity 
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experiments were not driven by the same prosurvival pathways downregulated 
by JQ1. 
Importantly, the fact that our group has previously reported the upregulation of 
prosurvival pathways in high-risk primary ALL tumours following DNA damage-
induction [248], and that JQ1 is able to downregulate multiple prosurvival 
pathways in primary ALL tumours, including high-risk tumours, suggests BET 
protein inhibition may provide a solution to targeting these pathways, at least in 
MRD high-risk leukaemias. Additionally, crosstalk between prosurvival 
pathways that may confer resistance to chemotherapy in tumour cells [541], 
may be circumvented with this alternative approach of targeting proteins such 
as the BET family of proteins on a level at which many signaling pathways 
converge. This may also explain why JQ1-mediated inhibition of BET proteins 
leads to such broad cellular effects and sensitises ALL tumours with a range of 
phenotypes in this study. Importantly however, despite potent anti-tumour 
activity, some tumours still demonstrate resistance to JQ1. Although two 
potential biomarker genes of JQ1 sensitivity were identified (PLAUR and REL), 
further studies are required to confirm this in a wider range of paediatric 
leukaemias. 
  
5.4 JQ1 activity induces multiple cellular effects on ALL tumour 
cells 
Since Myc expression plays a major role in driving tumour growth in a wide 
range of cancers including leukaemias and lymphomas [343], a clinically viable 
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strategy to downregulate its expression has long been sought after. Previous 
studies have reported that downregulation of Myc and disruption of the c-Myc-
induced transcriptional program constitutes one of the main mechanisms of cell-
killing following the inhibition of BRD4 [333, 334, 340, 341]. In line with this, 
malignancies driven by c-Myc such as AML, NMC and multiple myeloma, are 
sensitised by JQ1-mediated BRD4 inhibition through displacement of BRD4 
protein from the MYC gene promoter [334, 344, 488].  
Similar to previous reports, results in Chapter 3 showed that JQ1 led to uniform 
downregulation of c-Myc protein in all ALL tumour cells, as well as the 
downregulation of c-Myc target genes and cell cycle arrest. However, in 
contrast to previous findings, only transient reductions in MYC mRNA were 
observed by qRT-PCR in this study. This suggests that BRD4 influences c-Myc 
protein stability, which is in keeping with reports that implicate BRD4 in the 
regulation of protein stability of the papillomavirus-encoded E2 protein [448]. 
Indeed, this was later confirmed in experiments where ALL tumour cells were 
exposed to JQ1 in the presence or absence of the 28S proteasome inhibitor 
MG132, with MG132 coincubation completely abolishing JQ1-induced loss of c-
Myc expression (section 3.3.1). This observation highlights a potential role for 
BRD4 in the regulation of cellular proteins at the post-translational level, as well 
as the transcriptional level. 
The question of whether or not the cytotoxic effects induced by JQ1 can be 
entirely attributed to c-Myc downregulation remains debateable. Several studies 
suggest that this is not the case, since ectopic expression of MYC was shown to 
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be unable to prevent JQ1-induced cell death [344], and resistance to JQ1 can 
occur despite c-Myc downregulation [333].  
Results presented in Chapter 3 support the notion that BRD4 inhibition exerts 
an anti-tumour effect by different mechanisms and that the cytotoxic effects 
following BRD4 inhibition expand beyond c-Myc downregulation. Apart from 
results that showed JQ1 leads to substantial downregulation of prosurvival 
signaling pathways in non-cycling primary ALL tumour cells (an effect not 
previously reported in other malignancies), JQ1-induced cellular effects other 
than c-Myc downregulation included the perturbation of the DNA replication 
process. 
In section 3.3.2 results showed that replication fork progression rates were 
reduced in S phase ALL tumours cells following treatment with JQ1. This 
coincided with a dramatic increase in stalled replication forks. Taken together, 
these observations suggest that JQ1-mediated BRD4 inhibition has a direct role 
in the induction of replicative stress.  
Reduced fork progression rates observed after 24 hour exposure of ALL tumour 
cells to JQ1, were also observed at the shorter exposure of just 1 hour. This 
suggests that the reduction in fork progression rates is a direct effect induced by 
BRD4 inhibition and not an indirect effect caused by inhibition of the cell cycle. 
This was also supported by BrdU incorporation experiments (section 3.3.2) that 
showed that JQ1 led to a decrease in the proportion of S phase cells and did 
not affect S phase entry, suggesting a direct effect on the DNA replication 
process.  
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In section 3.3.2 JQ1 treatment led to an increase in the proportion of first label 
termination structures and not second label terminations. This confirms that the 
replication inhibitory effect induced by JQ1 is in fact due to fork-stalling and not 
an overall increase in terminations (i.e. successfully completed replication of 
DNA). This effect is supported by the fact that other drugs, such as etoposide, 
also induce fork-stalling (Peterman, unpublished observation). 
A role for BET proteins in replication is not unlikely, especially since BRD4 has 
been reported to interact with the RFC complex essential for DNA replication 
[443], and inhibition of BRD4 led to changes in expression of the gene encoding 
another key regulator of DNA replication, Claspin, as observed in the microarray 
experiment (section 3.2.2). 
Although further investigation is warranted, a possible explanation for the 
defective replication induced by JQ1 is that loaded transcription complexes are 
not completely processed once BRD4 is inhibited, thus preventing  transcript 
elongation and presenting a physical obstruction to faster proceeding replication 
machinery. Although little is known regarding collisions between transcription 
and replication machinery, there is evidence in the literature to suggest this 
phenomenon is not uncommon [542]. 
Results in (section 3.3.3) show that JQ1 induces the cleavage of proteins 
characteristic of apoptosis. Additionally, the onset of apoptosis appeared to 
mirror the degree of JQ1 sensitivity of ALL tumour cells in cytotoxicity 
experiments. This suggests that the mechanism of cell killing induced by JQ1 is 
indeed via programmed cell death, which is corroborated by results in previous 
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studies showing the induction of apoptosis following BRD4 inhibition in AML 
[344] and NMC [334]. 
In section 3.3.3 I showed that JQ1 treatment of ALL tumour cells did not induce 
the upregulation of p53, unlike treatment with the chemotherapeutic agent 
daunorubicin. This indicates that JQ1 does not cause the activation of the DNA 
damage response pathways, and that the induction of apoptosis is via a p53-
independent mechanism. To test this hypothesis, I probed for common anti-
apoptotic proteins associated with many different types of cancer and checked 
to see if JQ1 induced any changes in expression. Results in showed a dramatic 
loss in expression of the anti-apoptotic protein survivin, suggesting that the 
mechanism of apoptosis induction by JQ1 involves the downregulation of 
survivin. The fact that an anti-apoptotic protein such as survivin plays a role in 
JQ1-induced apoptosis is not surprising since anti-apoptotic proteins are 
commonly overexpressed in Myc-activated tumour cells, to inhibit the 
proapoptotic functions of Myc [447]. However, since microarray results did not 
highlight the BIRC5 gene that encodes survivin protein as being differentially 
expressed after JQ1 treatment, I decided to check whether or not survivin was 
being regulated by JQ1 at the post-translational level. Indeed results in section 
3.3.3 showed that this was the case, since co-incubation of ALL tumour cells 
with JQ1 together with the 28S proteasome inhibitor MG132 led to complete 
abrogation of the ability of JQ1 to downregulate survivin protein expression; an 
effect also observed for c-Myc protein. These observations suggest that BET 
proteins regulate the stability of oncogenic proteins. 
 
 233 
 
Additionally, results in this study show that JQ1 induces apoptosis independent 
of p53. Although mutations of the p53 gene in precursor-B-cell ALL are rare and 
occur at a frequency of approximately 2% [248, 543], p53 mutant ALL still holds 
significance since alterations of the p53 gene can confer resistance to treatment 
and a poor outcome [248, 544]. Thus, it is possible that JQ1 may prove to be 
beneficial in the treatment of patients with p53 mutant ALL. 
5.5 JQ1 prevents tumour growth in an ALL xenograft model and 
targets different ALL progenitors 
Results in section 3.4, involving the use of a murine xenograft model of an 
apoptotic-resistant B precursor ALL with high-risk MRD (ALL-105), showed that 
JQ1 potently inhibited the growth of xenografted primary leukaemia cells in vivo, 
when compared to vehicle-treated animals. Results also show a dramatic 
reduction in tumour growth in JQ1-treated mice with a subcutaneous 
engraftment of NALM-6 cells, when compared to those treated with vehicle. 
This suggests that JQ1 exhibits cytotoxic effects on ALL tumour cells both in 
vitro and in vivo, which is in agreement with the in vivo JQ1-mediated anti-
tumour effects observed in other studies using xenograft models of AML [344] 
and NMC [334].  Additionally, JQ1 targeted all the progenitor subpopulations 
that constituted the engrafted leukaemia and had the capacity to proliferate in 
vivo, with a slight increase being observed in the proportion of the CD34-
CD19+CD10- ALL subset. This suggests that JQ1 is able to target ALL 
progenitor cells regardless of their stage of differentiation, and potentially cause 
a shift towards more mature cells. The ability for JQ1 to induce differentiation of 
leukaemia progenitors has been confirmed in studies that show JQ1-treatment 
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of AML blasts leads to maturation via a JQ1-mediated impact on the 
transcriptional programme that controls myeloid differentiation [340, 344]. 
5.6. Summary I: BET protein inhibition as a novel therapeutic 
strategy to sensitise apoptosis-resistant B-precursor ALL 
• In this study, I have confirmed that the BET protein BRD4 is widely 
expressed in ALL tumour cells, and that the pharmacological inhibitor 
JQ1 can successfully target BET proteins to induce potent cytotoxic 
effects in vitro, irrespective of the cellular phenotype.  
• The tumour-specificity of JQ1 was supported by the fact that primary 
AML tumours were highly sensitive to JQ1 in this study (an observation 
in line with previous reports [344]), and that healthy PBMCs did not 
exhibit significant cytotoxic effects following JQ1 treatment.  
• Furthermore, I showed that JQ1 acts synergistically with 
dexamethasone, suggesting this drug combination may allow for the 
lowering of dexamethasone doses administered to ALL patients, and 
therefore reduce the toxic side-effects associated with its use.  
• Using microarray technology, I have elucidated the transcriptional effects 
of JQ1-mediated BET protein inhibition in a cohort of ALL primary 
tumours.  
• I have shown that JQ1 activity leads to the downregulation of major 
prosurvival signaling pathways that include the NFκB pathway, which our 
lab previously confirmed to be upregulated in high-risk ALL tumours 
 235 
 
[248], and the JAK-STAT pathway, which is a prosurvival pathway 
commonly activated in the tumour cells of high-risk ALL patients with a 
poor treatment outcome [190, 191].  
• I have also shown that JQ1 activity leads to downregulated expression of 
genes belonging to multiple cytokine signaling pathways that are often 
deregulated in haematological malignancies and are known to drive 
tumour growth and proliferation [545-548].  
• I confirmed that c-Myc and its associated target genes are also 
downregulated by JQ1. However, I have shown that this was an effect 
caused primarily by Myc downregulation at the post-translational level, 
rather than at the transcriptional level, highlighting a role for BET proteins 
in the modulation of c-Myc protein stability that has not previously been 
reported. 
• The impact of JQ1 on c-Myc expression is of great importance, since c-
Myc potently drives tumorigenesis and is frequently overexpressed in 
many cancers, including haematological malignancies [343]. Thus, an 
effective therapeutic approach towards the downregulation of c-Myc has 
long been sought after, and I show that BET protein inhibition using the 
JQ1 inhibitor provides a means by which to achieve this.  
• I have also shown that downregulation of c-Myc coincides with the 
induction of G1 arrest in actively proliferating ALL tumour cells treated 
with JQ1, together with a substantial reduction of the proportion of S 
phase cells. 
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• I have subsequently confirmed that inhibition of BET proteins has a direct 
impact on DNA replication, seen as a reduction in fork progression rates 
and an increase in replication fork stalling.  
• I have confirmed that the mechanism of JQ1-induced cell killing is 
mediated via a p53-independent mechanism that involves the 
downregulation of the anti-apoptotic protein survivin, and that like c-Myc, 
survivin is regulated by BET proteins at the post-translational level; most 
likely by BRD4.  
• The most striking results in this study were those obtained from animal 
studies. I showed that JQ1 was capable of inhibiting the proliferation of 
ALL xenografts in vivo, including a xenograft model of a high-risk ALL 
patient our lab had previously shown to be resistant to DNA damage-
induced apoptosis. Importantly, JQ1 targets both immature and mature 
ALL subpopulations, reducing the likelihood of treatment resistance as a 
result of the re-expansion of stem-like populations. Furthermore, during 
the writing of this thesis, with the assistance of Tracey Perry, additional 
results have been obtained by our group using our ALL mouse xenograft 
model, which show that high-risk primary ALL tumours are highly 
sensitised to dexamethasone when co-treated with JQ1 (personal 
communication). 
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5.7. Conclusion I 
Overall, results from this study support the rationale for the targeting the BET 
proteins, including BRD4, in B-precursor ALL using JQ1, which is capable of 
sensitising high-risk ALL tumours both in vitro and in vivo. This suggests that 
treatment involving JQ1 may be a clinically viable option for the treatment of 
high-risk ALL patients that respond poorly to conventional therapies. The fact 
that this study and several others have successfully demonstrated potent JQ1-
mediated anti-tumour activity in vivo, in which the JQ1 inhibitor was well 
tolerated by its recipient host and targeted tumours with great specificity, holds 
promise for the further development of this compound. Importantly, it should be 
relatively straightforward to include JQ1 into the current UK ALL clinical trial by 
further stratifying enrolled dexamethasone-resistant patients into two 
subgroups; one group receiving dexamethasone only, and the other receiving a 
JQ1/dexamethasone drug combination. 
Altogether, this study justifies further work in this area of research to aid the 
design of the first clinical trial based on BET inhibition in paediatric ALL.  
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6. DISCUSSION II: THE PIM-2 KINASE AS A SUITABLE 
CANDIDATE FOR FURTHER STUDY 
 
6.1. Evidence that the prosurvival PIM2 kinase is overexpressed 
in B-precursor ALL and is an ideal candidate for further study 
As described in section 1.10.3 the PIM kinases are overexpressed in a wide 
range of haematological malignancies and solid tumours, and have been shown 
to confer prosurvival activity by counteracting the increased sensitivity to the 
induction of apoptosis that is observed in tumours overexpressing c-Myc [356]. 
Furthermore, previous studies have confirmed that PIM1, and possibly other 
PIM proteins, play a key role in gene transcription by both regulating Myc-
transcriptional activity, and promoting the binding of the BET protein BRD4 to 
histone acetyllysine residues, which in turn recruits the P-TEFb complex 
required for transcript elongation [386, 388].  
In an attempt to prove my main hypothesis that primary B-precursor ALL can be 
sensitised following inhibition of oncogenic transcriptional activity, I previously 
showed that targeting BET proteins is an effective approach by which to do so.  
Here, I discuss an additional approach involving the targeting of PIM2, and 
evaluate preliminary evidence to support PIM2 as a promising additional target 
for the sensitisation of primary ALL, and therefore as an ideal candidate for 
further study.  
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The first step in investigating the feasibility of this strategy was to determine 
whether PIM kinases were overexpressed in B-precursor ALL. I needed to 
establish a suitable method by which to measure PIM expression, and 
proceeded to indirectly quantify PIM protein levels by measuring PIM mRNA 
using qRT-PCR. The qRT-PCR technique was an ideal method by which to 
determine the frequency of PIM overexpression, since I had access to a large 
cohort of 68 primary ALL RNA samples. I considered the use of this method on 
the basis that PIM2, and in some cases PIM1, is constitutively active once 
expressed [385] and no post-translational modifications of the PIM2 kinase 
have been reported. 
I found that PIM2 was significantly overexpressed in primary ALL tumours at a 
frequency of 25% relative to the expression levels in the K562 leukaemia cell 
line, whilst observing a similar proportion of tumours expressing PIM2 protein in 
a smaller cohort of primary ALL tumours I had analysed by Western blotting. 
This was unsurprising, since PIM genes are confirmed to be upregulated by 
activated STAT transcription factors that are downstream of prosurvival 
signaling pathways, such as the JAK-STAT and NFκB pathways [369], which 
our group has previously shown to be upregulated in primary ALL [248]. 
In addition, I observed a trend towards a positive association between PIM2 
expression in primary ALL tumours and the presence of MRD at Day 28 in the 
corresponding patients from which the tumours were obtained. However, 
although this result may suggest a role for PIM2 in chemoresistance in vivo, this 
has to be considered with caution, as I did not have access to MRD clinical data 
for all the primary ALL tumours I screened. Thus, it would be necessary to 
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increase the number of ALL tumours in the PIM screen for which we have full 
clinical information in future studies. 
Overall, my observations that PIM2 is significantly overexpressed in ALL and 
might play a role in chemoresistance in vivo, together with the already reported 
prosurvival functions of PIM2 in other haematological malignancies, support my 
rationale for proceeding with investigations into the role of PIM2 in B-precursor 
ALL. 
6.2. Evidence to support PIM kinases can be targeted in B-
precursor ALL 
I previously provided evidence to support that PIM2 is overexpressed in pre-B 
ALL and so I next wanted to determine whether PIM2 could be specifically 
targeted in order to sensitise primary ALL tumours. 
Since PIM kinases are also involved in normal haematopoiesis, it was 
reassuring to find data in the literature from studies using compound PIM1, 
PIM2 and PIM3 knockout mice that showed these animals were still viable and 
fertile [362]. Despite exhibiting a reduced body size at birth, the results from this 
study suggest that PIM kinases are important to mammalian development but 
are kinases mediating growth factor signaling that can be inhibited and not 
cause cytotoxicity to healthy developing lymphocytes [362]. 
I therefore proceeded to test ALL tumour cells with a pharmacological inhibitor 
of PIM kinases, K00135, which was obtained from our collaborator Prof. Stefan 
Knapp and had shown encouraging anti-tumour activity in PIM-expressing 
primary AML tumours [391]. In K00135-treated leukaemia cell lines, I failed to 
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see a clear correlation between PIM expression and induction of cytotoxicity, 
since cell lines not expressing any detectable PIM kinase protein (for example, 
REH and Jurkat) were sensitised in addition to the PIM-expressing ALL cell line 
SD1.  
This suggests that K00135-induced cytotoxicity observed in the leukaemia cell 
lines not expressing PIM protein may be due to off-target effects, despite the 
K00135 inhibitor having been shown to exert selective antileukaemic activity in 
other studies involving the use of several AML cell lines and primary AML 
tumours [391]. However, published structural data, involving a screen of 
K00135 against a panel of 50 kinase catalytic domains, confirms that this 
inhibitor cross-reacts with one additional kinase, namely Cdc-like kinase 1 
(CLK1) [391].  
The possibility that CLK1 inhibition leads to cytotoxic effects in the ALL cell lines 
I tested that do not express PIM kinases remains to be investigated. 
Interestingly, although the cellular functions of CLK1 are not yet fully 
understood, studies have shown that CLK1 plays an important, evolutionarily 
conserved role in pre-mRNA splicing; a process associated with increased 
protein expression and often deregulated in cancers to promote growth and 
survival [549].  
However, K00135-mediated cytotoxic effects in primary ALL tumours appeared 
to positively correlate with PIM2 expression with no significant cytotoxic effects 
being observed in healthy PBMCs.  
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I also noticed that there were some instances where tumours expressed PIM2 
and did not respond to K00135 treatment, as opposed to PIM2 negative 
tumours that were sensitised by K00135 treatment. This suggests that 
treatment with K00135 targets PIM-expressing ALL tumours with some degree 
of specificity, and that some tumours may be resistant to the effects of K00135-
mediated PIM inhibition.  
6.3. Cellular effects of K00135 on PIM-expressing B-precursor 
ALL tumour cells involves downregulation of c-Myc protein and 
induction of apoptosis 
The PIM2 kinase has been show to efficiently stabilise c-Myc protein in a range 
of cell lines derived from human solid tumours by phosphorylating c-Myc at 
Ser329, thus decreasing c-Myc transcriptional activity [531]. Given that c-Myc 
has been reported to regulate transcription by forming a complex with PIM1, 
and possibly other PIM family members, to promote BRD4-mediated transcript 
elongation [386-388], I decided to investigate whether c-Myc would be 
downregulated in PIM-expressing ALL tumour cells following treatment with 
K00135, as the PIM2/c-Myc interaction may be an important mechanism 
through which PIM2 is able to regulate gene transcription in ALL. 
Indeed, I found that K00135 treatment of both leukaemia cell lines and primary 
ALL tumours expressing PIM2 led to complete downregulation of c-Myc protein. 
Further investigation, perhaps in experiments involving the use of the 
proteasomal inhibitor MG132, as well as measurement of MYC expression 
before and after K00135 treatment, will be required to confirm that regulation of 
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c-Myc by PIM in ALL is at the post-translational level. Since my GSEA data 
shows that upregulation of the MYC signaling pathway was not associated with 
ALL tumours expressing PIM2, it is possible that c-Myc is regulated at the 
protein level. 
I found that K00135 induced caspase-dependent apoptosis in primary ALL 
tumours (ALL-103) and that this coincided with the induction of cytotoxicity 
observed in previous experiments. As studies have suggested that the 
oncogenic properties of PIM2 are partly dependent upon its regulation of 
prosurvival signaling [359], and PIM2 is reported to predominantly 
phosphorylate (and therefore inactivate) the Ser112 residue of proapoptotic 
BAD [380], I decided to test the effect of K00135 treatment on BAD 
phosphorylation in SD1 cells. Subsequently, I found that K00135 led to a 
decrease in BAD Ser112, suggesting this may be a mechanism by which PIM 
kinases are able to promote survival in ALL. 
Intriguingly, studies have confirmed that the Akt kinase of the PI3K prosurvival 
signaling pathway shares several overlapping substrates with PIM2, including 
proapoptotic BAD (both kinases phosphorylate BAD Ser112), and the 
translational repressor 4EBP1 [359]. However, PIM2-mediated survival was 
shown to be distinctly independent of Akt signaling, since the overexpression of 
PIM2 in haematopoietic cell lines conferred growth factor-independent survival 
that could not be inhibited by rapamycin; an inhibitor of the mammalian target of 
rapamycin (mTOR) kinase found downstream of Akt [385]. 
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Taken together, the effects of K00135 on c-Myc protein expression, and the 
phosphorylation of BAD in ALL tumour cells, indicate that the K00135 inhibitor is 
likely to be targeting PIM protein and that doing so sensitises ALL. Furthermore, 
it is possible that the observed complete downregulation of the c-Myc 
transcription factor has an impact on gene expression as a consequence. 
6.4. Patterns of gene transcription associated with PIM2 
expression in B-precursor ALL 
As mentioned, PIM kinases regulate gene transcription by forming a complex 
with c-Myc and promoting the binding of BRD4 to histones, which in turn 
recruits the P-TEFb complex [388]. The P-TEFb complex then phosphorylates 
RNA pol II at Ser2 leading to the elongation and subsequent termination of 
transcripts at promoter-proximal pause sites [337, 388]. Furthermore, I showed 
that treatment of SD1 cells with K00135 led to a decrease in RNA Pol II Ser2 
phosphorylation, hinting at a possible role for PIM kinases regulating gene 
transcription in ALL.  
To gain some insight into the genes and pathways PIM2 may regulate, I 
reanalysed microarray data previously obtained in our lab, which was derived 
from an independent cohort of 22 primary ALL tumours. I arranged the tumours 
in order of low to high basal PIM2 expression, and then identified the most 
significant genes associated with PIM2 expression.  
I took this approach as the K00135 inhibitor was not sufficiently specific to 
produce reliable microarray data, and an alternative, more specific PIM kinase 
inhibitor was not available. Furthermore I had also previously made multiple 
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attempts to generate stable PIM2 knock-down (KD) ALL cell lines using both 
lipid-based transfection and lentiviral transduction methods to introduce a short 
hairpin RNA (shRNA) to silence the PIM2 gene in ALL tumour cells. However, I 
was unsuccessful in doing so, despite having successfully cloned the PIM2 
gene into a lentiviral expression construct with the help of Dr. Phil Byrd.  
For the above reasons I proceeded with reanalysis of existing microarray data, 
which had its limitations as I was unable to confirm whether individual genes 
and pathways associated with PIM2 expression in primary ALL tumours were 
upstream or downstream of PIM2.  
Nevertheless, my approach produced interesting results that in many cases I 
could relate to existing findings reported in the literature, as well as other novel 
roles can be further investigated and confirmed in future. For example, I found 
that multiple NFκB target genes (for example XIAP, TNFAIP3, NLRP3 and 
CD48), which regulate NFκB-mediated survival and anti-apoptotic signaling, 
were associated with PIM2 expression.  
Interestingly, limited evidence derived from studies using the FL5.12 murine 
pro-B cell line data exists to support PIM2 being an upstream activator of NFκB, 
where PIM2 was shown to phosphorylate the oncogenic serine/threonine 
kinase, Cot, which in turn phosphorylates IκB [369]. IκB then releases NFκB 
dimers, which localise to the nucleus and activate gene transcription [369]. 
Thus, it remains to be confirmed whether inhibition of PIM2 activity 
downregulates NFκB activation. 
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In addition, previous studies have shown that PIM2 is upregulated following the 
induction of DNA DSBs during V(D)J recombination in developing B-
lymphocytes [550]. This supports my GSEA analysis data, where I observed an 
association between the upregulation of the DNA damage-response pathway 
and the expression of PIM2 in primary ALL tumours. The fact that this pathway 
is upregulated at basal levels in untreated primary tumours, could mean that 
tumours expressing high levels of PIM2 exhibit a greater level of endogenous 
DNA damage due to deregulated proliferation [551]. It would be interesting to 
test whether PIM-expressing ALL tumours, including PIM2-expressing tumours 
resistant to DSB-inducing chemotherapeutic drugs, can be sensitised by co-
incubation of a PIM inhibitor with a cytotoxic agent such as doxorubicin. 
Importantly, the most noticeable pathways and individual genes to be closely 
associated with high and low PIM2 expression were those belonging to cellular 
processes such as gene transcription (basal transcription factors), protein 
translation (mRNA translation, peptide chain elongation, ribosome metabolism), 
and DNA replication (regulation of origin recognition complexes). These 
processes were highly represented in GSEA analysis results, suggesting that 
PIM2 may play a key role in maintaining these processes in B-precursor ALL. 
The above observations are supported by aforementioned previous studies that 
show PIM1 enhances BRD4-mediated gene transcription [386, 388]. 
Furthermore, my observations from GSEA results that PIM2 expression is 
associated with protein translation, is supported by studies showing that PIM2 
activity leads to the phosphorylation and release of 4E-BP1 from EIF4E, which 
are key regulator proteins of the Cap-dependent translation pathway  [346, 383, 
 248 
 
385]. Ultimately, this allows for the recruitment of ribosomes and translation 
machinery to the ‘capped’ mRNA, and for the synthesis of oncogenic proteins 
such as c-Myc and Mcl-1 to take place [552]. 
However, very limited evidence exists in the literature to suggest PIM kinases 
regulate the DNA replication process. Intriguingly, PIM1 has been shown to bind 
and phosphorylate the latency-associated nuclear antigen 1(LANA-1), which is 
a protein essential for the maintenance of Kaposi's sarcoma herpes virus 
(KSHV) latency, resulting in the activation of viral replication [553]. Thus, it is 
possible that PIM2 regulates DNA replication in ALL, given that GSEA in this 
study showed its expression was also associated with pathways regulating DNA 
replication. As a side note, studies have shown that the BET proteins BRD4 and 
BRD2 also interact with LANA-1 to activate KSHV replication [554], suggesting 
overlapping activity between PIM and BET proteins; a feature I have noticed on 
various occasions throughout my studies. 
6.5. Evidence to suggest overlapping functions between PIM 
and BET proteins 
Previous studies have shown that PIM kinases enhance BRD4 activity, and thus 
promote transcript elongation [386, 388]. In this study I confirmed that inhibition 
of BET proteins leads to the transcriptional downregulation of genes involved in 
prosurvival signaling. Furthermore, I showed that the targeting of both these 
oncogenic proteins leads to the sensitisation of B-ALL tumour cells to apoptosis.  
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Taken together, it appears that a close relationship may exist between PIM 
proteins and BET proteins that promote tumorigenesis and chemoresistance in 
ALL.  
Here, I summarise observations that lend additional support to the existence of 
overlapping activity between PIM and BET proteins. 
Firstly, my observation that PIM2 expression is significantly and differentially 
upregulated in JQ1-resistant primary ALL tumours following treatment with JQ1, 
suggests that PIM2 may act as a compensatory pathway to help maintain 
survival and anti-apoptotic signaling. When highly specific PIM2 inhibitors 
become available, it will be interesting to determine whether JQ1-resisitant 
tumours also expressing PIM2 can be sensitised to JQ1 activity following co-
incubation with a PIM kinase inhibitor. 
However, although cytotoxicity could be induced in most primary ALL tumours 
following JQ1 treatment, I noticed that the JQ1-resistant primary ALL tumour 
ALL-103, expressing both PIM and BRD4, could be successfully sensitised to 
the cytotoxic effects of K00135 instead. In addition, primary tumours ALL-105 
and ALL-113, which were resistant to K00135 treatment, were successfully 
sensitised following exposure to JQ1. Taken together, this suggests that in 
some cases JQ1-resistance and K00135-resistance can be circumvented by 
targeting PIM kinases or BET proteins, respectively, and thus demonstrates the 
benefits of being able to target both PIM kinases and BET proteins in B-
precursor ALL. 
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In addition, I confirmed that treatment of ALL tumour cells with either PIM 
kinase inhibitor K00135 or the BET protein inhibitor JQ1 leads to complete 
downregulation of c-Myc protein. This highlights a further overlap in function 
between PIM and BET proteins that may promote tumorigenesis through the 
stabilisation of c-Myc; an oncogenic kinase known to be frequently 
overexpressed in haematological malignancies and potently drive cell 
proliferation [343]. 
With respect to gene expression, I also observed a similarity in the genes that 
appeared to be regulated by PIM kinases and BET proteins. For example, I 
found that BET protein activity was associated with the regulation of TMEM71, 
TMEM156, IL2RA and XIAP genes (which are all upregulated by JAK-STAT 
pathway activity), whereas PIM2 expression was associated with the 
upregulation of TMEM14B, IL2RG, and XIAP genes. This suggests PIM and 
BET proteins may co-operate in promoting tumorigenesis and may confer 
resistance to either K00135 or JQ1 by independently regulating similar genes. 
Taken together, these observations and other previously reported findings lend 
support to suggest PIM kinase and BET proteins may be cooperating together 
to maintain ALL, and may be doing so via the regulation of proliferation, survival 
signaling, and inhibition of apoptosis. 
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6.6. Summary II: Selection of the PIM2 kinase as a candidate 
therapeutic target for further study 
• In this study, I have validated the qRT-PCR technique as an efficient and 
reproducible method by which to indirectly screen ALL tumours for PIM2 
protein expression, since I confirmed that PIM2 mRNA closely correlates 
with PIM2 protein expression levels. 
• Subsequently, I screened a large cohort of primary ALL tumours (n=68) 
and determined the frequency of PIM2 overexpression in B-precursor 
ALL as being 25%. 
• In vitro cytotoxicity data derived using leukaemia cell lines were largely 
inconclusive. However, in contrast to PBMCs, primary ALL tumours were 
sensitised to the cytotoxic effects of treatment with the PIM kinase 
inhibitor K00135. Furthermore, a subset of primary tumours appeared to 
be resistant to PIM-inhibition.  
• Re-analysis of microarray data derived from an independent cohort of 
primary ALL tumours revealed that PIM2 expression was significantly 
associated with the upregulation of genes involved in NFKB and PI3K 
prosurvival signaling pathways, gene transcription, cell cycle 
progression, DNA replication, ribosome metabolism and protein 
translation. In addition, multiple DNA repair genes were negatively 
associated with PIM2 expression. 
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• I confirmed that K00135 treatment of ALL cell lines and primary tumours 
led to complete downregulation of c-Myc protein. 
• I also confirmed that exposure of ALL tumour cells to K00135 led to the 
induction of caspase-dependent apoptosis, which coincided with a 
decrease in BAD Ser112 phosphorylation; a post-translational 
modification known to inactivate this pro-apoptotic protein [380]. 
• Finally, several observations in this study hint toward a close relationship 
between PIM2 and BET proteins that require further investigation. 
 
6.7. Conclusion II 
Overall, the preliminary results from experiments investigating PIM kinases 
confirm that PIM2 is significantly overexpressed in B-precursor ALL, and can be 
targeted to induce ALL tumour cell death. Ultimately, the data presented in this 
thesis have initiated several lines of investigation, and support the rationale for 
the selection of PIM2 as a candidate for further study, and for its validation as a 
novel therapeutic target in B-precursor ALL in addition to BET proteins.  
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7. FUTURE WORK 
7.1 Extension of ALL tumour cohort 
To further evaluate my hypothesis that targeting BET proteins, such as BRD4, 
is an alternative strategy to the sensitisation of primary ALL tumours, including 
apoptotic-resistant high-risk tumours, it will be important to extend the ALL 
tumour cohort analysed in this study. Our lab has previously reported an 
association between ALL apoptotic-resistance in vitro and high-risk or relapsed 
ALL [247]. Since the data presented in this thesis confirms that BRD4 is widely 
expressed in ALL, independent of the phenotype, and that JQ1-mediated 
inhibition of BET proteins effectively induces a cytotoxic response in both 
apoptosis-sensitive and apoptosis-resistant primary ALL tumours, it will be 
interesting to find out how genetically diverse, refractory ALL tumours respond 
to BET inhibition. This would be highly relevant work, since an estimated 30% of 
ALL patients treated at Birmingham Children’s Hospital are diagnosed with 
either high-risk or relapsed disease (personal communication with Dr. Shaun 
Wilson).  
Refractory ALL tumours can be tested in vitro using the luminescent ATP-based 
cytotoxicity assay described in this study, as it is efficient and produces 
consistent results. Refractory ALL tumours can be treated with JQ1, and other 
highly specific BET inhibitors currently under development by our collaborator 
Prof. Stefan Knapp, in order to further validate that targeting BET proteins is a 
highly effective, novel approach to sensitising chemoresistant ALL tumours. 
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Given the range of in vitro responses of primary ALL tumours to JQ1 it will be 
important to determine whether or not the different responses are in part due to 
different rates of cycling among individual tumours. Since primary tumours are 
predominantly non-cycling in vitro and results in section 3.1.2 indicate that 
tumours most resistant to JQ1 are those with upregulated expression of the 
CDKN1A and GADD45A genes involved in cell cycle arrest, it would be ideal to 
compare the cytotoxic effects in non-cycling primary ALL cells with primary ALL 
cells that have been induced to cycle. This would be possible using a culture 
system containing CD40L, IL-3, IL-7, IL-10 and Flt3L previously established in 
our lab [555]. 
7.2 Investigation of the synergy between JQ1 and 
dexamethasone in vitro 
Results in this study show that JQ1 confers synergistic effects when combined 
with dexamethasone, as demonstrated by in vitro data that shows both ALL cell 
lines and primary tumours are sensitised to dexamethasone using this drug 
combination (section 3.1.3). Since dexamethasone is a key component of 
current ALL treatment protocols and sensitivity to glucocorticoid treatment in 
vivo is a major prognostic factor in B precursor ALL [556], it will be important to 
elucidate the mechanisms by which JQ1 is able to potentiate the cytotoxic effect 
of dexamethasone as this would allow for the identification of tumours that are 
most likely to benefit from addition of BET inhibitors to standard ALL protocols. 
The mechanisms behind such synergy can be investigated by first testing for in 
vitro synergistic cytotoxic effects of combined JQ1/dexamethasone in 
dexamethasone-resistant ALL tumours and then using genome-wide gene 
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expression profiling to compare the transcription profiles of dexamethasone-
resistant ALL tumours that can be sensitised by JQ1 and that are either 
untreated, treated with JQ1, treated with dexamethasone, or treated with a 
combination of JQ1/dexamethasone.  
It has been suggested that dexamethasone exerts its anti-tumour effect via 
downregulation of the NFκB and c-Myc pathways, and that the decision for a 
tumour cell to undergo either apoptotic death or cell cycle arrest is dependent 
upon the expression of the anti-apoptotic protein Bcl-2 and Bcl-2 protein family 
members [557-559]. It will therefore be important to monitor changes in 
expression of proteins such as Bcl-2, Bax, Bak and Bim, in response to different 
treatments using qRT-PCR and Western blotting techniques. Indeed, BIM 
expression has been shown to be essential to dexamethasone-induced 
apoptosis in ALL, and to be regulated mainly at the transcriptional level [560]. 
Interestingly, studies have shown that glucocorticoid resistance in primary B 
precursor ALL cells is not due to decreased GR expression, and instead occurs 
downstream of ligand-induced translocation of GR to the nucleus, and upstream 
of Bim induction [561], suggesting that elucidation of the exact signaling events 
between GR activation and Bim induction may aid attempts to overcome 
dexamethasone resistance in ALL. Furthermore, the mechanism of action of 
dexamethasone involves antagonism of Rel A (p65) activity by interfering with 
RNA Pol II-mediated gene transcription [562]. Since BET proteins such as 
BRD4 promote RNA Pol II transcription activity [442], it may be that 
sensitisation of ALL tumour cells to dexamethasone, when co-treated with JQ1, 
is in part due to favouring an overall inhibitory effect on RNA Pol II activity; this 
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will require further investigation. Should combined JQ1/dexamethasone 
treatment cause differential downregulation of NFκB target genes, chromatin 
immunoprecipitation (ChIP) may be used to determine whether or not exposure 
to both JQ1 and dexamethasone reduces the occupancy of NFκB at target gene 
promoters, compared to untreated cells, or cells treated with dexamethasone 
alone. 
7.3 Investigation of the in vivo effects of BET protein inhibition 
in xenograft models of refractory and dexamethasone-resistant 
ALL  
The high efficacy with which JQ1 sensitises apoptotic-resistant ALL cells 
derived from a high-risk ALL patients in vivo has been demonstrated in this 
study. To further support the concept of targeting BET proteins to sensitise 
chemoresistant ALL, it will be necessary to develop additional xenograft models 
of high-risk and refractory ALL, in order to test the anti-leukaemic effects of JQ1 
and other available specific BET inhibitors. It will be interesting to see how 
effective BET inhibition will be in eliminating leukaemia in vivo in models of ALL 
tumours with a range of cytogenetic abnormalities that are commonly 
associated with a poor prognosis. 
Additionally, results in this study indicate that treatment of ALL tumour cells with 
a JQ/dexamethasone combination leads to synergistic cytotoxic effects in vitro. 
To confirm that these synergistic effects are translatable in an animal model, it 
will be necessary to also develop primary xenograft models of dexamethasone-
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resistant ALL, in order to measure the effects combined treatment has on 
tumour load and ALL progenitor populations. 
 
7.4 Evaluation of transcriptional biomarkers 
Despite uniform expression of BRD4, not all primary tumours are sensitive to 
BET protein inhibition, which is why I set out to identify transcriptional 
biomarkers of sensitivity to JQ1 (section 3.2.5). It will be important to validate 
the biomarker genes I identified in an independent cohort of ALL tumours with 
known sensitivity to JQ1. This work may hold crucial clinical implications in 
future, which would allow for the prediction of a patient’s response to JQ1 based 
on biomarker gene expression levels, and avoid administering the JQ1 inhibitor 
to patients unnecessarily. 
7.5 Investigation of the role of BET proteins in protein stability 
Cellular proteins are targeted for proteasomal degradation following the activity 
of ubiquitin ligases (E1, E2 and E3), which transfer a chain of ubiquitin 
molecules to specific lysine residues on the target protein [563, 564]. 
Intriguingly, several studies have shown that the acetylation of lysine residues 
of key regulatory factors, such as p53, p73, Runx3, FOXO4 and E2F1, can lead 
to an increase in their protein stability [565-571]. As in the case of E2F1, 
acetylated lysine residues create a binding site for a binding partner, which 
when bound, masks the lysine residue and prevents its ubiquitination [565, 
566].  
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Upon consideration of these observations, together with the results I present in 
this thesis showing that inhibition of acetyllysine-binding BET proteins leads to 
proteasomal degradation of both c-Myc and survivin, it would interesting to 
determine whether BET proteins regulate protein stability by binding and 
masking lysine residues of cellular proteins.  
 
7.6 Investigation of the effects of BET protein inhibition on DNA 
replication and repair 
Since monotherapies tend to lead to treatment resistance, combined treatment 
of drugs with different mechanisms of action is preferred. Thus, it will be 
important to elucidate the role of BET proteins in DNA replication and repair and 
provide rationale for combined treatments for ALL involving JQ1, above 
combinations with dexamethasone. 
Results presented in this thesis suggest a JQ1-induced delay in replication fork 
progression and an increase in replication fork stalling. To further understand 
this effect, it will be necessary to verify whether replication fork stalling is 
associated with the induction of DNA damage and increased levels of single-
strand DNA (ssDNA) breaks. This can be measured by Western blot analysis, 
as well as immunofluorescence and quantification of phosphorylated RPA foci, 
which are a marker of ssDNA. Furthermore, increased levels of spontaneous 
γH2AX foci, a frequently used marker of DSBs, in ALL tumour cells treated with 
JQ1 will also be indicative of replication-associated DNA damage. 
 260 
 
Additionally, to test the hypothesis that the presence of incomplete transcription 
complexes in JQ1-treated cells has an impact on replication fork progression 
and stalling, it will be interesting to see if treatment of ALL tumour cells with the 
CDK9 inhibitor 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) leads 
to similar effects in DNA replication to JQ1-treated cells, since DRB inhibits 
transcription through a similar mechanism to that suspected for JQ1-mediated 
BRD4 inhibition [339, 572]. 
It will also be important to investigate the effects of BET protein inhibition on 
DNA repair. BET proteins interact with histone deacetylases [573], and it is 
conceivable that their inhibition may affect the configuration of chromatin [574]. 
Since chromatin status is an important determinant of the DNA damage 
response, including homologous recombination repair (HRR) [575-577], it will 
be interesting to see if replicative stress observed in JQ1-treated tumour cells 
exhibit deregulated HRR. This can be tested in experiments using 
immunofluorescence to determine whether JQ1 causes delayed resolution of 
IR-induced foci of phosphorylated γH2AX, which would indicate reduced 
efficacy of DSB repair. If this is the case, further investigation looking at IR-
induced foci of HRR proteins, such as RAD51, RNF168, BRCA1 and RAD18, 
will aid elucidation of changes to DSB repair kinetics. 
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7.7 Determine the role of other BET proteins in the regulation of 
ALL survival and proliferation 
Recent evidence suggests that in addition to BRD4, other BET protein family 
members might also play a role in cancer pathogenesis. For example, BRDT is 
frequently expressed in non-small-cell lung carcinoma (NSCLC), whereas 
BRD2 interacts with the Kaposi sarcoma associated herpes virus (KSHV) 
latency associated nuclear antigen 1 (LANA-1) that is required for replication of 
this tumour-promoting virus [554, 578, 579].  
Although evidence exists to show that JQ1 binds to the bromodomains of BRD4 
with the greatest affinity, bromodomains of other BET proteins are also targeted 
by JQ1 to some extent [334]. Thus, it will be important to determine the 
biological significance of individual members of the BET family, by studying the 
expression levels of BRD2, BRD3 and BRDT, as well as the effect of their 
downregulation, in a number of primary low-risk, high-risk, and relapsed ALL 
tumour cells, as well as in ALL cell lines NALM-6 and REH, which are 
representative of apoptosis-sensitive and apoptosis-resistant phenotypes, 
respectively. The establishment of stable shRNA knock-down in ALL cell lines 
for the BET proteins that are expressed in ALL and demonstrate an impact on 
survival, will also be important future work to link cytotoxic effects to the 
downregulation of specific members of the BET family of proteins. 
7.8 Validation of the PIM2 kinase as a viable therapeutic target 
in B-precursor ALL 
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The overexpression and oncogenic functions of PIM kinases have previously 
been demonstrated in a wide range of haematological malignancies [356]. 
Furthermore, the expression of PIM kinases is activated by JAK-STAT and 
NFκB prosurvival signaling pathways, both of which are frequently upregulated 
in high-risk ALL [67, 68, 189, 192, 248]. 
The results in this study indicate that PIM2 may play a role in maintaining pre-B 
ALL and so it will be important to further characterise its activity and confirm that 
pharmacological inhibition of PIM2 is an additional strategy by which to 
downregulate survival signaling and overcome apoptotic-resistance observed in 
a subset of chemoresistant primary ALL tumours [248]. 
Importantly, a next-generation PIM kinase inhibitor is currently being developed 
(personal communication with Prof. Stefan Knapp), which targets PIM2 with 
greater affinity and specificity than K00135, despite K00135 being found to 
cross-react with only one additional kinase, CLK1 [486]. Once available, it will 
be important to test the effects of the new PIM2 inhibitor in a larger cohort of 
primary ALL tumours, and to verify that targeting PIM2 in tumours exhibiting 
chemoresistance to clinically used cytotoxic agents leads to their sensitisation 
to apoptosis. This will need to be tested in vitro, as well as in vivo using our ALL 
xenograft mouse model. 
In addition, it will be important to test the effects of the new PIM inhibitor in 
combination with chemotherapeutic agents such as doxorubicin, vincristine and 
dexamethasone, since synergistic effects may improve the efficacy with which 
these cytotoxic agents eliminate ALL tumour cells, and allow for a reduction in 
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the doses used to treat patients. It will also be important to test the effects of 
combined treatment with a PIM kinase inhibitor and JQ1 in ALL tumours that 
are resistant to either of these compounds alone, since results in this study 
suggest a significant degree of overlap exists between PIM kinase and BET 
protein activity. 
Overall, further investigation into the targeting of PIM2 with specific 
pharmacological inhibitors will help fully evaluate this approach in the treatment 
of chemoresistant B-precursor ALL, and potentially provide scientific evidence 
to support inclusion of the first PIM kinase inhibitor in a B-ALL clinical trial.   
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8. APPENDICES 
 
 
8.1. Appendix 1- Clinical information for the AML patients used 
as positive controls in JQ1 cytotoxicity experiments 
Patient 
No. 
Age at 
diagnosis 
(years.months) 
WCC at 
diagnosis 
(x109/L) 
Cytogenetic 
profile 
In vitro 
response to 1 
µM JQ1 (EC50) 
AML-1 4.4 46.3 46XY, t(9;22) 0.118 
AML-2 7.6 6.5 46XY, t(15;17) 3.720 
 
 
 
Two primary AML tumours were used as positive controls for JQ1-induced 
cytotoxicity, since previous studies demonstrated potent anti-tumour effects of 
JQ1 in vivo, in a primary AML xenograft model [344] 
The above table shows clinical information for the two primary AML control 
tumours along with corresponding JQ1 EC50 that were derived from cytotoxicity 
experiments in this study. 
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8.2. Appendix 2- Clinical information for the B-precursor ALL 
patients used in the PIM2 qRT-PCR expression screen 
 
 
Patient No. Age Sex Karyotype Blast clearance (Day 8) Mol. MRD  (Day 28)
K00135 
EC50 µM
ALL-201 8.24 F
48,XX,+X,der(14)t(8;14)(q11;q32),+21c[8]/
47,XX,+21c[2] - - 0.53
ALL-202 15.2 M 54,XY,+X,+4,+6,+10,+14,+18,+21,+21[10] GER LR 0.48
ALL-203 - - - - HR 0.08
ALL-204 - - - - - 0.60
ALL-205 - - - GER LR 0.14
ALL-206 9.68 M
47,XY,dup(1)(q32q12),t(8;14)(q24;q32),+22[3]/
46,XY[14]
IGH/MYC positive [33/93] - - 0.44
ALL-207 11.9 M - GER HR 2.37
ALL-208 2.2 F
55,XX,+X,ins(1;?)(q2;?),+4,+6,+10,+14,+17,+18,+21,+21[9]/
46,XX[1] - HR 1.09
ALL-209 10.5 M
46,XY,del(9)(p1),der(19)t(1;19)(q23;p13)[9]/
46,XY[1] - HR 0.16
ALL-210 0.34 M 46,XY[20] - - 0.17
ALL-211 - - - - - 0.18
ALL-212 6.43 M
57~60,XY,+der(X)t(X;1)(q28;q2),+Y,+4,+5,+6,+8,+10,add (10)(q?),
+14,+17,add(17)(p1),+18,+18,+21,+21,+1~2mar[cp8]/46,XY[2] GER HR 0.54
ALL-213 18.1 F
46,XX,add(3)(p12),inv(5)(p15.3p14)c,add(20)(q1)[6]/
46,XX,inv(5)(p15.3p14)c[14]/ - - 1.75
ALL-214 17.9 F 44,X,-X,-7,t(9;22)(q34;q11)[12] - - 2.26
ALL-215 20.6 M
46,XY,t(2;7)(p1;p1)[8]/
46,XY[2] - - 1.53
ALL-216 14.7 M
47,XY,+X,t(4;11)(q21;q23)[10]
MLL rearrangement positive [5/5]      Metaphase FISH. GER HR 0.56
ALL-217 12.5 F
46,XX,t(3;10)(q25;p11.2),del(9)(p21p21),der(9)t(9;16)(p21;q22)del(9)(p21
p21),
der(16)t(9;16)(p21;q22)[11]/47,idem,+8[3]
- LR 0.16
ALL-218 0.78 F
46,XX,t(4;15)(q21;q15)[9]/
46,XX[1] - - 0.66
ALL-219 4.71 F 52~54,XX,+X,+4,+6,+10,+14,+17,+18,+21,+mar,inc[cp10] GER - 5.63
ALL-220 3.38 M
[ p
2] - - 0.45
ALL-221 8.56 M 48,XY,t(2;12)(p1;q1),-13,-20,+21c,+21,+3~4mar,inc[cp7] PER HR 0.30
ALL-222 8.91 M
46,XY,inc[8]/
47,XY,+12,?add(12)(p1)[7]   
p16 monoallelic deletion [40/113]/
p16 biallelic deletion [56/113]
12cen x3 [18/133]                            Interphase FISH analysis - LR 0.55
ALL-223 0.73 F
46,XX,t(4;11)(q21;q23)[9]/46,XX[1]
MLL rearrangement positive [74/105]      Interphase FISH analysis - - 0.16
ALL-224 0.53 M
46,XY,t(4;11)(q21;q23),t(14;18)(q32;q1)[10]
MLL rearrangement positive [96/99]  Interphase FISH analysis
MLL rearrangement positive [5]         Metaphase FISH analysis - - 0.27
ALL-225 10.1 F
57,XX,+X,+X,+4,+6,+8,+10,+14,+17,+18,+21,+21[8]/
46,XX[2] GER HR 0.30
ALL-226 14.2 M 46,XY,add(7)(q2),add(12)(p13)[10] GER HR 0.41
ALL-227 7.43 M - GER LR 0.42
ALL-228 14 M
46,XY,?del(9)(p2?1p2?1)[20]
p16 partial deletion x1 [22/49]               Interphase FISH PER HR 2.89
ALL-229 2.84 M
54,XY,+?X,+Y,+?4,+6,+10,+14,+18,+21,+21,inc[cp3]/
46,XY[1] GER LR 3.53
ALL-230 1.87 M TEL/AML1 positive [51/56]         Interphase FISH GER LR 1.55, , , , , , , , , ( )(p ), , , , [ p
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ALL-230 1.87 M TEL/AML1 positive [51/56]         Interphase FISH GER LR 1.55
ALL-231 2.59 M
, , , , , , , , , ( )(p ), , , , [ p
0] - LR 0.30
ALL-232 4.22 F
46,XX,der(19)t(1;19)(q23;p13)[9]/
46,XX[1]
E2A gene rearrangement [101/109]   Interphase FISH GER HR 0.07
ALL-233 3.51 M
46~47,XY,?add(12)(p1),?t(12;21)(p13;q22),?+21[cp8]
TEL/AML1 fusion, TEL deleted [43/80]
TEL/AML1 fusion, TEL deleted, gain of AML1 [12/80]   Interphase FISH GER LR 0.44
ALL-234 22.9 M 46,XY[20] - - 0.48
ALL-235 5.48 M
47,XY,+X,-14,-16,add(17)(p1),+2mar,inc[4]/
46,XY[6] - HR 1.83
ALL-236 18.2 M 46,XY[20] - - 0.34
ALL-237 11.6 F 46,XX[20] - - 0.22
ALL-238 3.96 M
46,Y,add(X)(q1),t(1;14)(q21;p1),der(6,)add(6)(p1)add(6)(q1),?t(12;21)(p1
3;q22),
add(22)(p1)[9]/
??,?idemx2,inc[?]/
46,XY[1]
GER LR 0.39
ALL-239 2.94 M TEL/AML1 positive [83/87] - - 1.20
ALL-240 3.82 F
45,X,-X[7]/46,XX[3]
Xcen x1[84/94]                                   Interphase FISH - 0.54
ALL-241 - - - - - 3.09
ALL-242 18.9 F
48,X,t(X;14)(p2;q32),+der(X)t(X;14)(p2;q32),+21c[7]/
47,XX,+21c[16]
IGH gene rearrangement positive [4/5]             Metaphase FISH 
analysis - - 0.84
ALL-243 10.6 F
47,XX,?t(12;21)(p13;q22),+21[5]/
47,XX,add(12)(p1),?t(12;21)(p13;q22),+21[4]/
47,XX,add(6)(q1),-9,?t(12;21)(p13;q22),+21,+mar,inc[3]
TEL/AML positive [101]
TEL deleted x 1 [95/101]       Interphase FISH - LR 2.28
ALL-244 8.11 M
46,XY,add(6)(q1),?t(12;21)(p13;q22)[4]/
46,XY,?t(12;21)(p13;q22)[6]                               G-band metaphase
TEL/AML1 positive [100/104]                             Interphase FISH - HR 0.52
ALL-245 7 F
58,XX,+4,+6,+7,+8,+10,t(10;12)(p1;q1),+11,+12,+14,+17,+18,+21,+21[
7]/ - - 0.58
ALL-246 - - - - - 1.33
ALL-247 18.2 M 46,XY[20] - - 0.18
ALL-248 10.2 M
46,XY,t(5;5)(q1;q31)[7]/
46,XY,t(3;20)(p21;q13),t(5;5)(q1;q31)[7]/
46,XY[1] PER HR 0.69
ALL-249 5.19 M
46,XY,?t(12;21)(p13;q22)[?6]/
47,XY,+10,?t(12;21)[2]/
46,XY[?3]
TEL/AML1 fusion positive             FISH analysis on previous sample  - - 1.15
ALL-250 5.72 M
46,XY,-
6,add(7)(p22),?del(9)(p21p21),add(10)(q2),?t(12;21)(p13;q22),+r[7]/
46,XY,-6,add(8)(p1),?del(9)(p21p21),?t(12;21),+r[5]/46,XY[18]                      
- NR 1.80
ALL-251 2.46 M 46,XY,del(9)(p11)[20] GER HR 2.09
ALL-252 5.95 F
59~61,XX,+X,t(2;12)(q14;p13),+4,+5,+6,+8,+10,+11,+14,+15,
+18,+21,+21,+mar[cp7]/
46,XX[6] - LR 0.68
ALL-253 2.93 F 55,XX,+X,+X,ins(1;?)(q21;?),+6,+10,+14,+17,+18,+21,+21[10] GER LR 0.29
ALL-254 2.11 M
45,XY,der(22)?t(2;9;22;10)(p1;q34;q11;q2),add(3)(p2),
-
7,der(9)?t(2;9;22;10)del(9)(q34q34),der(10)?t(2;9;22;10),der(22)?t(2;9;2
2;10)[9]/
46,XY[1] GER HR 0.46
ALL-255 6.88 M
54,XY,+X,+4,+6,+9,+14,+20,+21,+21[11]/
46,XY[1] GER HR 0.47
ALL-256 16.7 F 46,XX,+5,idic(5)(p1),t(14;19)(q32;q13)[10] - - 0.29
ALL-257 13.4 M - - 0.08
ALL-258 11 F
46,XX,der(19)t(1;19)(q23;p13.3)[11]/
46,XX[1]
TCF3 (E2A) rearrangement [45/60]            Interphase FISH GER LR 0.09
ALL-259 8.28 M
46,XY,t(12;21)(p13;q22),add(12)(p1)[23]/
46,XY,der(12)t(12;21),idicder(21)(p1)t(12;21)[9]/
46,XY,der(12)t(12;21),idicder(21)t(12;21),add(12)(p1)[39]/
46,XY[18]                                                      
                  
TEL/AML1 positive - - 0.37
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Data includes age, gender, cytogenetics, blast clearance (Day 8), molecular 
MRD (Day 28). 
K00135 EC50 values from cytotoxicity experiments are also included. 
‘-‘ denotes where clinical data was not available. M/F = Male/Female, PER =  
poor early response, GER = good early response, LR/HR = low-risk/high-risk 
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ALL-260 8.28 M - - - 0.27
ALL-261 5.2 M
46,XY,?del(12)(p13p13),?t(12;21)(p13;q22)[20]               G band 
analysis
- - 0.20
ALL-262 3.06 F
46,XX,?del(9)(p21p21)[4]/46,XX[1]                  Metaphase G-banding 
and FISH - LR 0.64
ALL-263 10.1 F
51~53,XX,+4,+6,del(6)(q1q2),+8,+14,+21,+21,+mar[cp9]/
46,XX[1] GER LR 0.32
ALL-264 8.76 F
45,X,-X,?del(12)(p1?p13),?t(12;21)(p13;q22),inc[6]/
46,XX[2]
TEL/AML1 rearrangement positive, partial TEL deletion [61/106]  GER LR 0.49
ALL-265 4.44 M
46,XY,t(9;22)(q34;q11)[5]/
46,XY[17]
BCR/ABL positive [1/20]           Metaphase FISH GER HR 0.16
ALL-266 3.85 F
45,XX,der(8;12)(q10;q10),?t(12;21)(p13;q22)[2]/
46,XX,add(12)(p1),?t(12;21)(p13;q22),+mar,inc[cp9]/
46,XX[4]
TEL/AML1 positive, TEL deleted x1[93/102]     Interphase FISH - HR 0.65
ALL-267 3.31 M
?46,XY,?del(9)(p?21p?21),?t(12;21)(p13;q22)[?]/46,XY[?]
TEL/AML1 positive [25/91]; p16 deleted (monoallelic) [21/96]        PER HR 0.37
ALL-268 3.63 F
53,XX,+X,+6,+14,+17,+18,+21,+21[12]/
46,XX[3] - LR 0.39
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8.3. Appendix 3- The PIM2 gene is among the most differentially 
upregulated genes in tumours resistant to JQ1 
 
 
 
 
Primary ALL tumours were ranked according to JQ1 EC50, as determined in 
previous cytotoxicity experiments. Fold-changes in gene expression showing 
the strongest positive correlation with JQ1 EC50 values were then identified  
using Spearman’s rank coefficient correlation (coefficient ≥0.6; p<0.05). 
Among those genes selected (shown in the above heatmap) PIM2 was shown 
to be one of the most differentially upregulated genes in JQ1-resistant primary 
ALL tumours indicated by black arrow), suggesting PIM2 may confer resistance 
of ALL tumour cells to the cytotoxic effects of JQ1. 
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8.4. Appendix 4- Photograph of original blot showing BRD4 
expression in ALL cell lines 
 
 
 
 
 
 
The above image is the original western blot produced in experiments 
investigating the expression of BRD4 in a panel of 6 ALL cell lines (NALM-6, 
NALM-17, REH, SD1, SUPB15, TOM-1), and is the same blot used to produce 
Figure 3.1a in Results Chapter 3. The arrow indicates the protein band 
representing BRD4 which was detected at the expected molecular weight of 
152 kDa. BRD4 was expressed at high levels across all ALL cell lines. 
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8.5. Appendix 5- Photograph of original blot showing BRD4 
expression in ALL primary tumours 
 
 
 
The above images are the original western blots produced in experiments 
investigating the expression of BRD4 in a panel of 10 ALL primary tumours and 
are the same blots used to produce Figure 3.1b in Results Chapter 3. BRD4 
protein was detected as a 152 kDa protein in all ALL primary tumours. The 
numbers ‘0’ and ‘6’ represent the time in hours that primary tumour cells were 
exposed to 1µM JQ1.  
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8.6. Appendix 6- Schematic showing the possible structures 
that can be identified using the fluorescent DNA replication 
fibre technique 
 
 
 
The above replication structures can be visualised using the fluorescent DNA 
fibre-labelling technique, whereby replication tracts are first labelled with the 
nucleotide analogue CIdU and then IdU (20 minutes incubation each), followed 
by immunostaining with appropriate antibodies conjugated to two different 
fluorophores. After laser-excitation, the fluorphores emit red light (1st label) and 
green light (2nd label), allowing replication structures to be identified, as well as 
the direction of DNA replication and the rate of progression (by measuring the 
lengths of red and green fibres). 
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